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Abstract
Maintenance of cellular failsafe pathways (apoptosis and senescence) is one
of the hallmarks of life, as fine equilibrium between proliferation and growth
arrest ensures that the cell can protect itself from the potentially danger-
ous mutations. Senescence is a mechanism distinguished by heterochromatin
modifications leading to silencing of the genes responsible for the entry to the
DNA synthesis [S] phase of the cell cycle. Involvement of epigenetic modifi-
cations in cancer development has been subject of a more intense research in
the past few years. It was shown that the Rb-associated histone methyltrans-
ferase Suv39h1 is a critical mediator of senescence in a Ras-induced mouse
lymphoma model. Additional mechanisms of the senescence regulation are
currently being under investigation. In this thesis Eµ-myc transgenic mice,
crossed to mice deficient for Suv39h1, were shown to succumb to the same
type of B-cell lymphoma (similar to Burkitt’s lymphoma in humans). Over-
expression of Myc, as seen in human and mouse tumors will primarily induce
an apoptotic response using p53 as a mediator of this response. In Eµ-myc,
Suv39h1−/− mouse model deficiency in Suv39h1 has significantly shortened
life expectancy, but it did not affect spontaneous apoptosis rates. This find-
ing established Suv39h1 as a tumor suppressor in Myc-lymphomagenesis.
Further, an additional mechanism of mediating oncogene-induced senescence
involving cytokine signaling was identified and reported here. When intact
Suv39h1 is present in the tumor, TGFβ is able to mediate oncogene-induced
senescence in vivo. Finally, in the treatment studies it was shown that
Suv39h1 deficient lymphomas have an impaired response to chemotherapy,
caused by their inability to execute drug-induced senescence. This finding
can be of use for the design of novel cancer therapies.
Zusammenfassung
Die Aufrechterhaltung der sogenannten failsafe Programme ist ein wichtiges
Kennzeichen des zellulären Lebens, da das genaue Gleichgewicht zwischen
Proliferation und Wachstumsarrest es sicherstellt, dass die Zelle sich selber
vor potentiell gefährlichen Mutationen schützen kann. Apoptose und Senes-
zenz bewahren die Zellhomeostase und sind von aüsserster Bedeutung dafür,
die Zelle vor maligner Transformation zu bewahren. Die Seneszens zeich-
net sich dabei durch Veränderungen des Heterochromatins bei Genen aus,
welche für den Eintritt in die DNA-Synthese-Phase des Zellzyklus verant-
wortlich sind. Insgesamt wurde die Bedeutung epigenetischer Modifikationen
bei malignen Erkrankungen (hautsächlich fehlende oder zusätzliche DNA-
Methylierung und Veränderungen der Histon-Modifikationen) in den letzten
jahren immer deutlicher. So konnte gezeigt werden, dass die Rb-assoziierte
Histon-Methyltransferase Suv39h1 ein entscheidender Vermittler der Senes-
zenz in Ras-induziertem Maus Lymphom-Modell ist. Andere Mechanismen,
die verantwortlich sind für den Übergang von der anfänglichen Hyperproli-
feration zur Seneszenz in vivo, sind momentan Gegenstand der Forschung in
zahlreichen Gruppen weltweit.
In dieser Arbeit wurde gezeigt, dass die transgenen Eµ-myc Maüse (ähn-
lich dem Burkitt’s Lymphom im Menschen), wenn sie mit Suv39h1-defizient-
en Maüsen gekreuzt werden. Die Überexpression von Myc, wie sie in humanen
und murinen Tumoren zu beobachten ist, induziert primär ein apoptotische
Antwort mit dem zentralen Vermittler p53. Allerdings bewirkte die Suv39h1
Defizienz, obwohl sie die Lebenserwartung signifikant verkürzte, keine Verän-
derung der Apoptose-Rate in diesem Modell. Dieses Ergebnis demonstriert
die Tumor-suprimierende Wirkung des Suv39h1 in Myc-getriebener Lym-
phomagenese. Weiterhin wurde in dieser Arbeit ein zusätzlicher Mechanis-
mus zur Vermittlung Onkogen-induzierter Seneszenz unter Einbeziehung des
Zytokin-Signaling identifiziert. Im Falle der Expression von intaktem Suv-
39h1 in der Tumorzelle kann TGFβ die Onkogen-induzierte Seneszenz in
vivo beeinflussen. Schliesslich ergaben die Untersuchungen, dass die Suv39h1-
defizienten Lymphome über eine beeinträchtigte Therapie-Anwort verfügen,
da sie keine Therapeutika-induzierte Seneszenz ausführen können. Insbeson-
dere dieses Ergebnis könnte von grossem Wert bei der Entwicklung neuer
Krebs-Therapien von Nutzen sein.
iv
Za Dadu
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”Njega su za sve spremali, izuzev za mene.” Ilija Cvorovic aka Balkanski
spijun
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Chapter 1
Introduction
1.1 Aim and scope of the thesis
The maintenance of cellular failsafe pathways (e.g., apoptosis and senescence)
is an essential prerequisite for most of the living creatures, since mutations in
them potentially carry harmful consequences. It is crucial for the organism
that failsafe pathways properly function and that they remain activated in
response to different stress that cells are exposed to. When oncogenic sig-
naling is imposed on cell, cell cycle ”checkpoint” genes will force it to arrest
and undergo apoptosis or senescence.
Part of the work presented in this thesis focuses on lymphoma devel-
opment in animals with disrupted senescence machinery. Senescence is a
permanent arrest in the first gap phase [G1] of the cell cycle. Senescence,
like apoptosis, is established as a failsafe program responding to the different
stress stimuli cell is exposed to: like oncogene activation, DNA damaging
agents as well as agents that alter chromatin structure. Recent publications
have shown that the oncogene-induced senescence is a barrier to the fur-
ther tumor progression. However, signaling events mediating senescence are
not yet fully identified, and a main part of this thesis work aimed at their
identification. The second part of the work presented in this thesis focuses
on elucidating a role of senescence in lymphoma therapy in vivo utilizing
mouse model with specific genetic disruption of senescence machinery. Re-
sults obtained in this part could potentially be used as prognostic markers
and consequently exploited for the better treatment design.
1
21.2 Introduction to thesis work
Mouse model used in this thesis comprises of two parts: Eµ-myc transgenic
mice were crossed to Suv39h1 knockout mice in order to obtain animals devel-
oping lymphomas (driven by Myc over-expression) lacking gene that is known
to mediate senescence by heterochromatin associated histone modifications
(Suv39h1), to test for the Suv39h1 contribution to the tumor formation and
the treatment. Therefore introduction is divided in three main parts. The
first part of the introduction will describe senescence as a cellular failsafe
mechanism, and its response to constant oncogenic stimuli, as well as key
molecules implicated in mediating senescence response, lymphoma develop-
ment and treatment. In the second part of the introduction most prominent
histone modifications will be described. Last part of introduction will de-
scribe mouse models used in this thesis.
1.3 Cellular failsafe mechanisms in cancer
During many years tremendous efforts and resources have been employed,
and some major breakthroughs have been made: cancer is classified as a com-
plex genetic disease [HW00], promoting uncontrolled growth of cells which
have lost their ability to execute apoptosis (programmed cell death) or senes-
cence. In the course of its lifespan cell is facing the risk of malignant trans-
formation. In order to prevent it cell can utilize one of failsafe programs
available (apoptosis and senescence), and stop uncontrolled proliferation and
consequent oncogenic transformation [Sch03](Figure 1.1).
The mechanism of apoptosis is well researched and understood, and in
patients apoptosis is still considered the major response to treatment with
the chemotherapeutic drugs [SL99]. However, when senescence is concerned
we still do not have a full understanding of the components involved in its
execution. Recently it became more obvious that the clearer understanding
of the processes involved in senescence will be of tremendous benefit to the
design of better and more straightforward treatment strategies.
1.3.1 Senescence
The phenomenon of replicative senescence was first recognized by Hayflick
and Moorhead in vitro, observing that human diploid fibroblasts are display-
ing limited division potential. Later they revealed that division potential is
dependent on the number of divisions a cell has undergone [HM61], [HAY65],
[Sed98]. Excessive telomere shortening, leading to senescence is implicated
3Figure 1.1: Oncogenic stress and cellular failsafe mechanisms. Apoptosis
and senescence are two cellular failsafe mechanisms preventing oncogenic
transformation. For the development of the full blown malignancy cells have
to overcome these mechanisms.
4in the loss of regenerative and proliferative potential in aging tissues, which
contributes to the decrease in the tissue function [CddF07]. Premature senes-
cence is characterised by a permanent arrest in the G1 phase of the cell cycle
[HAY65], and this arrest can be provoked by diverse types of cellular stress,
like oncogenic signaling, DNA damaging chemo-, radio-therapy, and lesions
caused by reactive oxygen species and finally by a diverse range of cytokine
signaling.
Characteristics of senescent cells
Senescent cells, unlike apoptotic cells, remain intact and viable for extended
periods of time. Distinct morphological changes are following irreversible
G1 growth arrest, cells become bigger and flattened, as well as displaying
vacuole rich cytoplasm. Also, they show striking changes in expression of
certain genes and proteins, some of which are cell cycle inhibitors and acti-
vators [JPS06],[CSS+02],[MJL04],[SCW+99],[TSPG06],[YKK+04]. Amongst
the most prominent changes are activation of the cyclin dependent kinase
inhibitors (CDKI) p21Cip and p16INK4a [Cam01],[BLL+05], upregulation of
p53 [SLM+97],[HSW+93], p19Arf [DIAC00],[KZR+97] and promyelocytic-
leukemia protein (PML)[FdSQ+00],[PCS+00]. Genes coding for proteins im-
portant for the cell cycle progression, like cyclin A, cyclin B and proliferat-
ing cell nuclear antigen (PCNA) are repressed in senescent cells [NNH+03]-
,[PC94],[SC90],[SDR+91]. Genes encoding for secreted proteins like CXC
motif ligand 6 and insulin like growth factor 2 associated protein (IGF2A)
are also found to have deregulated expression in senescent cells when com-
pared to the normal proliferating cells [JPS06],[CSS+02],[MJL04],[SCW+99]-
,[TSPG06],[YKK+04].
The oldest, and best known marker for a senescent cell is increased lyzo-
somal activity of the enzyme β-galactosidase, which is easily detectable by
an assay using X-gal as substrate, at a non-physiological pH [5,5 for murine
cells, and 6,0 for the human cells] and can be identified by the change of color
(senescent cells display blue cytoplasmic staining) [DLB+95]. Lack of DNA
replication, as it occurs in senescent cells can be measured by incorporation
of either BrdU (5-bromo-2’-deoxyuridine) or 3H-thymidine; however by this
incorporation it is not possible to distinguish senescent (irreversibly arrested)
from quiescent (reversibly arrested) cells. There are also cytological markers
of senescence, visualizing senescence associated heterochromatic foci (SAHF)
by binding of the DNA dye 4‘6-diamidino-2-phenylindole (DAPI)[NNH+03].
This can be accompanied with the presence of certain heterochromatin as-
sociated histone modifications (tri-methylation of lysine 9 residue on the
histone H3, H3K9me3) and by heterochromatin proteins 1 (HP1). It is still a
5matter of the debate that so far there is no truly validated molecular marker
existing that would be able to identify senescent cells [Sed98].
Key molecules involved in regulation of cellular senescence
At the molecular level, the p53 and retinoblastoma (Rb) tumor suppressor
pathways serve as critical cell cycle checkpoints that mediate both replicative
and oncogene-induced senescence. The main function of the Rb gene is lim-
iting cell proliferation by preventing entry into the DNA synthesis [S] phase
of the cell cycle. When Rb protein is maintained in its hypophosphorylated
(anti-proliferative) form by p16INK4a, it is blocking E2f transcription factors
from activating genes needed for DNA replication and nucleotide metabolism
[GBBP07]. Progression into the S phase of the cell cycle is accelerated when
Rb is phosphorylated, and its ability to block E2f is disrupted, that process
is catalysed by cyclin D and E dependent kinases during the G1 phase of
the cell cycle. Ras-induced senescent cells display Rb-mediated senescence
associated heterochromatic foci (SAHF), these transcriptionally silenced het-
erochromatin regions map to E2f responsive promoters and have been shown
to be an area with highly tri-methylated lysine 9 residues on the histone H3
(H3K9me3)[NNH+03]. Tumor suppressor gene p16INK4a, a critical mediator
of G1/S phase transition, is also found overexpressed during replicative and
premature senescence[Ser97],[SPE+95]. It regulates senescence by inhibition
of cyclin D-dependent kinases (CDK4 and 6) which are crucial for the entry
in S phase of the cell cycle.
Further, the p53 protein is the most important sensor of stress in the cell.
Under normal conditions p53 protein is rapidly degraded[Ore99]. When the
cell is exposed to DNA damage or oncogenic signaling transcriptional activity
of p53 increases, and a complex cascade that ends with elimination of dam-
aged cells through apoptosis or senescence is triggered. Activity of p53 is
regulated by posttranslational modifications (acetylation, phosphorylation,
etc.), and transcriptionally by oncogenes, like Myc or Ras, as well as by the
DNA damage (mediated via ATM/ATR pathway)[CHH+00]. Genes that are
activated by p53 include ones that encode the cyclin E and A-dependent ki-
nase inhibitor p21Cip, as well as many others implicated in apoptosis. The p53
protein directly activates its own negative regulator murine double minute
2 protein (MDM2), and in turn MDM2 induces ubiquitylation consequently
leading to degradation of p53[JGO99]. Stabilization of p53 on the other
hand is induced by p19Arf , one of the main p53 regulators, by associating
with MDM2, thereby blocking its ability to interact with the p53. p19Arf
expression is reported to be increased in murine cells during the course of
the cellular senescence[KZR+97],[JKM+99]. p21Cip is inhibiting activity of
6cyclinD/CDK4, E/CDK2 and A/CDK2 complexes, which leads to the G1
arrest[HAW+93], p21Cip was also found to be expressed in human senescent
cells[NNV+94], and was shown to be associated with the expression of wild-
type p53 involved in G1-checkpoint control[eDTV+93].
In summary, it has become clear during the past few years that activation
of both p53/p19Arf and the pRb/p16INK4a pathways is promoting growth
cessation via senescence and apoptosis, underlining p53s importance as a
key molecule in this process (Figure 1.2).
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Figure 1.2: Cellular failsafe pathways activated in a response to oncogenic sig-
naling. Oncogenic Ras signaling through p16INK4a and cyclin D-dependent
complexes helps to cancel Rb suppression, liberating E2fs and stimulating
S-phase entry. Oncogenic Myc signaling through p19Arf inhibits MDM2 and
initiates p53 transcriptional response triggering either apoptosis or senes-
cence. Induction of p21Cip by p53 inhibits cyclin E-Cdk2 and returns Rb to
its hypophosphorylated (inhibitory) state. p21Cip action connects the Myc-
p19Arf -MDM2-p53 axis to Ras-p16INK4a-Rb axis
7Additional stimuli inducing senescence
DNA damage response (DDR) recently emerged as a biological tumorigene-
sis barrier evident in early stages of tumor development. It has been shown
that in tumor specimens from human cancer patients there is a constitu-
tive activation of DNA damage signaling, which is most prominent in the
early pre-invasive stages of tumors [BHK+05]. Further, markers of activated
DDR are correlating to markers of cellular senescence in samples from human
tumors, and data in vitro revealed that intact DDR machinery is a prerequi-
site of the oncogene-induced senescence [BRL+06], [DMFC+06]. It has been
reported that accumulation of the reactive oxygen species (ROS) plays an
important role in senescence induction as well[MGLF07]. Tumor microenvi-
ronment, especially oxygen tension, is also triggering premature senescence.
It was reported that the proliferative lifespan of human diploid fibroblasts
can be extended by changing their growth environment from hyperoxic con-
ditions (when levels of oxygen exceeded 40%), to hypoxic conditions (3%
oxygen) [CFR+95]. It was shown that Ras protein can induce senescence via
changes in intracellular levels of ROS [LFI+99]. Cytokine induced reactive
oxygen species [IKKM06] and potentially senescent growth arrest in a Ras
setting could be related to TGFβ effects. TGFβ has at least two probable
roles in carcinogenesis. In premalignant cells and cells in the early stages
of the carcinogenesis TGFβ inhibits proliferation and may induce apoptosis
or senescence [CBPC04]. Later, as the carcinogenesis process is more ad-
vanced cells lose their ability to respond to the previously inhibitory effects
of TGFβ which most probably occurs via decreased expression of the TGFβ
receptors or, as shown by repression of the TGFβ signaling by oncoproteins
in hematological cancers [KMI+98], [MMT+01]. And at the advanced stages
of cancer TGFβ promotes tumor progression [Ben04]. For example it was
shown that in a response to TGFβ-1 signaling another cyclin-dependent ki-
nase inhibitor (CDKI) p27Kip mediates G1 cell cycle arrest [LEJ+99], and
it has been demonstrated that cytoplasmic promyelocytic leukemia protein
(PML) plays an essential role in the modulation of TGFβ-1 signaling, whereas
cells deficient for the PML displayed resistance towards TGFβ-1 induction
of cellular senescence or apoptosis [LBP04].
Three recent reports show an important role of secreted proteins in en-
forcing the senescence response [KMV+08], [AOB+08], [WSZ+08]. The work
by Kuilman and co-workers provides a link between p15INK4b, heterochro-
matin and the IL-6/ C/EBP pathway. It points to a coordinated function of
IL-6 and C/EBP in upregulation of p15INK4b expression, leading to the Rb
activation and consequently oncogene-induced senescence[KMV+08]. Work
done by Acosta et al established a direct connection between DNA damage re-
8sponse and chemokine signaling[AOB+08]. And finally, Wajpaeyee et al show
negative feedback signaling response of insulin growth factor binding protein7
(IGFBP7) as an executor of antiproliferative effects in melanocytes contain-
ing activating mutations in the BRAF oncogene[WSZ+08](Figure 1.3).
Senescent
Proliferating
Transformed
Apoptotic
Figure 1.3: IGFBP7 and BRAF-induced senescence (adapted from Chien
et al 2008). Early in melanoma progression, melanocytes acquire BRAF
mutations that both stimulate proliferation and trigger senescence, partially
via enhanced secretion of IGFBP7. Silencing of IGFBP7 enables BRAF ex-
pressing melanocytes to progress to melanoma stage. Melanoma cells remain
sensitive to the induction of apoptosis by addition of IGFBP7.
c-Myc and its role in the oncogene-induced senescence
The Myc oncoprotein is a basic helix-loop-helix-leucine zipper transcription
factor that coordinates cell growth and division by binding to specific DNA
elements through dimerization with Max protein, and by this interaction it
modulates transcription of a wide variety of genes [DDGK92]. Expression of
the Myc gene is tightly coupled to the proliferation status of the cell. When
9mitogen signals are added to cells Myc expression is rapidly increased, also
Myc expression is enough to force quiescent cells into the cell cycle [Eil99].
To achieve its full oncogenic potential Myc cooperates with the deregulated
function in certain pro-apoptotic and anti-apoptotic genes. Most prominent
of those would certainly be loss of p53, closely followed by the overexpression
of bcl-2 [EWR+99].
Myc overexpression provokes genomic instability and sensitizes cells to
apoptosis, which is executed via p19Arf -MDM2-p53 pathway [ZER+98]. Ac-
tivation of Myc can be achieved via different mechanisms: chromosomal
translocation, gene amplification, viral insertion, and by direct transcrip-
tional effects [NTP99]. There have been reported a great variety of direct
and indirect targets of Myc. Targets upregulated by Myc are for example:
cyclin D2, cyclin E and CDK4, all of which are involved in G1/S transition.
These activated cyclin/CDK complexes are able to inactivate the restriction
point controlled by the Rb [BBK+00]. In addition Myc successfully downreg-
ulates genes important for the negative regulation of the cell cycle (p21Cip,
p27Kip, p15INK4b) [SLM02], [MBP92], [YSW+01]. Downregulation of p21Cip
occurs via interaction of Myc with Myc-interacting zinc finger-1 protein (Miz-
1) [WCMA+03], [HWB+02] (Figure 1.4), in that way regulating p53 activity
as well. By the same mechanism p15INK4b, an important target of TGFβ is
being repressed. However, p15INK4b is responsive to signals from the SMAD
machinery as well [YSW+01], [SPK+01].
1.3.2 Apoptosis
So far apoptosis is the most thoroughly studied cellular failsafe mechanism.
It was first described by Kerr et al in 1972. Apoptosis is characterised
by distinct morphological features: chromatin condensation followed by its
fragmentation, membrane blebbing, and at the end phagocytosis of the cell
fragments[MG95]. Biochemical features of apoptotic cell include internucleo-
somal cleavage of DNA, leading to an oligonucleosomal ”ladder”, and finally
proteolytic cleavage of a great number of intracellular substrates. As a re-
sult of changes in the plasma membrane apoptotic cells are rapidly phago-
cytised before intracellular contents are released and without induction of
the inflammatory response [MG95]. Apoptosis is a tightly regulated pro-
ces, mainly driven by the caspase cascade [TL98]. Apoptosis is triggered
by growth factor depletion, hypoxia and radiation, as well as DNA dam-
age, telomere malfunction and inappropriate proliferative signals produced
by oncogenic mutations [KZRVU+97]. The majority of the anticancer agents
identified to date mediate their cytotoxic effects via apoptosis. Since p53 is
the first tumor suppressor gene linked to apoptosis [WBL99], a particular
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Figure 1.4: Mechanism of transcriptional repression by c-Myc (adapted from
Eilers et al 2003). c-Myc binds to specific DNA sequences (E-boxes) through
heterodimerization with Max, activating transcription of several target genes.
Myc transcriptionally represses several target genes via interaction with Miz-
1.
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degree of chemosensitivity in a certain tumor can be directly connected to
its p53 status [SL99].
1.3.3 Lymphoma development and treatment
The term ”cancer” embodies hundreds of forms of a disease arising as a
result of genetic and epigenetic changes, and all of the tissues and organs
carry a risk to develop tumor during the lifetime. To become malignant
the cell must lose or gain certain attributes, such as an ability to produce
and convey signals sufficient for its growth, sustained angiogenesis, ability
to evade failsafe programs, unlimited replicative potential, and ability to
methastasise [HW00].
Normally mitogenic oncogenes, like Ras and Myc provoke checkpoint-
mediated failsafe programs, e.g. senescence [EWG+92] or apoptosis [Lan95].
However, when acting together Myc and Ras were able to transform normal
rodent cells, and evoke proliferation by cancelling each others failsafe pro-
grams [She96] (Figure 1.5). Transforming potential of Myc and Ras together
and their ability to cancel each others failsafe programs showed that with the
disrupted apoptosis and senescence cells will progress to the stage of fully
blown malignancy.
Key molecules involved in lymphoma development
Defects in tumor suppressor genes or activation of proto-oncogenes are fre-
quently found in human malignancies. Retinoblastoma (Rb) gene mutations
are occurring widely in human cancers [VLL00]. Almost all of the human tu-
mors have certain dysregulation of p53 activity [VH06]. Compared to other
tumor suppressors p53 is most frequently involved in the pathogenesis of
B-cell non-Hodgkin lymphomas [BTO+95].
Alterations in the expression of c-Myc oncogene are found in the pa-
thogenesis of several human malignancies, including Burkitt’s lymphomas
[KK85]. For example inactivation of p53 occurs following c-Myc transloca-
tion in Burkitt’s lymphomas [BTO+95]. Burkitt’s lymphomas are character-
ized in more than 80% of the cases by chromosomal translocation occurring
between c-Myc gene on chromosome 8, and one of the Ig (immunoglobu-
lin) genes on either of chromosomes 2, 14 and 22 [AHP+85]. This chro-
mosomal translocations are also typical for the human B and T cell acute
lymphocitic leukemias (ALL) [MBP92]. The Eµ-myc transgene is derived
from a translocation found in a murine plasmacytoma, juxtaposing the en-
hancers of the immunoglobulin heavy chain to the proximal region of the
c-Myc gene [AHP+85]. In Eµ-myc transgenic mice p53 loss has been shown
12
Oncogenes
[Myc or Ras]
      Apoptosis                Senescence
         [Myc]                          [Ras]
  Evan et al. [1992]            Serrano et al. [1997]
Oncogenes
[Myc and Ras]
Land et al. [1993]
Tumorigenesis
[Myc + Ras]
Figure 1.5: Oncogenic transformation. Each Ras and Myc are inducing the
cellular failsafe machinery. However, when together they are cancelling each
others failsafe programs and this leads to oncogenic transformation.
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to reduce tumor latency [BTO+95]. Chromosomal translocations, involving
bcl-2 gene are characteristic for follicular lymphomas, there immunoglobulin
heavy chain enhancer is juxtaposed to the bcl-2 gene, resulting in high ex-
pression of bcl-2 [NCLW+88]. Bcl-2 overexpression is associated with a poor
treatment prognosis, resulting from resistance to chemotherapy and radiation
treatment [WBL99].
Histone modifications and lymphoma development
Deregulation in the balance of epigenetic modifications may lead to alter-
ations in gene expression and can result in cellular transformation, which
would lead to the full blown malignancy. As observed in the Ras-induced
lymphoma model disruption of histone methyltransferase leads to signifi-
cantly shortened tumor latencies, showing that deregulation in epigenetic
regulator impacts on tumor formation latencies [BLL+05].
Tumor treatment
Search for the therapeutics that would inhibit oncogenic Myc provided in-
sights in potency of Myc as an anti-cancer target. It is known that in the
different tissues induction of oncogenic Myc will lead to the full-blown ma-
lignancy [PKE02], [FB99]. When Myc activity is blocked it will in most of
the cases lead to tumor regression [JB04]. So far all of the therapy strategies
were based on targeting regulatory steps (from transcription to translation),
or to inhibit protein-protein interactions necessary for Myc action (e.g., tar-
geting Myc-Max interaction). All of the above mentioned approaches utilize
apoptosis as a response to therapy. A study by te Poele et al showed for the
first time a correlation between the senescent response and chemotherapeu-
tic treatment in clinical cancer. They also detected spontaneous senescence
occurring in a low number of tumor cases [tPOJ+02]. In Eµ-myc mouse lym-
phoma model, both senescence and apoptosis were contributing to the in vivo
response to chemotherapy [SL02]. When apoptosis was blocked in Eµ-myc
lymphomas senescence became the principal tumor response to chemother-
apy. Recent work done by two independent groups [MBSE06], [XZM+07]
showed how reactivation of intact p53 in different models of aggressively
growing cancer leads to a near-complete regression, exposing senescence as a
primary mechanism of tumor regression.
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1.4 Histone modifications
Changes in histone modifications can regulate gene expression, and are de-
fined by the term ”epigenetics”. This term refers to all of the modifications
in chromatin, but not including alterations in the DNA sequence [Kou07].
As opposing opinion to the DNA dogma (DNA-RNA-protein transfer of in-
formation) the ”Histone code” model was proposed at the begining of this
century [SA00], explaining that acess to certain genome regions is regulated
via histone modifications, which are involved in changing the higher order
of chromatin structures, and by this are able to regulate transcriptional
states[WP96]. This model has changed the view on the regulation of the
processes involved in tumor formation. Histones are small basic proteins con-
sisting of a globular domain and a more flexible and charged NH2 terminus
(called ”histone tail”) protruding from the nucleosome. The basic, multiple
repeating unit of the chromatin is consisting of histone octamere (comprised
of pair of each of the histones H2A, H2B, H3 and H4) arround which the
DNA is wrapped in two almost full circles, and an linker histone (H1) con-
necting each of the histone octameres[Kor74],[KT74],[LMR+97],[ABW+91].
The epigenetic changes, which can ultimately cause differences in the tran-
scription of the various genes, can be accomplished via hypo- or hyper- DNA
methylation or by a diverse range of the histone modifications[FT04].
In the last couple of years intensive research pointed in the direction
of lysine methylation of histone residues as an important factor in gene
silencing[LJ02],[LOJ03],[BK04]. Local hypermethylation of tumor suppres-
sor genes is promoting oncogenesis[LPA+04], and also global hypomethy-
lation enhances oncogene expression, and contribute to the genomic insta-
bility[JB02]. Phosphorylation of serine and threonine histone residues is
mediating transcriptional gene activation, as well as apoptosis. This phos-
phorylation is executed by histone specific kinases (e.g., Rsk-2, Aurora B,
ATM, ATR, DNA-PK)[DS99].
Histones undergo post-translational modifications which alter their inter-
action with both DNA and proteins[Ito07]. The tails of histones H3 and
H4 can be covalently modified at several places. These modifications are
reversible, which makes the chromatin structure dynamic, it can rapidly
switch from non-accessible to accessible[CASC00]. Covalent modifications
of histone tails include: acetylation of lysine residues, methylation of ly-
sine and arginine residues, phosphorylation of serine and threonine residues,
ADP-ribosylation of glutamic acids and ubiquitinylation and sumoylation
of lysine residues[RE02]. Histone methylation, which can occur on the ly-
sine or arginine residues and its exclusive dependency on the site where it
occurs, may lead to the transcriptional activation or repression. Euchro-
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matic structures are mostly characteristic for the ”on” transcriptional states,
where histones are hyperacetylated, and histone H3 is methylated on three
main lysine residues (K4, K36 and K79)[JA01]. Heterochromatic structures
are characteristic for the ”off”-transcriptional states, mostly present in the
non-dividing, arrested cells. In these structures histone H3 displays tri-
methylation on three main lysine residues (K9, K20 and K27), and histone
H4 on the single lysine residue (K20)[SA00],[Tur00]. Histone acetylation, as
well as hyperacetylation in general correlates with transcriptional activity.
This process is executed by histone acetyltransferase (HAT) enzymes, and
can be reversed by histone deacetylase (HDAC) enzymes[HMT+06]. Some
histone modifications function as molecular switches, disabling or enabling
occurrence of an additional covalent mark. If histone H3 is subjected to
phosphorylation on the serine 10 residue, governed by Aurora kinase, it fa-
cilitates acetilation on lysines 9 and 14 and methylation on lysine 4, but
methylation of lysine 9 residue is not any more possible. This modification is
involved in both transcription and cell division, and is present on metaphase
chromosomes. The same residue becomes de-phosphorylated as soon as the
cell exits mitosis. This is a very dynamic process, and well organized inter-
play between phosphorylation of serine 10 residue and methylation of lysine
9 residue of the histone H3 and is crucial for the maintenance of healthy
growing cell[Wat93].
1.4.1 Suv39h1 histone methyltransferase
As previously mentioned histone methylation is executed by histone methyl-
transferases (HMT), some of which are: Suv39h1, Set9 and Ezh2. Histone
methyltransferases can mono-, di- or tri- methylate lysine residues, and mono-
or di-methylate arginine residues. Depending on the methylation state and
the residue methylated biological responses will differ[PK71].
Genes of the Su(var) [suppressor of variegation] group encode numerous
histone deacetylases (HDAC) and protein phosphatases, as well heterochro-
matin associated proteins, one of which is Su(var)3-9, that was identified in
D. melanogaster and S. pombe[WSTR89],[RS92]. In H. sapiens and M. mus-
culus SUV39H1 and Suv39h1, were identified respectively[REO+00]. These
proteins were shown to execute HMT functions, methylating histone H3 at
lysine residue 9 (H3K9). By methylating this lysine residue Suv39h1 is cre-
ating a docking site for the HP1γ, a heterochromatin protein involved in
a formation of a higher order chromatin (heterochromatin), therefore lead-
ing to the gene silencing (Figure 1.6 and Table 1.1). It was shown that
Suv39h proteins are essential for the epigenetic regulation in the mammalian
development[POS+01].
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Figure 1.6: Suv39h1 promotes chromatin silencing. Suv39h1 methylates ly-
sine 9 residue on histone H3; this creates a docking site for heterochromatin
proteins like HP1 that bind to the tri-methylated lysine 9 mark (H3K9) as
well as to Suv39h1/Rb complex. This leads to the stabilization of the het-
erochromatic region. At the same time acetylation of lysine 9 leads to the
relaxed chromatin structure, and enable E2f to dock on a promoter of the
S-phase genes.
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Table 1.1: Chromatin states
Active chromatin Silenced chromatin
H3K9Ac H3K9me3
H3S10P HP1 docked on H3K9me3
Hyperphosphorylated Rb Hypophosphorylated Rb
E2f on promoters of the S-phase genes E2f bound to Rb
SUV39H family members are highly conserved from yeast to humans by
their structure and function. The proteins consist of two highly conserved
chromatin regulatory motifs, one is located at the N-terminus, and is known
as ”chromo” domain, and the second is located on the C- terminus and is
known as the SET [SUV39H SU(VAR)3-9; E(Z); TRX] domain (Figure 1.7).
SET domain properties are not straightforward, because only some of the
SET domain containing proteins are reported to have histone methyltrans-
ferase activity, where SUV39H family belongs[FCHC00],[JLDR98]. During
the mouse embryogenesis, as well as in adult mice Suv39h1 is expressed in
various tissues. Suv39h1/Suv39h2 double knockout mouse embryo fibrob-
lasts (MEF) show changed patterns of the methylated lysine 9 residue from
the pericentric heterochromatic regions, pointing out the role of Suv39h1
and Suv39h2 as safeguards of the pericentric chromatin regions[OSP+00],
[POS+01].
Among the many Suv39h1 interacting proteins Rb is of particular interest.
Suv39h1 interacts with the Rb protein on the euchromatic portions of the
genome. It was demonstrated that Rb is crucial for directing methylation of
the histone H3. Suv39h1 is binding to Rb in a complex with HP1γ, which pre-
dominantly localizes to euchromatic regions, and contains a chromodomain
capable of recognizing methylated lysine 9 on histone H3[BZP+01],[LOR+01].
This is pointing out that the Suv39h1-HP1γ complex is not only in charge
of methylating pericentric regions of heterochromatin leading to silencing,
but also has a role in repressing genes in the euchromatic region, which are
connected to Rb[NSB+01](Figure 1.8).
1.5 Mouse models
The following mice were used: Eµ-myc transgenic mice[AHP+85], Suv39h1
knock-out mice[POS+01], p53 knock-out mice[JRW+94], p19Arf knock-out
mice[KZR+97] and p16INK4a knock-in mice[KQM+01].
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Figure 1.7: Suv39h1 structure. The Suv39h1 protein consists of two highly
conserved elements: SET domain and chromodomain. SET domain confers
HMTase activity of Suv39h1, while the chromodomain serves as a binding
site for HP1 proteins.
Figure 1.8: Suv39h1 as a putative executor of cellular senescence. Suv39h1
interacts with Rb, when it is hypophosphorylated and E2f-bound. This a-
ssociation is a consequence of tri-methylated lysine 9 residue on hisvtone H3
and is preventing the transcription of the genes important for the progression
to the S-phase of the cell cycle.
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1.5.1 Eµ-myc transgenic model
The Eµ-myc transgene is derived from a translocation originally found in the
mouse plasmocytoma. It was engineered in a way that the immunoglobulin
heavy chain enhancer (Eµ) was juxtaposed to the proximal region of the c-
Myc gene [AHP+85]. This Eµ-myc transgene is mediating constitutive over-
expression of the c-Myc oncogene in predominantly the B cell lineage. Mice
carrying this transgene succumb to pre-B cell lymphomas resembling hu-
man non-Hodgkin lymphomas. These lymphomas are monoclonal[AHP+85],-
[ASA87],[LHCA86]. Eµ-myc animals are a very attractive model for the
treatment studies in vivo[SWBR+00], one of the advantages of working with
this mouse model is that tumor burden can be easily monitored by palpation
of the peripheral lymph nodes, therefore making lymphomas detectable be-
fore mice succumb to the disease[SL02] (Figure 1.9). Also, it was previously
shown in this model that p53, as well as the INK4a/Arf mutations have a
distinct effect not only on tumorigenesis, but also on the therapy outcome
by partially disabeling apoptosis[SL02].
B-cell lymphoma   Normal              B-cell lymphoma           
Spleen
Lymph 
node
Lymph 
node 
histology
Blood 
smear
Tumor onset
Birth
Figure 1.9: Eµ-myc mouse model. Left: The Eµ-myc mouse model is a
well tractable lymphoma model, since the onset of the disease can be moni-
tored by palpation of the peripheral lymph nodes (depicted in red). Middle:
Mice with B-cell lymphomas have significantly enlarged spleens and lymph
nodes. Right: Lymph nodes in patients with B-cell lymphomas display typi-
cal ”starry sky” morphology, as a result of macrophage infiltrations arround
apoptotic cells. Their blood smears display severely increased numbers of
blastic cells.
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1.5.2 Suv39h1 knock-out model
Peters et al generated mice deficient either for Suv39h1 or Suv39h2. Single
knock-out animals are born at Mendelian ratios, displayed normal viabil-
ity and fertility, and without any overt phenotype[POS+01]. The murine
Suv39h1 locus on the X-chromosome was disrupted by homologous recom-
bination replacing the N-terminal chromo domain with a Neo-cassette. By
intercrossing mice deficient for both Suv39h1 and Suv39h2 it was shown that
deficiency in both genes leads to chromosomal instabilities and severely im-
paired viability. Despite viability Suv39h1 and Suv39h2 double knockout
mice are born only at sub-mendelian ratios, due to an increased rate of pre-
natal lethality[POS+01]. In a EµN-Ras model Suv39h1−/− or Suv39h1+/−
mice are prone to B-cell lymphoma, and the remaining Suv39h1 allele of
Suv39h1+/− animals is inactivated in tumors[BLL+05].
1.5.3 Other mouse models used in this thesis
p19Arf and p16/p19INK4aArf knock-out and p16INK4a knock-in model were
used in this thesis work as well. Since the main scope of this thesis does
not reside on the p53, p19Arf , INK4a/Arf and p16INK4a models, they were
merely used as controls in certain experiments performed, and therefore I
am limiting myself from further introduction. A detailed description of the
above mentioned mice can be found in the following publications: Jacks et
al, Current Biology 1994(for p53 knock-out mouse[JRW+94]); Krimpenfort
et al, Nature 2001 (for p16INK4a knock-in mouse[KQM+01]) and Kamijo et
al, Cell 1997 (for p19Arf knock-out mouse[KZR+97]).
In summary, This thesis provides insights in oncogene-induced senes-
cence evoked by a constant Myc-signaling, requiring an intact epigenetic
machinery to achieve permanent arrest in the first gap [G1] phase of the
cell cycle, a mechanism that has previously been described for Ras-induced
senescence. This signaling involves retinoblastoma (Rb) tumor suppressor as
a central mediator of heterochromatin formation, and consequent silencing
of the genes necessary for the entry into the DNA synthesis [S] phase of the
cell cycle. Rb is able to exert its silencing functions only when histone H3 is
adequately tri-methylated by a histone methyltransferase Suv39h1. Further,
the extent of cells entering this permanent arrest depends on the intact DNA
damage signaling machinery, as well as on the extent of cytokine signaling.
The tumor suppressor protein p53 resides in the centre of the DNA damage
signaling cascade, and only intact p53 will ensure that both apoptosis and
senescence are executed, making it a critical cell cycle checkpoint. Further,
recently emerging mechanism is the cytokine mediated induction of senes-
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cence as a response to oncogene signaling, but currently only little is known
about this phenomenon. Recent reports unveiled senescence as a program
promising great tumor therapy potential. Hence, long term treatment re-
sponses in a Burkitt’s like B-cell lymphoma model that additionally carries
specific genetic disruption targeting senescence machinery were investigated
in this thesis.
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Chapter 2
Materials and Methods
2.1 Materials
2.1.1 Antibodies
All of the primary and secondary antibodies used are listed in table 2.1 and
table 2.2.
2.1.2 Bacteria Strains
E.coli DH5α-Genotype: F-j80dlcZDM15D(lacZYA-argF)U169 deoR, recA1
endA1 hsdR17 rk-mk+phoA supE44l- thi-1 gyrA96 relA1
2.1.3 Bacteria Media
All of the bacteria media used are listed in table 2.3 and table 2.4
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Table 2.1: Primary Antibodies
Name Number Supplier
Anti-α tubulin(T-5168) B-5-1-2 Sigma
Anti-CDK4 (DSC156) 2906 Cell Signaling
Anti- c-Myc N-262 Santa Cruz
Anti-Histone H3 Lysine 9 tri-methylation 8898 Abcam
Anti-human pRb G3-245 BD Pharmingen
Anti-HP1γ 42s2 Upstate
Anti-Ki67 antigen TEC-3 DAKO
Anti-p16INK4a M-156 Santa Cruz
Anti-p21 Cip1 C-19 Santa Cruz
Anti-p27 Kip1 2552 Cell Signaling
CyclinA CY-A1 Sigma
CyclinE (HE12) 4129 Cell Signaling
Anti-p53 CM5 Novocastra
Anti-phospho p53 (Ser15) 9284 Cell Signaling
Anti-phospho Histone H3 (Ser10) 9701 Cell Signaling
CD11b 550282 BD Pharmingen
FITC conjugated CD 90.2 553003 BD Pharmingen
FITC conjugated CD 5 553020 BD Pharmingen
FITC conjugated sIgM 553437 BD Pharmingen
R-PE conjugated CD 19 557399 BD Pharmingen
R-PE conjugated CD 45R (B220) 553090 BD Pharmingen
Table 2.2: Secondary Antibodies
Name Number Supplier
Anti-rabbit IgG (donkey) NA934 Amersham
Anti-mouse IgG (sheep) NXA931 Amersham
Alexa Fluor 488 goat anti-mouse A21121 Invitrogen
Alexa Fluor 488 donkey anti-rat A21208 Invitrogen
Alexa Fluor 594 donkey anti-rabbit A212027 Invitrogen
Alexa Fluor 594 goat anti-mouse A11005 Invitrogen
Table 2.3: Bacteria Media 1
LB-Medium (Luria-Bertani) quantity (g) in 1 l [pH 7.2-7.5]
Trypton 10
Yeast Extract 5
NaCl 10
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Table 2.4: Bacteria Media 2
LB-Medium (Luria-Bertani)+Ampicilin quantity (g) in 1 l [pH 7.2-7.5]
Ampicilin 100mg/ml
Trypton 10
Yeast Extract 5
NaCl 10
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2.1.4 Buffers and Solutions
Table 2.5: Red Blood Cells Lysis Buffer
ACK buffer quantity (g) in 1 l [pH 7.2-7.5]
NH4Cl 10
Yeast Extract 5
NaCl 10
Table 2.6: Blocking Buffer
Blocking agent Solvent
5% dry milk 1xTBS-T
5% BSA 1xTBS-T
Table 2.7: CaCl2
CaCl2 (g) H2O (l)
5,88 0,02
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Table 2.8: Chloroquine [100mM]
Chloroquine-diphosphate (g) H2O (l)
0,516 0,01
Table 2.9: DEPC water
DEPC (%) H2O (l)
0,1 1
Table 2.10: DNA lysis buffer
name quantity
Tris-HCl, pH 8,5 100 mM
EDTA 5 mM
SDS 0,2%
NaCl 200 mM
Table 2.11: Fixative solutions
Assay fixative solvent
IHC 2% paraformaldehyde 1xPBS
SAβ-galactosidase 2% paraform-, 0,25% glutar -aldehyde PBS-Mg
Table 2.12: 2x Hepes Buffered Saline [HBS]
components concentration in 0,1 l [pH 7.05]
NaCl 280 mM
KCl 10 mM
Na2HPO4 x 2H2O 1,5 mM
Dextrose 12 mM
HEPES 50 mM
Table 2.13: 0,5M Hepes
components quantity (g)
HEPES 11,9
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Table 2.14: Loading Buffer
type components quantity/concentration
6x-DNA Bromphenol-blue 0,25%
loading Xylene-cyanol 0,26%
buffer Glycerol 30%
5x-protein Tris-HCl [pH 6,8] 0,1 M
loading Glycerol 30%
buffer SDS 4%
Mercaptoethanol 1µM
Bromphenol-blue 0,2%
Table 2.15: Lysis Buffer: Proteins
components quantity/concentration in 0,05l
Tris-base [pH 7.6] 50mM
NaCl 150mM
NP-40 1%
Na-deoxycholate 0,25%
Na-orthovanadate 1mM
NaF 10mM
PMSF 1mM
Table 2.16: Potassium cyanide (KC)
components quantity(mg) in 0,025l
K3Fe(CN)6 20
K4Fe(CN)6 x 3h2O 1,050
Table 2.17: Phosphate Buffered Saline [PBS]
components quantity (mM) in 1 l [pH 7,4]
NaCl 137
KCl 2.7
Na2HPO4 10
KH2PO4 2
Table 2.18: PBS/MgCl2
components quantity (mM) in 1 x PBS[pH 5,5]
MgCl2 1
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Table 2.19: Plasmid Mini Preparation Solutions
solution components quantity (mM)
I Glucose 50
Tris [pH 8,0) 25
EDTA [pH 8,0] 10
II NaOH 0,2 N
SDS 0,5 %
III KAc 5M
CH3COOH 15%
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Table 2.20: 10 x Protein Running Buffer
components quantity (g) in 1l [pH 8,3]
Tris-base 30
Glycin 144
SDS 10
Table 2.21: 50 x TAE
components quantity in 1l
Tris-base 242 g
Glacial CH3COOH 57,1 ml
EDTA [pH 8,0] 50 mM
Table 2.22: 10 x TBS
components quantity in 1l
Tris [pH 8,0] 0,1M
NaCl 300 ml
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Table 2.23: 1 x TBS-Tween [TBS-T]
components quantity in 1l of 1 x TBS
Tween-20 0,2%
Table 2.24: TE-buffer
components quantity (mM) in 1l [pH 7,5]
EDTA 0,1
Tris 10
Table 2.25: T-PBS
components quantity in 1x PBS
Triton X-100 0,2 %
Table 2.26: 1 M Tris-HCl pH6,8
components quantity(g) in 0,1l [pH 6,8]
Tris-base 12
Table 2.27: 1 M Tris-HCl pH8,8
components quantity(g) in 0,1l [pH 8,8]
Tris-base 18
Table 2.28: Washing Buffer, Protein
components quantity in 1l TBS-T
Dry milk 0,5 %
Table 2.29: 40x X-Gal Solution
components quantity (mg) in 1ml of DMFO
X-gal 40
Table 2.30: X-Gal Staining Solution
components quantity
X-gal solution 1x
KC solution 1x
PBS/MgCl2 9,25 ml
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2.1.5 Chemicals and Reagents
Table 2.31: Chemicals I
Name Number Supplier
Acetone 8002 J.T.Baker
Acrilamide-bis 30% 10688 Serva
Adriamycin D1515 Sigma
Agar-Agar 5210.2 ROTH
Agarose 11404 Serva
Albumin Fraktion V 8076.2 ROTH
Ammoniumperoxisulfat (APS) 9592.3 ROTH
Ampicilin, sodium salt K029.1 ROTH
5-Bromo-2Õ deoxy uridine B5002 Sigma
Bromphenol blue 018069 Eurobio
Calcium chloride (CaCl2) 5239.1 ROTH
Chloroform 1.02431.1000 Merck
Chloroquine-diphosphate C6628 Sigma
DAPI D9542 Sigma
DEPC (Diethyl pyrocarbonate) D5758 Sigma
DMF (Dimethylformamide) T921.1 ROTH
DMSO (Dimethylsulfoxid) 1.02952.1000 Merck
DTT 018742 Eurobio
EDTA (Ethylenediaminetetraacetate) 8043.2 ROTH
Ethanol, absolute P075.1 ROTH
Ethidium-bromide powder E8751 Sigma
FBS (Fetal bovine serum) 40Q7441K Biochrom
5-Fluoro-2«-deoxyuridine F0503 Sigma
5-Fluorouracil F6627 Sigma
Formaldehyde P733.2 ROTH
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Table 2.32: Chemicals II
Name Number Supplier
Glacial acetic acid 971803 Merck
Glucose 6887.1 ROTH
a-D(+) Glucose (Dextrose) 6887.1 ROTH
Glutaraldehyde 4995.1 ROTH
Glycerine 4043.1 ROTH
Glycine 23390 Serva
Hydrocloric acid, HCl 1.00317.1000 Merck
HEPES 9105.3 ROTH
Interleukin 7, recombinant RDI-207 RDI
1 kb ladder N3232 NEB
L-Glutamine K0283 Biochrom
Magnesium chlorid [MgCl2x6H2O] 2189.2 ROTH
β- Mercaptoethanol 4227.1 ROTH
Methanol 5370 J.T.Baker
Milk powder T145.2 ROTH
MgCl2 2189.2 ROTH
Nonident 40 (NP-40) 74385 Fluka
dNTP K0391 ROTH
PBS Dulbecco 0699H Biochrom
pBR mix 328 902.1 ROTH
PCR buffer 4379876 ABI
Penicillin-streptomycin A22139120 Biochrom
Paraformaldehyde P6184 Sigma
PMSF (Phenylmethylsulfonylfluoride) P7626 Sigma
Polybrene (Hexademethrinebromide) H9268 Sigma
Potassium bicarbonate [KHCO3] P-9144 Sigma
Potassium ferricyanide [K3Fe(CN)6] P3667 Sigma
Potassium ferrocyanide [K4Fe(CN)6 x 3 H2O] P9387 Sigma
Potassiumchloride (KCl) 319309 Sigma
Potassiumacetate (KAc) 4986.1 ROTH
2-propanol I9030 Sigma
Propidium iodide P4170 Sigma
Protease inhibitors 11873580001 Roche
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Table 2.33: Chemicals III
Name Number Supplier
Puromycin 540222 Calbiohem
ROTI- prestained T852.1 ROTH
RotiQuant, Bradford reagent 0038.2 ROTH
SDS 2326.2 ROTH
Sodiumchloride (NaCl) 1.06400.5000 Merck
Sodium citrat [C6H5Na3O7 x 2 H2O] 3580.1 ROTH
Sodium-desoxycholate D6750 Sigma
Sodiumfluoride (NaF) S1504 Sigma
Sodiumhydroxide (NaOH) 6771.1 ROTH
Sodiumorthovanadate S 6508 Sigma
Sodium pyrophosphate [Na4P2O7 x 10 H2O] S6422 Sigma
Taq polymerase N8080171 ABI
Tris(hydroxymethyl) aminomethane 1.08382.0500 Merck
TEMED (Tetramethylethylenediamine) T7024 Sigma
TGF-β 100-B-001 R&D Sys
Triton-X 100 1.08603.1000 Merck
TRIZOL 15536-026 Invitrogen
Trypan-blue T6146 Sigma
Trypsin-EDTA L 2153 Biochrom
Trypton/Pepton 8952.3 ROTH
Tween 20 9127.1 ROTH
Vecta-Shield, mounting medium H-1400 Vector
X-Gal 2315.3 ROTH
Xylene-cyanol 018074 Eurobio
Xylol 9713.1 ROTH
Yeast extract 2363.3 ROTH
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2.1.6 Cells
Table 2.34: Cell Lines
Cell Line Description
NIH 3T3 Adherent mouse embryonic fibroblast cell line;
ATCC number:CRL-1658
Phoenix Adherent human embryonic kidney cell line 293T,
Eco j− adenovirus transformed and stably transfected with plasmids
encoding the MML virus sequence (gag, pol, env).
www.stanford.edu/group/nolan.html
Table 2.35: Primary Cells
Primary Cell Description
B-Lymphoma Primary murine Myc-driven lymphoma cells,
cells isolated from the lymph-nodes of animals
with the different genetic background.
Grown in suspension, requiring feeder cells.
FLC Primary murine fetal liver cells,
isolated from the E15.5 mice.
Grown in suspension, requiring feeder cells.
MEF Primary murine embrionic fibroblasts,
isolated from E12.5 mice.
Adherent cells.
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2.1.7 Cell Culture Media
Table 2.36: DMEM
medium components
DMEM Dulbecco’s modified Eagle medium
Glucose 4500 mg/l
L-Glutamine
Pyruvate
Table 2.37: IMDM
medium components
IMDM Iscove’s modified Eagle medium
L-Glutamine
HEPES 25 mM
Table 2.38: Adherent Cell Culture Medium(ACCM)
medium components
ACCM DMEM
10 % FCS
Penicilin-Streptomycin (100 U / ml)
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Table 2.39: B-Cell Medium(BCM)
medium components
BCM DMEM+IMDM 1:1
20 % FCS
Penicilin-Streptomycin (100 U/ ml)
4 mM L-Glutamine
25 mM β- Mercaptoethanol
Table 2.40: Freezing Medium(FM)
medium components
FM 90 % FCS
10 % DMSO
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2.1.8 Mouse Strains
Table 2.41: Mouse Strains
Mouse strain (modification) Description
C57BL/6 (Eµ-Myc transgenic) Adams et al, Cell 1985
WEHI, Melbourne, Australia
C57BL/6 (Suv 39h1 knock-out) Peters et al, Cell 2001
IMP, Vienna, Austria
C57BL/6 (p 53 knock-out) Jacks et al, Current Biology 1994
Whitehead institute, Cambridge, USA
C57BL/6 (p 16 knock-in) Krimpenfort et al, Nature 2001
NKI, Amsterdam, The Netherlands
C57BL/6 (p 19 knock-out) Kamijo et al, Cell 1997
Howard Hughes Medical Institute,
Memphis, USA
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2.1.9 Enzymes
Table 2.42: Enzymes
Name Supplier
BamH I NEB
Bgl II NEB
Cla I NEB
Hind III NEB
EcoR I NEB
Xho I NEB
Xba I NEB
Proteinase K Merck
Rnase A Fluka
RNAsin RNAse Inhibitor Invitrogen
Superscript REverse Transcriptase II Invitrogen
2.1.10 Expression Vectors
Used plasmids are ecotrophic vectors based on the Moloney Murine Leukemia
Virus (MMLV) and taken for retroviral transduction of rodent cells.
The Murine Stem Cell Virus (MSCV) vector contains the packaging se-
quence, the gene of interest in the multiple cloning site (MSC) driven by a
Phosphoglycerate kinase (PKG) promoter and a selectable marker (antibi-
otic resistance) or Green Fluorescent protein (GFP) between the 5’ and 3’
LTR. (Figure 2.1).
Table 2.43: Expression Vectors
Vector Insert
MSCV-bcl2-IRES-GFP murine bcl2 fcs
MSCV-IRES-GFP -
MSCV-bcl2-puro murine bcl2 fcs
MSCV-puro -
pBabe-MycER-puro human c-myc fused to human estrogen receptor
40
  
Figure 2.1: Plasmid maps, adapted from clonotech.org and addgene.org
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2.1.11 Kits
Table 2.44: Commercial Kits
Name Number Supplier
Cell Proliferation Kit RPN 20 Amersham
In situ cell death detection kit 111684809910 Roche
Leukostat kit CS430-A4 Fischer Diagnostics
Quantikine MB100B R& D systems
Reverse transcription kit 11917-010 Invitrogen
RNeasy Mini Kit 74104 Qiagen
Supersignal West Pico 18561357-36 Pierce
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2.1.12 Plastic-ware and other dispensable materials
Table 2.45: Plastic and Dispensable Materials
Name Number Supplier
Cell culture dishes, various sizes - TPP
Centrifuge tubes, various sizes - Falcon
Cryotubes PK-100 Simport Plastics
Einmal-Kuevetten 8129 ROTH
Frosted slides 76x26 mm S9105 Engelbrecht
Hybond ECL RPN303D Amersham
Immersion oil 56822 Fluka
Microlance tm3 25Gx1′′, Nr18 REF300400 BD
Neubauer cell-counter chamber 0640030 Superior
Marienfeld
Nylon mesh (35 µm) 17-35/22 Sefar
Omnifix 2 ml luer lock REF4617029V BRAUN
Omnifix 10 ml luer lock REF4617100V BRAUN
Pasteur Pipettes 230 mm, glass VWRI1822 VWR
International
Polystirene tubes (5 ml) 352005 Falcon
Syringe filter sterile 0.45 µm P667.1 ROTH
Syringe filter sterile 0.22 µm P666.1 ROTH
Scalpel, disposable No23 Feather
Serological pipetes, various sizes - Falcon
Syringe 1 ml luer REF300013 BD Plastik
Whatman paper Z132403 Schleicher
Schuell
X-omat tm LS 18x24 8688681 KODAK
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2.1.13 Machines
Table 2.46: Machines
Name Supplier
Bio Photometer, 8.5 mm Eppendorf
Block termostat 100 Kleinfield Labortechnik
Centrifuge, 5415D Eppendorf
Centrifuge, Rotina 35R Hettich
Cytospin inserts, 1670 Hettich
Cytospin plastics, 1688 Hettich
Electrophoresis Power Supply, E802 Consort
FACS Calibur Becton Dickinson
Fluorescence microscope, Axioplan Zeiss
Flow Hood Typ UVF 6.18S BDK
Megafuge 1.0R Haraeus
Microscope, Televal 31 Zeiss
Micro-wave Bauknecht
PTC-1 MJ Research, Inc
Shaker Heidolph UNIMAX 1010
Steri-cult 200 incubator Labtect
TRANSBLOT SD BIORAD
UV detection system, Biometra T13 Biometra
Vortex-Genie ROTH
Western-blot Chamber C.S.B. Scientific CO
All materials/ machines not listed in detail are standard lab equipment.
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2.1.14 Oligonucleotides
Table 2.47: Genotyping PCR Primers
Name Sequence Product size
Eµmyc 5’-CAGCTGGCGTAATAGCGAAGAG-3’ transgene
5’-CTGTGACTGGTGAGTACTCAACC-3’ 830 bp
Suv39h1 5’-GTTGATGCTTCCTGGTGTGTAGG-3’ wt 417 bp
5’-TTTGAGGGGACGACGACAGTATG-3’ ko 588 bp
5’-AACAGATGTGGGGTTGGTGGAG-3’
p53 5’-TATACTCAGAGCCGGCCT-3’ wt 450 bp
5’-ACAGCGTGGTGGTACCTTAT-3’ ko 600 bp
5’-TCCTCGTGCTTTACGGTATC-3’
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Table 2.48: RT-PCR Primers I
Name Sequence Product size
Activin-A 5’-AGGACCTGTACCCAACAAC-3’ 195 bp
5’-ACATCTGCTGGAAGGTGGAC-3’
cEBP/β 5’-CAAGCTGAGCGACGAGTACA-3’ 157 bp
5’-CAGCTGCTCCACCTTCTTCT-3’
Culin 2 5’-TGGCAGTTCTTCTTGCCTTT-3’ 243 bp
5’-GTGGCGTATCCTTCTGCATT-3’
Cyclin A1 5’-GAGAGGGAAATTGCAGCTTG-3’ 240 bp
5’-TCAGTCCTGATGCACACTCC-3’
Cyclin D1 5’-AGTGCGTGCAGAAGGAGATT-3’ 238 bp
5’-CACAACTTCTCGGCAGTCAA-3’
Fgf 1 5’-GGACACCGAAGGGCTTTTAT-3’ 151 bp
5’-ACAGCTCCCGTTCTTCTTGA-3’
Foxo3a 5’-GGGAGTTTGGTCAATCAGA-3’ 193 bp
5’-GCCTGAGAGAGAGTCCGAGA-3’
H2aX 5’-TACCTCACTGCCGAGATCCT-3’ 192 bp
5’-GCTCTTCTTGGGCAGCAG-3’
HP1β 5’-AGCGCAAAGCTGATTCTGAT-3’ 265 bp
5’-GAATGCCACGTTAGCCTTTC-3’
HP1γ 5’-GAGATGCTGCTGACAAACCA-3’ 189 bp
5’-GCTCCTCGTAGAAGGCAATG-3’
Jumonji 2B 5’-AAGGCTGAGGAGGAGAGGAG-3’ 215 bp
5’-CCCTGTGAAGGTAGCAGCTC-3’
Lsp 1 5’-CCTGAACCGCTCCATTAAAA-3’ 358 bp
5’-AGTGGCCACGAACTTGTACC-3’
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Table 2.49: RT-PCR Primers II
Name Sequence Product size
Myst 4 5’-ATGGGAGGCAGTATCTGTGG-3’ 465 bp
5’-TGCATAGGAGGTCACAGCAG-3’
Mei 5’-CCTGTTAATTGGGCTCCAGA-3’ 262 bp
5’-TTCACGTGAGAGGACACAGC-3’
p15 5’-TTACCAGACCTGTGCACGAC-3’ 159 bp
5’-GCAGATACCTCGCAATGTCA-3’
p16 5’-TCAACTACGGTGCAGATTCG-3’ 194 b
5’-TCGCACGATGTCTTGATGTC-3’
p19 5’-GTCGCAGGTTCTTGGTCACT-3’ 246 bp
5’-CGAATCTGCACCGTAGTTGA-3’
p21 5’-GTACTTCCTCTGCCCTGCTG-3’ 173 bp
5’-TCTGCGCTTGGAGTGATAGA-3’
p27 5’-CAGAATCATAAGCCCCTGGA-3’ 224 bp
5’-TCTGACGAGTCAGGCATTTG-3’
PAI-1 5’-AGTCTTTCCGACCAAGAGCA-3’ 209 bp
5’-ATCACTTGCCCCATGAAGAG-3’
PAN-1 5’-TCCAGAGAATGTTGCTGCAC-3’ 190 bp
5’-AGAGGGCAGCTTTTCACAAA-3’
PCNA 5’-TTGGAATCCCAGAACAGGAG-3’ 287 bp
5’-CAGTGGAGTGGCTTTTGTGA-3’
PPGB 5’-ACAGCCCCTTCCAACTACCT-3’ 243 bp
5’-GAGCGAATCCACAAACCACT-3’
SMAD 2 5’-GGAACCTGCATTCTGGTGTT-3’ 150 bp
5’-ACGTTGGAGAGCAAGCCTAA-3’
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Table 2.50: RT-PCR Primers III
Name Sequence Product size
SMAD 3 5’-CTGGGCCTACTGTCCAATGT-3’ 239 bp
5’-GCAGCAAATTCCTGGTTGTT-3’
SMAD 4 5’-AGCTCCAGCCATCAGTCTGT-3’ 188 bp
5’-GCAGGACTTCATCCAAGAGC-3’
Suv39h1 5’-CGAGTTCTTAAGCAGTTCCAC-3’ 743 bp
5’-TGCAGGTTGGGATCACAACTATGG-3’
Taf4b 5’-TGGTTGCCCTAAGACAGCTT-3’ 366 bp
5’-TCTCAGGCTGAAGGGACACT-3’
TGF-β1 5’-ATACGCCTGAGTGGCTGTCT-3’ 301 bp
5’-TTCTCTGTGGAGCTGAAGCA-3’
TGF-β2 5’-CCTTCGCCCTCTTTACATTG-3’ 250 bp
5’-TTCGATCTTGGGCGTATTTC-3’
TGF-β3 5’-GCATCCACTGTCCATGTCAC-3’ 257 bp
5’-GCGGAAGCAGTAATTGGTGT-3’
βIGH3 5’-TGACAAGGTCATTTCCACCA-3’ 384 bp
5’-GTGGCCAGGATGTCTTTGTT-3’
TBP 5’-AACAGCCTTCCACCTTATGC-3’ 681 bp
5’-CATGTTCTGGATCTTGAAGTC-3’
Primers were designed using the Primer3 program, Whitehead Istitute,
Massachusetts Institute for Technology.
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2.2 Methods
2.2.1 Mice
Breeding and maintenance
Mice recieved a standard laboratory diet and drinking water ad libitum, and
were bred and maintained under specific pathogen free (SPF) conditions at
the Animal Facility of Campus Virchow Hospital, Charite Universitätsmedi-
zin Berlin. All experiments with live animals were performed according to
the regulations of the institutional animal care.
Tumor onset monitoring
Mice were monitored for the onset of the disease every 3 days by palpation of
the peripheral: prescapular and cervical lymph nodes (LN). ”Well palpable”
lymphoma reflects LN enlargements of 5mm or more.
Statistical comparison of Kaplan-Meier curves is based on the log-rank
test. For comparisons of means and standard deviations (”s.d.” denoting a
significant P-value of < 0.05) the unpaired t-test was applied. All error bars
represent the s.d.
Peripheral blood smears
Table 2.51: Materials Used-BS
Blood smears-Materials Used
Glass slides
Scalpel
LeukostatTM kit
Blood samples were obtained by tail artery bleeding, one drop of blood
was smeared onto the glass slide and stained as follows:
Slides were submerged into the LeukostatTM fixative solution, briefly
dried, then submerged in LeukostatTM Solution I for 1 minute. Remain-
ing Solution I was removed from the slide and slide was submerged into the
LeukostatTM Solution II for 30 seconds. Post staining slides were washed in
H2O and dried for 5-10 minutes, afterwards they were examined under the
microscope.
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Table 2.52: Materials Used-DNA extr
DNA Extraction - Materials Used
Lysis Buffer
Proteinase K [20mg/ ml]
Ethanol
Isopropanol
TE buffer
DNA isolation and PCR-based determination of genotype
0.5 cm of mouse tail was cut off and incubated in 450 µl lysis buffer and 50
µl Proteinase K in a Eppendorf tube at 55OC for at least 2 hours. Post incu-
bation resulting product was spun down at maximum speed for 20 minutes
to pellet down the undigested left-overs. Supernatant was transfered into a
new tube, already containing 500 µl isopropanol, contents inside the tube
was mixed by inverting it several times. At this point DNA formed visible
precipitate, and can be ”fished out” by pipet tips and briefly washed in 75%
ethanol. Post washing DNA was briefly dried and transferred to a new tube
containing 200 µl 0.1 TE buffer.
Table 2.53: Materials Used-genotyping
Determination of Genotype- Materials Used
DNA (0.5 µg/ml)
PCR buffer
MgCl2
dNTP
Taq polimerase
Primer mix
PCR products
6x DNA loading buffer
1kb ladder
pBr marker
Agarose
TAE
Ethidiumbromide
Mice were genotyped for following modifications: Myc transgene, Suv39h1
knock-out, p53 knock-out, p16 knock-in, Arf knock-out.
PCR reactions were prepared according to the following protocol:
50
Table 2.54: Materials Used-PCR
PCR Reaction- Materials Used
10x PCR buffer (including 15mM MgCl2)
dNTP 10 mM
Taq polymerase [5U/ml]
Primer mix 1mM
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Mastermix was prepared in a volume of 24 µl per 2µl of DNA sample and
PCR reaction was run on the cell cycler as follows:
Table 2.55: PCR Reactions
Genotype tested temperature (OC) time (minutes) number of cycles
Eµ-myc 94 5 1
94 , 64 , 72 1,1,1 32
72 5 1
Suv39h1 94 5 1
94 , 55.9 , 72 0.5 , 0.5 , 0.5 35
72 10 1
p53 94 5 1
94 , 62 , 72 0.5 , 1, 1 34
72 5 1
p 16 94 5 1
94 , 62 , 72 0.5 , 1, 1 34
72 5 1
Arf 94 5 1
94 , 62 , 72 0.5 , 1, 1 34
72 5 1
Agarose gels were prepared according to the following procedure: agarose
was dissolved in 1x TAE at the desired concentration and boiled in a mi-
crowave until the agarose was completely melted.The agarose solution was
cooled down to about 50OC and ethidiumbrodmide was added to the final
concentration of 0.2 µg/ml.
Gel chamber was filled with 1x TAE and 10 µl aliquots of the PCR sam-
ples, including the corresponding amount of loading buffer were loaded into
the wells. After samples were loaded, electrophoresis was run at 120 V until
the desired resolution of DNA fragments was achieved. In order to determine
DNA size of the fragments, standard marker was used. DNA products was
visualized by UV-light, and documented by taking a photomicrograph.
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Lymphoma processing
Table 2.56: Materials Used-lymphoma
Lymphoma Processing- Materials Used
LN of the lymphoma bearing mice
Ethanol
PBS
Mouse dissection tools
Frosted glass slides
Nylon mesh
ACK buffer
Formaldehyde
Post CO2 sacrification animal was bathed in ethanol, and fixed onto the
dissection board. Mouse was opened as follows: skin along the ventral midline
from the groin to the chin was carefully cut not to damage the muscle wall
underneath.
Incision was made above the knee on both sides of the animal and skin
was reflected back. Pre-scapular, cervical and back leg LN were measured
and excised with scalpel, and placed in a dish containing sterile PBS.
Transparent peritoneal wall was cut carefully, body cavity was opened up
and reflected back to have access to the structures underneath.
Mesentheric LN was excised and measured, and other internal organs
(liver and spleen) were measured and observed for signs of pathological infil-
trations and or any abnormalities.
After removing the diaphragm on the bottom of the breast, the sternum
was opened by lifting it up with forceps and cutting along each side up to
the girdle to have access to the thoracic organs.
Thymus size was examined and peripheral blood smear was obtained by
intracardial aspiration. LN were either fixed in 4% Formalin, snap frozen in
liquid nitrogen or prepared as a single cell suspension.
LN in 1x PBS were minced between two frosted glass slides. Mixture was
filtered through a sterile 35 µm nylon mesh membrane and centrifuged at
1200 rpm for 5 minutes (4OC). To lose the reminder of the red blood cells,
pellet was resuspended in 3 ml of ACK lysis buffer and incubated at RT for
5 minutes. Before centrifugation (1200 rpm, 5 min, 4OC), 27 ml of B cell
medium were added for neutralization. Cells were either plated as a single
cell suspension on a feeder layer or frozen down in liquid nitrogen. The same
procedure applies if preparing spleen or thymus single cell suspensions.
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Lymphoma reconstitution and treatment in vivo
Table 2.57: Materials Used-reconstitution and treatment
Lymphoma Reconstitution, Treatment- Materials Used
Primary, non cultured lymphoma cells
Bcl2-transduced lymphomas
PBS
Syringe
Needle
Mouse restrainer
Cyclophosphamide (CTX)
Non-cultured or bcl2 transduced lymphoma samples were transplanted in
a pair of genetically matched, wild-type 6-10 week of age female mice by tail
vein injection. Prior to the transplantation mice were heated for 5 minutes
for the better visualisation of the tail vein. Total of 200 µl of cell suspension
(5x106 viable lymphoma cells in PBS) was transplanted per mouse.
Recipient mice were palpated for tumor formation every 3 days, and when
tumors became well palpable a single dose (300 mg/kg of body weight) of
cyclophosphamide (CTX) was administered intraperitoneally, and mice were
further monitored by palpation of the peripheral LN for treatment response.
Animal treatment in vivo
Animals were exposed to either: 0.4 mg/ml of caffeine in drinking water
starting at birth; 0.5% w/v solution of N-Acetylcysteine in drinking water
starting at birth; or 60 mg/L of lisinopril in drinking water starting at three
weeks of age.
Mice were monitored for time to tumor onset latencies, and lymph nodes
were used for the subsequent analysis.
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2.2.2 Bacterial Transformation
An aliquot of DH5α competent bacteria was thawn on ice for 5 minutes, then
100 ng of the desired plasmid was added. Mixture was left on the ice for 10
minutes, then it was transferred to 42OC for 90 seconds. After that mixture
was returned to ice for 5 minutes, then 500 µl of LB medium was added, and
left for 30 minutes at 37OC, gently shaking. Mixture was centrifuged, and
350 µl of the supernatant was removed, while bacteria were resuspended in
the rest of it, and plated on the LB-Amp agar plates.
Bacteria were allowed to form colonies overnight in 37OC.
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2.2.3 BrdU incorporation
Table 2.58: Materials Used-BrdU
BrdU incorporation- Materials Used
BrdU[10mg/ml]/FU[1mg/ml] labeling solution
4% paraformaldehyde in PBS
Xylene
Ethanol
Permeabilization buffer
Blocking solution
TBST
Syringes
2N HCl
Cell proliferation kit
anti-BrdU primary antibody
Secondary antibody
Lymphoma cells
24 hours prior to CO2 euthanasia, 10 µl labeling solution/g body weight
was intraperitoneally injected. Lymphoma cells and lymph nodes were har-
vested at the end of labeling. For BrdU detection in situ whole lymph nodes
were either fixed for 24 hours in 4% neutral buffered formalin, and later
in PBS for the long-term storage or alternatively lymph nodes were cry-
opreserved. Formalin fixed lymph nodes were paraffin embedded and sub-
sequently slides were made from samples. Deparaffinization was done as
follows: 2x 5 minutes in Xylene, 2x5 minutes in decreasing ethanol series
(95-70%), and 2x 5 minutes in PBS. For BrdU detection in suspension lym-
phoma cells were fixed for 15 min in 1 ml of 4% paraformaldehyde. Cells
were permeabilized in TBS-TritonX100 for 5 minutes at RT, and washed in
TBST. DNA was denatured with 2N HCl for 5 minutes at RT. Afterwards
cells were neutralized with 0.1M Sodium Borate for 5 minutes at RT, and
blocked with 5% bovine serum albumin. First antibody was incubated for
60 minutes, and the secondary one for 30 minutes. For tissue sections DAB
substrate was added according to the manufacturers instruction, and sections
were evaluated under the light microscopy. Cell suspensions were incubated
with the DNA staining solution for 30 minutes at RT and evaluated by flow
cytometry.
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2.2.4 Cell Culture
Adherent cell culture
NIH3T3 fibroblasts and Phoenix eco cells were used in various experiments.
Table 2.59: Materials Used-adherent cells
Adherent Cell Culture- Materials Used
DMEM medium
PBS
Trypsin
NIH 3T3 fibroblasts or Phoenix cells were seeded 50% confluent in DMEM
medium and cultivated under standard conditions (37OC, 21% O2, 5% CO2,
95% humidity) until they reached confluency. Cells were split by removing
the medium and washing with 1x PBS. Cells were deatached by adding 1ml
of trypsin at 37OC for 5 minutes. After resuspending the cells in culture
medium, cells were re-seeded in the desired density onto new cell culture
plates containing 10 ml of the fresh medium.
Table 2.60: Materials Used-feeder cells
Feeder Cell Preparation- Materials Used
NIH 3T3
DMEM medium
B-cell medium
PBS
Trypsin
Trypan blue
NIH 3T3 fibroblasts were seeded in DMEM medium and allowed to reach
70% confluency, cells were irradiated with 20Gy. 12 hours post irradiation
cells were split according to standard procedures and resuspend in fresh B cell
medium. Cell number and viability was assessed by by trypan blue exclusion.
104/cm2 of cells was seeded in a B-cell medium,and cultured under standard
conditions (37OC, 21% O2, 5% CO2, 95% humidity). 24 hours later feeder
layers were ready to use. Feeder layers were not used more than 10 days after
the irradiation, when first flattened or vacuole enrichment was observed.
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Fetal liver cells
FLCs were used for the direct transplantation experiments, with minimal
(1-2 hours) or no culturing at all.
Table 2.61: Materials Used-FLC
Fetal Liver Cells- Materials Used
PBS
Frosted slides
BCM
Breeder cages were set up to produce the genotype of interest. Females
were checked for pregnancy by vaginal plugging. Animals were sacrifised at
gestation day 14,5-15,5 by CO2 sacrification. Abdominal cavity was opened
and uterus was resected. Placenta was cut out and placed in a 10 cm2 plate
containing PBS. Maternal part of placenta was removed and embryos were
released into the PBS. Yolk sac was dissected. Head of the embryo was saved
for the further genotyping.
Liver was well visible and was isolated from the abdomen by scalpel sec-
tion. Liver was minced between the frosted slides and as a single cell sus-
pension was used for the transplantations.
DNA isolation was equal to the tail material and the follow up genotyping
PCR was as previously described.
Lymphoma cell culture
Table 2.62: Materials Used-lymphoma culture
Lymphoma Cell Culture- Materials Used
Lymphoma cells
Feeder cells (irradiated NIH 3T3)
Conditioned B-cell medium (incubating on feeder cells)
PBS
Trypsin
Trypan blue
For primary lymphoma cell culture, single cell suspension of mouse lym-
phoma was seeded (about 5 x 106 total) onto the feeder plate containing
10 ml of conditioned B cell media. Cells were cultured under the standard
conditions (37OC, 21% O2, 5% CO2, 95% humidity).
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When density of lymphoma population reached 5 x 106 cells/ ml, cells
were passaged. Also, even if cells did not reach high confluence, but the
medium changed colour from its normal red to acidic orange yellow cells
were passaged.
Passaging of primary lymphoma cells was done in either of 2 ways, mostly
depending on the quality of the feeder layer:
I by reseeding on same feeder layer
II by seeding on a fresh feeder layer
10 ml of B-cell medium containing lymphoma was centrifuged for 5 min-
utes at 1200 rpm, at 4OC, 8ml of the medium was removed and remaining 2
ml of B-cell medium with lymphoma cells inside was pasaged into new plates
containing feeder layer with 8 ml of conditioned B-cell medium.
Passaging of the cells, depending on their doubling speed, was done every
3-5 days.
Mouse embryo fibroblast (MEF) culture
Table 2.63: Materials Used-MEF
Mouse Embryo Fibroblast Cell Culture- Materials Used
0,05% TRYPSIN-EDTA
PBS
DMEM
Breeder cages were set up to produce the genotype of interest. Females
were checked for pregnancy by vaginal plugging. Animals were sacrifised at
gestation day 11,5-12 by CO2 sacrification.
Abdominal cavity was opened and uterus was resected. Placenta was
cut out and placed in a 10 cm2 plate containing PBS. Maternal part of
placenta was removed and embryos were released into the PBS. Yolk sac was
dissected, afterwards, all the red structures, representing early stages of the
internal organs and vessels were also resected. Head of the embryo was saved
for the further genotyping.
Leftover embryo was transferred to a 10 cm2 plate with trypsin inside.
Embryo was then disrupted with a scalpel and a 18G needle/syringe. After
cutting and mincing and multiple aspirations plate was incubated for 20
minutes at 37OC. Trypsin- cell suspension was resuspended by pipetting,
and suspension was placed in 10 cm2 plates, medium was added up to 10 ml.
Medium was changed the next day.
DNA isolation was equal to the tail material and the follow up genotyping
PCR was as previously described.
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MEFs were usually passaged every 2 days, when reached confluent. Pas-
sage 1 MEFs were used for the further experiments.
Cryopreserving and thawing of cells
Table 2.64: Materials Used-cryopreserving
Cryopreserving of Cells- Materials Used
Cells (all types)
DMEM
B-cell medium
Freezing medium
PBS
Trypsin
Cryo-tubes
Cryopresrving
Adherent cells:
Media was removed from the plate. Cells were washed with PBS, detached
with 1ml Trypsin and resuspend in DMEM medium, and centrifuged (1200
rpm, 5 min, RT).
Cells grown in suspension:
Cells were directly harvested from the culture plate and centrifuged (1200
rpm, 5 min, RT).
After centrifugation supernatant was removed and pellet was resuspend in
ice-cold freezing medium. Cells were frozen in the density of 2x106 cells/ml,
and transferred immediately onto dry ice (-20OC) ice and after 1 hour trans-
ferred to the liquid nitrogen for a long term storage.
60
Table 2.65: Materials Used-thawing
Thawing of Cells- Materials Used
Frozen cells (all types)
DMEM
B-cell medium
Feeder layer
PBS
Cells were thawn at 37OC for no more than 2 minutes, and dropwise
transferred to 10 ml of the respective medium. After centrifugation (1200
rpm, 5 min, 4OC), supernatant was removed and pellet was resuspend in 1 ml
of the respective medium. Cells were seeded in an appropriate cell number
on culture dishes or on feeder cells, depending on the cell type.
Flow cytometric analysis
A flow cytometric analysis was used to characterize viable/ senescent/ dead
(SSC/FSC scan or Annexin V/PI staining) cell populations, measure effi-
ciency of retroviral transduction (when GFP was used as a selectable marker)
was performed with Becton-Dickinson FACScan using 488-nm laser (emis-
sion wavelengths are FL1: 515-545 nm, FL2:564-606 nm and FL3: 650 nm).
Data were analyzed using CELLQUEST software (Becton-Dickinson), and
approximately 10 000 cellular events were counted.
Detection of senescent cells. 500,000 of each freshly prepared lymphoma
Table 2.66: Materials Used-Flow cytometry-senescence
Flow cytometry for senescence- Materials Used
Lymphoma cells
PBS
was washed and resuspended in PBS and immediately measured by forward/
side scatter on flow cytometer. Senescent cell population is bigger and more
granular, shifting in both light scatter parameters from normally viable cells
and creating a distinct subpopulation.
AnnexinV/PI protocol : cells were resuspended in 1mg/ml freshly pre-
pared dilution of Annexin V and incubated for 10 minutes at RT in the dark.
Solution of PI was added to the cells (to a final concentration of 1mg/ ml)
prior to the analysis on flow cytometer.
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Table 2.67: Materials Used-Flow cytometry-apoptosis
Flow cytometry for AnnV/PI- Materials Used
Lymphoma cells, treated or untreated with ADR
PBS
AnnexinV
Propidium Iodide (PI)
2.2.5 Immunofluorescence
Table 2.68: Materials Used-IF
Immunofluorescence- Materials Used
LN (parrafin embeded or snap frozen)
Primary lymphoma cells
Primary spleenocytes
PBS
T-PBS
Xylol
Ethanol
Fixative solution
Blocking solution
Primary antibodies
Secondary antibodies
Mounting medium
Tissue protocol
Tissues sections (8 µm thick) were processed as follows:
Paraffin embeded sections: Slides with the paraffin embeded sections were
heated at 55OC for 30 minutes, and afterwards submerged into xylol for 5
minutes, repeating this step 2 times. Following, cells were re-hydrated in the
reducing gradients of ethanol (starting at absolute ethanol, finishing at 70%
ethanol). Slides were kept for 5 minutes in each of the ethanol concentrations.
Post ethanol slides were submerged into PBS. Sections were permeabilized
in T-PBS for 30 minutes at room temperature(RT), then incubated in the
primary antibody over-night at 4OC. Slides were washed three times in PBS
and subsequently incubated in corresponding secondary antibody for 60 min-
utes (RT) in dark. Final washing was in T-PBS (3x 15 min), and slides were
mounted and fluorescence was detected under the microscope immediately.
62
Frozen tissues:
Tissues were fixed in 1-2 % Paraformaldehyde/Glutaraldehyde mix for
10 minutes (4OC), slides were washed in PBS/ MgCl2 and stained for the
β-galactosidase activity for 6-8 hours.
Cell protocol:
Cells were either thawn or harvested at the appropriate time point from
the culture or the tumor-bearing animal, centrifuged (1200 rpm, 5 min, 4OC)
and washed PBS. Cell number and viability was assessed by trypan blue
exclusion. 500µl were transferred to a slot of the cytospin plastic and cen-
trifuged at 700 rpm for 8 minutes (15OC). Supernatant was carefully removed
by aspiration and cells were fixed by a freshly prepared fixation solution. Af-
ter incubation (15 minutes, RT), slides were washed three times in PBS and
permeabilized in T-PBS for 30 minutes (RT). Cells were incubated in the
first antibody over-night at 4OC. Slides were washed three times in PBS and
subsequently incubated in corresponding secondary antibody for 60 minutes
(RT) in the dark. Cells were washed in T-PBS (3x 15 min), and slides were
mounted and fluorescence was detected under the microscope immediately.
Alternatively cells were fixed in the 1-2% Paraformaldehyde/Glutaraldehyde
mix for 10 minutes (4OC), then washed in PBS/MgCl2 and stained for the
β-galactosidase activity for 6-8 hours.
2.2.6 Immunophenotyping
Table 2.69: Materials Used-IPh
Immunophenotyping- Materials Used
Primary lymphoma cells
Primary spleenocytes
Primary thymocytes
PBS
FITC or PE-conjugated antibodies
Flow cytometer
106 primary lymphoma cells as well as the spleenocytes and thymocytes
(antibody-controls) were centrifuged (1200 rpm, 5 min, 4OC) and washed in
PBS. Antibodies were diluted in 100 µl PBS, and cell pellet was resuspend
in the staining mixture, and incubated for 30 minutes on ice in the dark.
Post staining cells were thoroughly washed in PBS, filtered through a 35 µm
nylon mesh and transferred on ice for immediate analysis by Flow cytometry.
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2.2.7 Mitotic Trap
Table 2.70: Materials Used-mitotic trap
Mitotic trap- Materials Used
Lymphoma cells
Nocodazole
H3S10P antibody
4% paraformaldehyde
TBS-TritonX-100
PBS
Flow cytometer
Eµ-myc and Eµ-myc, Suv39h1−/− cells were freshly isolated and sub-
jected to 100µM of Nocodazole for 0, 3, 6 and 9 hours. After the exposure
cells were immediately fixed in 4% formaline (15 minutes, RT), permeabilized
in TBS-tritonX-100 (10 minutes, RT) and stained for the phosphorylated ser-
ine 10 residue on the Histone H3 (H3S10P; 1 hour, RT), washed two times
with PBS and stained for secondary, fluorescent conjugated antibody (1 hour
at RT), and analyzed by flow cytometry.
2.2.8 Reactive oxygen species quantification
Table 2.71: Materials Used-ROS
ROS quantification- Materials Used
Lymphoma cells
DCF
PBS
Flow cytometer
Eµ-myc lymphoma cells from untreated and N-Acetylcysteine treated
mice were quantified for the reactive oxygen species (ROS) by exposure to the
2’7’- dichlorofluorescein (DCF), and flow cytometric analysis. DCF positive
cells were visualised by immunofluorescence.
2.2.9 Retroviral Transduction
Phoenix cells transfection
Phoenix cells were grown in a 10 cm2 plate to a maximal density of 70%.
20µg retroviral plasmid DNA, 15µg helper plasmid DNA and 62.5µl CaCl2
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Table 2.72: Materials Used-retroviral Transduction
Retroviral Transduction- Materials Used
Phoenix cells (low passage)
Primary lymphoma cells
NIH 3T3
MEF
B-cell medium
Feeder layer
PBS
Retroviral plasmid DNA
Ecotropic plasmid helper DNA
H2O
CaCl2
HBS
Glass pasteur pipettes
Chloroquine
Polybrene
Puromycin
Blasticidin
Hygromycin
FLOW equipment
were mixed and adjusted with sterile water to 500µl. 500µl of HBS was
added dropwise under constant agitation (air bubbles). Precipitate became
visible within 5 minutes at RT. Meanwhile, old medium of Phoenix cells was
exchanged for 9 ml of conditioned B-cell medium containing 25 mM Chloro-
quine and the precipitate (1 ml) was added dropwise. Cells were cultured
under the standard conditions (37OC, 21% O2, 5% CO2, 95% humidity).
Retroviral transduction
12 hours post phoenix cells transfection medium including the precipitate was
removed. Cells were washed carefully with 1x PBS and 3 ml of conditioned
B cell medium or a fresh DMEM (depending on the desired cell type to be
transduced) was added to collect the first virus supernatant in the next 24
hours, post collection virus supernatant was filtered through a 0.45 µm filter.
Adherent cells:
Media was removed from the plate. Cells were washed with PBS, and
covered with 3 ml of the medium containing virus supernatant including
polybrene.
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Cells grown in suspension:
Viable and well growing cell population was pelleted by centrifugation
(1200 rpm, 5 min, RT) and resuspended in the virus supernatant including
polybrene.
New medium (3 ml) was added to the Phoenix cells for the next round of
transduction. After 8-12 hours of incubation, the second virus supernatant
was harvested and added according to the upper mentioned procedure to the
adherent or lymphoma culture with the first supernatant.
Cells were then spinoculated (1500 rpm, 10 min, 32O) and grown for the
next 8-12 hours. New medium (3 ml) was added to the Phoenix cells for the
next round of transduction.
The third and forth virus supernatant was collected after 8-12 hours, and
proceeded according to the first two prior described rounds of transduction.
12 hours post last transduction, medium was removed from the cells, and
replaced with the new conditioned B-cell medium or DMEM, according to
the cell type.
Cells were grown for an additional 24 hours in order to express the gene of
interest. For cells transduced with GFP (green fluorescent protein)-plasmids,
percentage of positive cells was determined by Flow cytometry, while for cells
transduced with an antibiotic marker (puromycin, hygromycin or blasticidin),
the cell population was selected with puromycin or blasticidin (for 3-4 days)
and hygromycin (5 days) until non-transduced cells were no more viable.
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2.2.10 RNA
Isolation
For RT-PCR:
Total RNA from the mouse lymph nodes was isolated with TRIZOL (In-
vitrogen) according to the manufacturers protocol. 106 cells were pelleted
by centrifugation in centrifuge at 12,000g, 10 minutes at 4OC. It was fol-
lowed by lysing in 1 ml of TRIZOL reagent. Upon adding of Trizol samples
were incubated for 5 minutes (RT), which permited complete dissociation
of nucleoprotein complexes. 200 µl of chloroform were added to each sam-
ple. tubes were shaken vigorously by hand for 15 seconds and incubated for
3 minutes (RT). Afterwards samples were centrifuged at 12,000 x g for 15
minutes at 4OC. Following centrifugation, the mixture separated into a lower
red, phenol-chloroform phase, an interphase, and a colorless upper aqueous
phase. RNA remains exclusively in the aqueous phase.
Aqueous phase was transferred to a fresh tube, and RNA was precipitated
by mixing with 500 µl of isopropyl alcohol. Samples were incubated at RT
for 10 minutes and centrifuged at 12,000 x g for 10 minutes at 2 to 8OC.
Supernate was removed and RNA pellet was washed once with 1 ml of 75%
ethanol. Sample was mixed by vortexing and centrifuged at 7,500 x g for 5
minutes at 4OC. RNA pellet was briefly air-dried (5-10 minutes). RNA was
dissolved in RNase-free water(DEPC-mqH2O) and incubated for 10 minutes
at 55OC.
For microarray and semi-quantitative-RT-PCR:
Prior to lysing 5x106 cells were washed once in PBS, then lysed in 2 ml
of RLT buffer, and immediately homogenized by passing 10 times through
18 gauge needle with syringe. 2ml of 70% ethanol was added and mixed
thoroughly.Samples were transfered to RNeasy Midi column in 15ml tube,
and centrifuged at 3000 x g for 5 minutes; flow-through was discarded and
4ml of buffer RW1 was added onto the column. Columns were centrifuged at
3000 x g for 5 minutes; flow-through was discarded, 10 µl of DNAse I stock
solution together with 70 µl of RDD buffer was added to the membrane, and
incubated at RT for 15 minutes, 800 µl of the buffer RW1 was added and
columns were eluted by centrifuging at 300 x g for 5 minutes, afterwards
flow-through was discarded. Following this, 2.5ml of buffer RPE was added
onto the column, and centrifuged at 3000 x g for 2 minutes; flow-through
was discarded. Again, 2.5ml of buffer RPE was added,and samples were
centrifuged at 3000 x g for 5 minutes; flow-through was discarded. RNeasy
Midi column was transferred to clean 15ml tube, and 150 µl of RNAse free
H20 was added, and incubated for 1 minute at RT. RNA was eluted by
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centrifuging at 3000 x g for 3 minutes. At the end 260/280 O.D was measured.
And 1 µg of the samples was run on the denaturising gel to visualise RNA 28
S and 18 S bands, while 5S band was not visible due to the Rneasy column
cleanup.
2 µl of the total RNA was used for the cDNA synthesis.
cDNA synthesis
Table 2.73: Materials Used-cDNA synthesis
cDNA synthesis- Materials Used
RNA extracted from lymphoma or spleenic B-cells
Random hexamere (500 ng)
DEPC-mqH2O
5x first strand buffer
0.1 M DTT dNTP mix (10 mM each)
1 U RNasin (RNAse inhibitor enzyme)
200 U Superscript Reverse Transcriptase II [SSRT-II]
2 µg of RNA and 1µl of random hexamere primer were mixed and volume
was adjusted to 10 µl with DEPC H2O. In order to destroy secondary RNA
structures samples were incubated for 10 minutes at 70OC, and subsequently
stored on 4 OC. For each sample following cDNA synthesis mix was prepared:
4 µl of the first strand buffer, 1µl of DTT, 1.5µl of dNTP and 1.5µl of RNAsin.
Mix was added to each sample and incubated for two minutes on 42 OC, and
then 2 µl of SSRT-II was added to each sample and incubated for further
58 minutes. Reaction was stopped by incubating samples on 70 OC for 15
minutes; samples were stored at 4 OC for the short term storage (up to one
day) or -20 OC for the long term storage.
2.2.11 Short Term (24 hours) Cytotoxicity Assay
Table 2.74: Materials Used-cytotoxicity Assay
Short term cytotoxicity assay- Materials Used
Lymphoma cells
Adriamycin
Trypan blue solution (diluted in PBS)
Neubauer counting chamber
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Eµ-myc; Eµ-myc, Suv39h1−/− and Eµ-myc p53 −/− cells were seeded
onto feeder layers at a density of 250 000 cells/ cm2. 12 hours later cells were
exposed to 0, 0.001, 0.005, 0.01, 0.05 and 0.1µg/ml adriamycin (ADR), and
after 24 hours percentage of surviving cells was generated using trypan blue
dye exclusion method (at least 200 cells, both dead and alive) were counted
per each sample.
2.2.12 TGFβ ELISA
Table 2.75: Materials Used-TGF β ELISA
TGF β ELISA- Materials Used
Lymphoma cells
PBS
Quantikine commercial TGFβ ELISA kit
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Eµ-myc and Eµ-myc, Suv39h1−/− cells were seeded onto feeder layers at
a density of 250 000 cells/ cm2 for 5 days. Supernatant was collected and
processed according to the manufacturers (Quantikine) instructions. Eµ-
myc and Eµ-myc, Suv39h1−/− lymph nodes were resected, weighed, placed
in 200 µl PBS and the tissue was disrupted by ultrasonic homogenisator.
Supernatant was collected and processed according to the manufacturers
(Quantikine) instructions.
2.2.13 TGFβ treatment
Table 2.76: Materials Used-TGFβ treatment
TGFβ treatment- Materials Used
Lymphoma cells
TGFβ-1
Trypan blue solution (diluted in PBS)
Neubauer counting chamber
Lyophilized purified human TGFβ-1 was prepared according to manu-
facturers instructions. Eµ-myc and Eµ-myc, Suv39h1−/− cells were seeded
onto feeder layers at a density of 250 000 cells/ cm2. One day later cells
were exposed for 24 hours (for the RNA isolation), or alternatively for 5 days
to 0, 10, 100 and 1000 pM TGFβ Post treatment percentage of surviving
cells was generated using trypan blue dye exclusion method (at least 200
cells, both dead and alive) were counted per each sample. Eµ-myc/bcl2;
Eµ-myc, Suv39h1−/−/bcl2; Eµ-myc, p53 −/−/bcl2 and Eµ-myc, Arf−/−/bcl2
cells were seeded onto feeder layers at a density of 250 000 cells/ cm2. One
day later cells were exposed for 5 days to 0, 10, 100 and 1000 pM TGFβ. Post
treatment percentage of surviving cells was generated using trypan blue dye
exclusion method (at least 200 cells, both dead and alive) were counted per
each sample. Wild type and Suv39h1 mouse embryo fibroblasts were stably
retrovirally transduced with pBabe-MycER-puro plasmid and selected for
the puromycin resistant clones. Post selection cells were treated with 100
pM TGFβ.
2.2.14 Trypan blue dye exclusion method
Cell viability estimates were obtained by briefly mixing lymphoma cells with
trypan-blue dye (30µl of lymphoma cell suspension with 30µl of trypan-
blue reagent) and placed on Neubauer hemacytometer, observed under the
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Table 2.77: Materials Used-dye exclusion method
Trypan blue dye exclusion method- Materials Used
Lymphoma cells
Trypan blue solution (diluted in PBS)
Neubauer counting chamber
microscope and counted. Counting for each lymphoma population was done
in triplicate.
2.2.15 Western blot
Preparation of SDS-PAGE gel: glass plates were cleaned well with ethanol
before they were set in the casting apparatus.
Gel mixture was vortexed and casted between the fixed and closed glass
plates. 2-propanol was added on top of the casted gel in order to prevent
evaporation. Upon polimerization 2-propanol was removed from the gel.
Mixture was vortexed and casted between the fixed and closed glass
plates, on top of the separating gel, comb was inserted. After polymerization
comb was removed, slots were rinsed with mqH2O and the gel was inserted
into the gel running apparatus.
Protein isolation (whole cell protein extracts): cells were once washed in
1x PBS and centrifuged at 1200 rpm for 5 minutes (RT). Cell pellet was
resuspend in protein lysis buffer (vol=3x volume of cell pellet) and incu-
bated 40 minutes on ice. To separate cell debris from proteins, lysates were
centrifuged (14.000 rpm, 20 minutes, 4OC) and supernatant containing the
proteins was transferred to a new tube. Protein concentration was deter-
mined by a standard Bradford assay and aliquots were kept at -80OC for the
long term storage. Protein measurement (Bradford«s protein micro-assay).
A ready-to-use Bradford solution was prepared by diluting Bradford reagent
1:4 with H2O using 1 ml per cuvette and sample. A BSA standard curve was
set up in the following concentrations: no BSA, 1, 2, 4, 6, 8 and 10 mg BSA
including each 1 µl of the protein lysate (corresponding to the volume of the
protein lysate that is measured afterwards). To create a standard curve, the
absorbance of the individual BSA-samples were determined in a photome-
ter at a wavelength of 595 nm against the mock control. Standard curve
appeared in a linear regression (R2 values close to 1.0). For the individual
protein lysates, each 1 ml was pipetted to 1 ml of the pre-diluted Bradford
solution and measured in accordance to the standard curve. Preparation of
the protein samples: protein samples were thawed on ice. Volume for the
desired protein concentration was calculated and the respective amount of
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Table 2.78: Materials Used-Western blot
Western blot- Materials Used
Lymphoma cells
MEFs
Protease inhibitors
Protein lysis buffer
RotiQuant
BSA
Tris-HCl [pH 6.7]
Tris-HCl [pH 8.8]
Acrylamide-bis
SDS
TEMED
2-propanol
Methanol
Running buffer
Roti-prestained marker
Hybond ECL
Whatman paper
TBS-T
Blocking solution
Primary antibodies
Secondary antibodies
Supersignal West pico
Kodak X-O-mat films LS
loading buffer (sample buffer) was added before the samples were boiled for 10
minutes at 95OC. Running the gel: gel apparatus was filled with 1x running
buffer. 100 µg of boiled protein samples were loaded into the slots using 15µl
of a molecular weight standard (Rotimark Prestained) as a marker. Gel was
started at a voltage of 60 V until dye front reached the front of the separating
gel. Gel was run at a voltage of 150 V until dye front was close to the bottom.
After disassembling the gel apparatus, stacking gel was carefully removed and
separating gel was immediately used for further blotting. Semi-dry blotting
procedure: a Hybond ECL blot membrane and six pieces of Whatman paper
were cut in the size of the gel and semi-dry blotting chamber was cleaned.
Membrane was activated with methanol for a few seconds, rinsed with H2O
and soaked in transfer buffer. A semi-dry blotting ”sandwich” was set up
in the following order: 3 Whatman papers, Activated blot membrane, Gel,
3 Whatman papers. Air bubbles were removed and the ”sandwich” was
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Table 2.79: Materials Used-separating gel
Separating- Materials Used
mqH2O
30% Acrylamide
Tris pH 8,8
SDS
APS
TEMED
Table 2.80: Materials Used-stacking gel
Separating- Materials Used
mqH2O
30% Acrylamide
Tris pH 6,7
SDS
APS
TEMED
blotted for 60-180 minutes and 0.8 mA each cm2 gel. Afterwards, blotting
apparatus was disassembled membrane was labelled. Antibody incubation:
labelled membrane was blocked for 30 minutes at RT in blocking solution
under gentle agitation. Meanwhile, the first antibody was diluted in an ap-
propriate concentration. Membrane was incubated either 4 hours (RT) or
over night (4OC) under gentle agitation. Afterwards, membrane was washed
3x 5 minutes in washing buffer. Subsequently, membrane was incubated for
60 minutes in the corresponding secondary antibody (RT) under gentle agi-
tation followed by three washing steps (3 x 15 minutes). Two components of
the ECL detection kit were diluted 1:1 in the dark and transferred onto the
wet membrane. After 5 minutes, membrane was wrapped in a transparent
cover and put into a cassette. Membrane was exposed to an X-O-Mat LS film
for 5-30 minutes, depending on the individual antibodies and the amount of
protein.
Chapter 3
Results
3.1 Tumor development
3.1.1 Animal models used and main breeding setting
To assess the role of Suv39h1 in Myc-driven lymphomagenesis male Eµ-myc
mice were bred to female Suv39h1 +/− and Suv39h1−/− mice (Figure 3.1).
Both of the mouse strains were bred in a C57BL/6 background. Approxi-
mately 3 weeks after birth offspring was separated and genotyped using stan-
dard protocol procedures described in the method section. Since Suv39h1 lo-
cus is X-linked, Suv39h1 heterozygous mice can only be Suv39h1+/− female
mice. Mice deficient for a functional Suv39h1 can be Suv39h1 −/y (male) or
Suv39h1 −/− (female). Cohorts of mice were monitored for tumors every three
days by palpation of the peripheral lymph nodes, starting at approximately
three weeks post birth. Also, animals were observed for any sign of sickness,
like severe weight loss and hyperventilation. When scored as palpable (P) or
well palpable (PP) in two consecutive times animal was sacrificed and lymph
nodes, spleen, liver and thymus were extracted. Cells from lymph nodes and
spleen were isolated as described in the method section. From each animal
one lymph node was fixed in the 4% formaldehyde for immunohistochemistry
assays on paraffin embedded sections, and one lymph node was immediately
frozen in liquid nitrogen for subsequent enzymatic assays. Other isolated
organs were fixed in 4% formaldehyde. Isolated lymphoma cells, as well as
the lymph nodes were used for all the subsequent experiments. All of the
animal experiments described in this thesis were in accordance with animal
welfare protocols.
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Figure 3.1: Breeding outline. Eµ-myc mice were bred to mice bearing tar-
geted genetic lesions in the Suv39h1 locus. Mice were monitored for tumor
latencies by palpation of peripheral lymph nodes every 3 days. When animal
developed a tumor (depicted as pre scapular and cervical lymph node in red)
scored palpable (P) or well palpable (PP) in two consecutive palpations (3
days apart each) it was sacrificed and lymphoma cells were isolated and used
in subsequent experiments.
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3.1.2 Phenotypic characteristics of Myc-driven lym-
phomas with different Suv39h1 status
Histology and hematology of Myc-driven lymphomas
Histological examinations at terminal stages of disease in both Suv39h1 pro-
ficient and deficient Eµ-myc animals showed lymphoma exhibiting the same
grade of aggressiveness. Hematoxylin and eosin (HE) staining in lymphoid
as well as non-lymphoid organs revealed that in both cohorts dissemination
of lymphoma is not overtly different (Figure 3.2: done in collaboration with
C. Loddenkemper et al).
Eµ-myc      
Suv39h1+/+
            
Eµ-myc      
Suv39h1-/-
     Lymph node                 Spleen
            Liver                        Thymus                 Bone marrow  
Eµ-myc      
Suv39h1+/+
            
Eµ-myc      
Suv39h1-/-
Figure 3.2: Histopathology of Myc- driven lymphomas does not differ be-
tween Suv39h1 proficient and deficient lymphomas. Hematoxylin and eosin
(HE) staining of representative organs affected by Myc-driven lymphoma re-
vealed no overt differences in lymphoma infiltration rates between Suv39h1
proficient and deficient animals (n=3 for each genotype done in collaboration
with C. Loddenkemper et al).
Further hematological examination, by testing blood smears of mice at
the stage of terminal disease revealed lymphatic cell infiltration, occuring
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frequently in Myc overexpressing lymphomas, with equal distribution in both
genotypes (Figure 3.3).
Eµ-myc, Suv39h1+/+                                                       Eµ-myc,Suv39h1-/-
Figure 3.3: Mice of both genotypes show equal extent of immature lympho-
blast cell infiltration. Peripheral blood samples obtained from both Suv39h1
proficient and deficient animals were stained according to Wright’s staining
protocol. Staining revealed drastic increase in the immature lymphoblastic
cell population (dark purple cells) in both genotypes (note: in healthy mice
number of lymphoblastic cells per vision field should not exceed 1). Inlay:
magnified image of blood smear (lymphoblastic cell population is belonging
to larger and light blue cells).
Concluding from the histological and hematological examinations no overt
differences were found in the lymphoid infiltrations of Eµ-myc tumor bearing
animals in Suv39h1 proficient and deficient lymphomas, indicating similar
phenotype of invasiveness.
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Immunophenotypical characteristics of Myc-driven lymphomas
Myc transgenic animals develop B-cell lymphomas without any differentia-
tion block, therefore in order to test for the lineage comitment as well as for
the differentiation status in lymphomas deficient for Suv39h1 gene freshly
prepared single cell suspensions from lymph node tissues were stained for B
cell immunological markers (CD45R [B220] surface IgM [sIgM] and CD19),
as well as for a T-cell marker (CD90.2 [Thy1.2]) and a marker for myeloid
cells (CD11b [Mac-1]). Wild-type lymph node, thymus, spleen and periferal
blood were used as controls for B-cell, T-cell, B- and T-cell mixed population
and myeloid marker respectively. Viable fraction of lymphoma cells could be
diferentiated from dead cells and cellular debris having lower forward/ side
scatter parameters, on the basis of foward/ side scatter analysis viable pop-
ulation of lymphoma cells was further plotted in a dot-plot according to the
parameters set by controls (Figure 3.4 shows representative pictures, exper-
iment was conducted on 10 different lymphomas from each genotype).
Analysis revealed that both groups are commited to the B cell lineage (as
seen by positivity for B-cell markers CD45R and CD19, and negativity for
the T-cell marker CD 90.2). Further by assesing differentiation attributes
it is shown that lymphomas of both backgrounds are equally distributed
between pre-B cell (early; sIgM negative) and immature- B cells (late; sIgM
positive) B cell lymphomas (Eµ-myc were 45,45% sIgM positive; Eµ-myc
Suv39h1−/− were 40% sIgM positive). Only one Eµ-myc lymphoma case
had both sIgM positive and sIgM negative B-cells. Additionally, lymphomas
tested using a myeloid marker (CD11b) show indistinguishable phenotype in
both genotypes ( <5% CD11b positive cells in both of the genotypes).
Results shown above confirm that there are no immunophenotypical dif-
ference in the two tested genotypes. They are belonging to B-cell lymphomas
with no visible maturation defect.
Level of c-Myc expression in Myc-driven lymphomagenesis
The expression of c-Myc, as well as Myc’s target CDK4 was tested in cells
extracted from lymph nodes of animals at terminal stages of disease. Proteins
extracted from the whole cell lysates of lymph nodes (4 different animals
each genotype) were tested in a Western blot analysis for c-Myc and CDK4
expression levels (Figure 3.5).
Results show that loss of Suv39h1 does not alter level of Myc expression,
nor it blocks Myc-induced signaling as seen by no impact on the expression
of Myc’s target CDK4.
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Figure 3.4: Suv39h1 proficient and deficient Myc-driven lymphomas display
similar immunological phenotype. Immunophenotypic analysis of lymphoma
cells extracted from lymph nodes of animals belonging to Eµ-myc and Eµ-
myc, Suv39h1−/− or−/y revealed no overt differences. Two-color flow cytome-
try of lymphoma populations for B-cell markers (CD45R-PE [Phycoerythrin
excitation laser 488nm, peak emission 575 nm, detected in FL2 channel] and
CD19-PE) and T-cell marker (CD90.2-FITC [Fluorescein-Isothiocyanat-exci-
tation laser 488nm, peak emission 518 nm, detected in FL1 channel]) revealed
that both lymphoma groups are committed to the B-cell lineage. Two-color
flow cytometry of lymphoma populations for B-cell marker (CD45R-PE) and
a B-cell differentiation marker (sIgM-FITC) revealed that both of the lym-
phoma groups belong to the same stages of B-cell development. Flow cytom-
etry for the myeloid marker (CD11b) revealed similar distribution in both
lymphoma genotypes [Wild-type thymus was used as a positive control for
the CD90.2 staining, wild-type lymph nodes were used as a positive control
for the CD45R and CD19 stainings, wild-type spleen was used as a posi-
tive control for both CD90 and CD45R staining and peripheral blood from
wild-type mice was used as a positive marker for CD11b staining].
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Figure 3.5: Myc is equally expressed in lymphoma belonging to both Suv-
39h1 proficient and deficient group of Eµ-myc transgenic mice. Western blot
analysis of lymphoma cells extracted from lymph nodes of animals with in-
tact and disrupted Suv39h1 gene. TOP: c-Myc expression, MIDDLE: CDK4
expression and BOTTOM: Tubulin expression (used as a loading control) in
Eµ-myc (n=4) and Eµ-myc, Suv39h1−/− (n=4).
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Impact of Suv39h1 loss on Myc-driven lymphomagenesis
The offspring from cross of Eµ-myc and Suv39h1 knock-out mice was mon-
itored for tumor latencies. As shown in here, Suv39h1 loss has a significant
impact on acceleration of the Myc-driven lymphomagenesis.
Eµ-myc mice, with no additional targeted genetic lesions (referred to as
controls, n=93) succumbed to lymphoma with a median age of 144 days,
while mice lacking one (Eµ-myc, Suv39h1+/−; n=41) or both Suv39h1 alleles
(Eµ-myc, Suv39h1−/−; n=31) developed lymphomas at a median age of 54
and 57 days respectively (P <0,0001). Interestingly, lymphomas developing
in Eµ-myc, Suv39h1+/− and Eµ-myc, Suv39h1−/− animals share virtually in-
distinguishable tumor latencies (P=0,4634). Kaplan-Meier ”Time-to-tumor-
onset” latencies plot is shown in figure 3.6.
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Figure 3.6: Defects in Suv39h1 accelerate Myc-lymphomagenesis. Kaplan--
Meier ”Time-to-tumor-onset” latencies of Eµ-myc (n=93, black line); Eµ--
myc, Suv39h1 −/− (Suv39h1 −/− and −/y, n=31; red line); Eµ-myc, Suv39h1
+/− (n=41, blue line).
Results shown here reveal that loss of gene implicated in epigenetic si-
lencing, and mediating Ras-induced senescence provides growth advantages
81
for lymphomas arising in environment with overexpressed Myc. As Myc is
primarily utilizing apoptosis as a program to terminate malignant cell out-
growth, this finding provided an interesting addition to the network of Myc’s
action. Results of in vivo Myc lymphomagenesis shown in here had 2 major
points: Suv39h1 plays an important role in Myc-driven lymphoma forma-
tion; additionally lymphomas arising in Suv39h1+/− background follow the
same latency pattern as Suv39h1−/− lymphomas, and both of the findings
provided to be of importance for the further research.
In Suv39h1+/− setting Myc-lymphomas are composed of cells which
have randomly inactivated intact Suv39h1
Parallel to the observation that Suv39h1 deficiency accelerates Myc driven
lymphoma formation, it was also found that Suv39h1−/− and Suv 39h1+/−
animals share identical tumor latency (Figure 3.6). This finding could be ex-
plained through deregulation in several mechanisms: either intact Suv39h1 is
necessary for full Suv39h1 function, similar to many haploinsufficiency mod-
els. However the important difference in this model is that one of Suv39h1
alleles will be inactivated via random X-chromosomal inactivation, normally
occuring in cells. In this respect it is only possible that Myc expressing
cells acquire additional growth advantages when Suv39h1 is absent. Hence,
when Myc is overexpressed in cells which have inactivated allele with the
intact Suv39h1 they will accumulate faster than cells still containing intact
Suv39h1, as seen in tumors developed in Suv39h1+/− mice. In order to test
this hypothesis Suv39h1 mRNA expression levels of Suv39h1+/+, Suv39h1+/−
and Suv39h1 −/− lymphomas were evaluated by an RT-PCR approach. In
all of the tested cases (5/5 for Suv39h1+/−) there was no detectable Suv39h1
transcript, showing invariable loss of the Suv39h1 expression occuring in Eµ-
myc Suv39h1+/− lymphomas (Figure 3.7).
Loss of Suv39h1 in a course of Myc-driven lymphomagenesis provides
growth advantage for tumor cells, as seen by shortened tumor latencies in
figure 3.6. Additionally, as shown in figure 3.6 and figure 3.7 favourable
environment for the faster development of Myc-driven lymphoma will be one
without expression of Suv39h1, directly pointing out to an in vivo tumor
suppressive role of Suv39h1.
Proliferation of cells in Myc-driven lymphomagenesis
In accordance with results shown previously revealing the tumor suppressive
potential of Suv39h1 (as seen by the shortened tumor latencies when Suv39h1
is disrupted), the contribution of Suv39h1 loss to proliferation rates was
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Suv39h1
TBP
  Eµ-myc;                                            Eµ-myc;                                                Eµ-myc;
Suv39h1-/-                                       Suv39h1+/-                                           Suv39h1+/+
Figure 3.7: Myc-driven lymphomas develop in a setting where remaining
Suv39h1 allele was inactivated via random X-chromosomal inactivation. RT-
PCR analysis. TOP: Suv39h1 mRNA status in Myc driven lymphomas
was assessed in Suv39h1−/− (n=1); Suv39h1+/− (n=5); Suv39h1+/+ (n=2).
BOTTOM: TBP (TATA-box binding protein) mRNA status was used as a
loading control.
tested.
For that purpose the cell cycle marker Ki67 in situ (Ki67 antigen is a
cell cycle related nuclear protein expressed by proliferating cells in all phases
of the active cell cycle [S, G2, M, G1]; done in collaboration with C. Lo-
denkemper et al) was employed on lymph nodes from manifest lymphomas.
This staining was also employed on a single cell lymphoma population by
immunofluorescence and flow cytometric analysis (as a negative control in
the flow-cytometry assay G1 arrested NIH 3T3 cells were used, figure 3.8).
As shown by the staining there is a larger fraction of Ki67 positive cells in
Eµ-myc, Suv39h1−/− lymphomas (89,4 ± 5,2%) when compared to the Eµ-
myc lymphomas (76,4 ± 7,7%; P=0,0096). Difference observed here could
provide an explanation to shortened tumor latencies found in mice bearing
defects in Suv39h1 gene. Maintaining approximately 15% more of cells ac-
tively participating in the cell cycle would ensure Suv39h1 deficient animals
develop tumors significantly faster then Suv39h1 proficient animals.
Approach alternative to Ki67 in situ staining is incorporation of 5-bromo-
2’- deoxyuridine (BrdU a synthetic thymidine analogue that incorporates into
the newly synthesised DNA strands of actively proliferating cells) in tumor
bearing mice. BrdU was used together with 5-fluoro1H-pyrimidine-2,4-dione
(FU, blocker of thymidine synthase) incorporation in vivo protocol (for more
detail please see method section 2.2.3) in order to analyze the proliferative
capacity of lymphoma cells. Lymphoma bearing mice of Suv39h1 proficient
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Figure 3.8: Suv39h1 −/− lymphomas display more cells in cycle. LEFT:
Assesment (done in collaboration with C. Lodenkemper et al) and quan-
tification of Ki67 stainings in situ in Eµ-myc (n=9), Eµ-myc Suv39h1−/−
(n=7) lymphomas. RIGHT: Flow cytometric analysis based on Ki67 assess-
ment in Eµ-myc (n=18) and Eµ-myc Suv39h1−/− (n=11), and subsequent
immunofluorescent Ki67 analysis of lymphoma cells in Eµ-myc (n=18) and
Eµ-myc Suv39h1−/− (n=11) [20 Gy γ-irradiated 3T3 cells were used as a
Ki67-negative control for the flow cytometric analysis and immunofluores-
cence staining].
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and deficient background were injected intraperitoneally with a single dose
of BrdU/FU mixture and sacrificed after 24 hours. Lymph nodes and single
cell extracts were subjected to further analysis. BrdU positivity was ass-
esed in a whole lymphoma single cell suspension by flow cytometry analysis
(Figure 3.9).
Eµ-myc; Suv39h1+/+ 
or 
Eµ-myc; Suv39h1-/-
BrdU 
[proliferation]
24 hours
BrdU
Eµ-myc; Suv39h1+/+ Eµ-myc; Suv39h1-/-
Figure 3.9: Suv39h1 deficient mice display more cells in cycle in vivo. TOP:
Eµ-myc (n=3); Eµ-myc Suv39h1−/− (n=3) lymphoma bearing mice were in-
jected intraperitonealy with 100 mg/kg of body weight BrdU and 10 mg/kg
of body weight FU mixture and sacrificed after 24 hours. Lymphoma cells
were isolated and subjected to the analysis of BrdU incorporation. BOT-
TOM: quantification of BrdU incorporation in vivo by flow cytometry anal-
ysis, plotted as relative to values for Suv39h1−/− lymphomas.
Results obtained here show that a higher fraction of Suv39h1 deficient
cells incorporated BrdU when compared to control lymphomas. However 24
hour exposure to BrdU prevented us to interpret this result as a speed of the
cell cycle assessment.
Further, the possibility of hyperproliferation as a cause of shortened la-
tencies in Suv39h1 deficient Myc lymphomas was tested.
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To determine the speed of cell cycle in both genotypes staining with
a specific mitotic marker histone H3 phosphorylated on serine 10 residue
(H3S10P) was used. Immunofluorescent staining in situ was done on the
lymph node sections from Suv39h1 proficient and deficient lymphomas (n=3
for each; figure 3.10 upper panel done in collaboration with C. Lodenkemper
et al). Although in the in situ staining there is apparently more cells staining
positive for H3S10P marker in Suv39h1 deficient lymphomas, it was reasoned
that this might be a consequence of the overal difference in number of cells
in cycle between Suv39h1 deficient and control lymphomas.
To further investigate the possibility of a different cell cycle speed as a
cause of difference observed in the overall number of cells in cycle a ”mitotic
trap” protocol using the drug Nocodazole (NOC) was employed. Nocodazole
is a known anti-neoplastic agent, which exerts its effects by depolymerizing
microtubules, therefore causing an arrest in mytosis [M] phase of the cell cycle
(cells are arrested in prometaphase). Freshly explanted lymphoma cells were
treated with NOC in the concentration 100 ng/ml of media for the period
of 0, 3, 6 and 9 hours. Cells were collected at the indicated time periods,
stained for the H3S10P and subjected to the flow cytometric analysis [here
is shown 0-6 hours change] (Figure 3.10, bottom panel).
This result shows, that although initially there are more cells in cycle
observed in Suv39h1 deficient lymphomas, cells from both genotypes are
proliferating with the same average speed through the cell cycle in vitro
(values for the ”mitotic trap” experiment from figure 3.10 are for Eµ-myc
8,92 ± 6,04% and Eµ-myc, Suv39h1−/− 7,53 ± 4,19%; P=0,247).
To further test if the observation from the previous experiment could be
explained on a molecular basis of possibly deregulated cyclin-CDK signaling,
which would impair proliferative capacity of cells, protein levels of cyclin A,
which is required for the S phase progression, and cyclin E, which is playing
a role in G1/S transition were assessed by Western blot (Figure 3.11).
Differences observed on a molecular level with upregulated E2F target
cyclin A and cdk2 binding partner cyclin E reflect the findings that Suv39h1
deficient lymphomas have more cells activelly participating in the progression
through the cell cycle, enabeling them to develop fully grown tumor with
shorter onset latencies.
Impact of p53 loss on Suv39h1 status in Eµ-myc lymphomas
According to previously published research it is known that p53 has an im-
portant role in Eµ-myc lymphomagenesis in vivo, and that in the setting
when Myc is overexpressed tumor cells are developing in an environment
where expression of the remaining p53 wild-type allele in p53+/− setting is
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Figure 3.10: Histone H3 Serine 10 phosphorylation. TOP: Immunofluores-
cent histone H3 serine 10 phosphorylation (H3S10P) staining in situ on Eµ-
myc (n=3) and Eµ-myc, Suv39h1−/− (n=3) lymphomas. BOTTOM. Left:
Freshly explanted lymphoma cells were treated with Nocodazole (NOC) and
tested for H3S10P in 3, 6 and 9 hours periods. Right: Histogram bar repre-
sents difference in Eµ-myc (black, n=6) and Eµ-myc, Suv39h1−/− (red; n=5)
between time points 0 and 6 hours of NOC treatment.
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Figure 3.11: Suv39h1 deficient lymphomas show upregulation in cyclin E
and A protein expression as seen by western blot analysis of lymphoma cells
extracted from lymph nodes of animals with intact and disrupted Suv39h1.
TOP: Cyclin E status with respective tubulin as a loading control. BOT-
TOM: Cyclin A status with respective tubulin as a loading control in Eµ-myc
(n=4) and Eµ-myc, Suv39h1−/− (n=4).
lost. This is a consequence of the loss of heterozygosity (LOH), and results
in the shortened tumor latencies.
Here was investigated whether loss of Suv39h1, as observed in Eµ-myc,
Suv39h1+/− could potentially prevent p53+/− loss of heterozygosity. For this
purpose Eµ-myc mice were crossed to Suv39h1+/−, p53+/− mice. Mice were
monitored for tumor latencies by palpation of peripheral lymph nodes every
three days, and latencies were plotted as a Kaplan- Meier ”Time-to-tumor
onset” plot (Figure 3.12).
As expected, all of the animals succumbed to lymphoma, as seen in the
tumor onset latencies plot. Time to tumor onset in Eµ-myc p53+/− Suv39h1
+/− (n=9) was 27 days and in Eµ-myc, p53+/−, Suv39h1 −/− (n=5) was 32
days (when compared to either Eµ-myc, Suv39h1+/− or Eµ-myc, Suv39h1
−/− ; P <0,005).
Further, all lymphomas arising in p53 +/− background were tested for the
potential loss of the remaining p53 allele (loss of heterozygosity), often ob-
served in Eµ-myc p53+/− lymphoma setting. In addition loss of the Suv39h1
expression was tested in the same setting (Figure 3.13).
These results indicate that Myc tumors with disrupted Suv39h1 primarily
select against the remaining p53 allele, as all of the p53+/− animals (9/9
cases tested) have lost their remaining wild-type allele. Concluding from
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Figure 3.12: Defects in Suv39h1 and p53 accelerate Myc-driven lymphoma-
genesis: TOP: Breeding outline. Eµ-myc mice were crossed to mice bearing
targeted genetic lesions in the Suv39h1 and the p53 locus. Tumor latencies
were recorded and tumor cells were isolated and submitted to the analysis of
p53 and Suv39h1 transcript. BOTTOM: Kaplan-Meier ”Time-to-tumor-on-
set” latencies: Eµ-myc, Suv39h1−/− (n=31; red line); Eµ-myc, Suv39h1 +/−
(n=41; blue line); Eµ-myc, p53+/− (n=3; green line); Eµ-myc, Suv39h1+/−,
p53 +/− (n=9; orange line); Eµ-myc, Suv39h1−/−, p53 +/− (n=5; light blue
line).
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Figure 3.13: Lymphoma cells primarily select against p53 during Myc-lymp-
homagenesis. p53 status was tested in allele-specific PCR to detect mutant
(upper band) or wild-type (lower band) p53 allele in Suv39h1+/−, p53+/−
lymphomas (n=9), Suv39h1−/−, p53 +/− lymphomas (n=3), Suv39h1+/+,
p53+/− lymphomas (n=3); as a control p53+/− (1), p53−/− (2), Eµ-myc
(3) and Eµ-myc, Suv39h1+/− (4) animals were used. In addition, Suv39h1
mRNA levels were tested for the lymphomas developed in the same animals,
with TBP as a loading control.
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these results p53 loss of heterozygosity is set as an early event in Myc driven
lymphomagenesis, and it provides enough survival advantages to protect from
further loss of Suv39h1 (observed in 7/9 cases tested). This results are well
in line with p53’s central role in apoptosis and senescence.
3.1.3 Defects of failsafe machinery in Suv39h1 defi-
cient lymphomas
Impact of Suv39h1 loss on apoptotic machinery
Apoptosis is a hallmark of Myc-driven lymphomagenesis, and a significant
proliferative advantage has been observed when tumors are deficient for p53,
since deficiency in p53 is leaving them apoptotically incompetent. There-
fore when it was revealed that Suv39h1 deficiency accelerates Myc-driven
lymphomagenesis, as well as that Suv39h1 loss is dispensable in the p53 de-
ficient setting, possible defects in apoptotic machinery of Suv39h1 deficient
lymphomas were tested.
Spontaneous apoptosis rates of lymphomas arising in both Suv39h1 pro-
ficient and deficient animals were assessed. When observing Hematoxin and
Eosin (HE) staining (done in collaboration with C. Loddenkemper et al)
a ”starry sky” phenotype becomes visible [macrophage infiltrations around
apoptotic cells, which is a typical feature of human Burkitt’s lymphomas].
In TUNEL staining in situ (terminal deoxynucleotidyl transferase dUTP
nick end labeling; marking fragmented DNA typical for apoptotic cells)
no overt differences in spontaneous apoptosis rates between two lymphoma
groups were detected(Eµ-myc 11,168 ± 2,56%; Eµ-myc, Suv39h1−/− 13,863
± 4,418%; P=0,2117; Figure 3.14).
Results in the figure 3.14 clearly show that there is no detectable difference
in the spontaneous apoptosis rates as a response to Suv39h1 loss in Myc
lymphoma model in vivo. Therefore differences in tumor latencies did not
arise due to the defects in apoptosis.
This finding indicated a possibility of defects in senescence machinery in
Suv39h1−/− lymphomas.
Impact of Suv39h1 loss on senescence machinery
Observation from previous experiments revealed that control lymphomas
have overall less cells in cycle when compared to the Suv39h1 deficient lym-
phomas, however both genotypes share an almost identical speed of cell cycle.
To directly evaluate oncogene induced senescence as a potential mech-
anism contributing to the prolonged time of tumor formation in Eµ-myc
91
Eµ-myc                              Eµ-myc
  Suv39h1+/+                        Suv39h1-/-
Hematoxylin/
Eosin
TUNEL
Quantification of apoptotic cells
TU
N
E
L 
po
si
tiv
e 
ce
lls
 [%
]
Figure 3.14: Ability to undergo spontaneous apoptosis does not depend on
Suv39h1 status in Eµ-myc lymphomas. LEFT: Hematoxilyn and Eosin stain-
ing of Eµ-myc (n=3) and Eµ-myc, Suv39h1−/− (n=3) lymph nodes with
”starry sky” phenotype (typical for Burkitt’s lymphomas, done in collabo-
ration with C. Lodenkemper et al). RIGHT Top: TUNEL in situ staining
of Eµ-myc (n=3) and Eµ-myc, Suv39h1−/− (n=3) lymph nodes. Bottom:
quantification of TUNEL staining in situ.
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mice senescence-reminiscent characteristics of lymphoma cells were assessed
by flow cytometric light scatter analysis. Single cell preparations of Eµ-
myc lymphomas (n=5) when compared to Eµ-myc Suv39h1−/− lymphomas
(n=4) demonstrated that a fraction of cells is displaying typical morphologi-
cal alterations present in senescent cells (enlargment and granularity), while
Suv39h1−/− were lacking cells with those attributes (Figure 3.15). Further,
cells tested for typical senescence marker H3K9me3 (tri-methylated lysine 9
residue on histone H3) revealed positive staining only in Eµ-myc lymphomas
(20,537 ± 3,148%), while in Eµ-myc Suv39h1−/− lymphomas no positive
staining was observed (5,29 ± 2,857%; P=0,0004).
This experiment indicates that Suv39h1 deficient lymphomas show no
detectable sign of a senescent phenotype as enlarged cells with granule rich
cytoplasm, or positive marks for tri-methylated histone H3 lysine 9 residue,
while in control lymphomas those marks are present in a fraction of whole
lymphoma. Shown in here, Eµ-myc lymphomas with intact Suv39h1 retain
the possibility of executing sporadic oncogene-induced senescence, and this
could explain the initial difference observed in tumor latencies.
Senescence in vivo at the stage of terminal illness was tested in lymphoma
tissue by 2 senescent markers: senescence associated β-galactosidase (SA
β-gal) reactivity in situ and tri-methylated lisine 9 residue on histone H3
(H3K9me3; figure 3.16).
While Eµ-myc lymphoma cells sporadically display senescent phenotype,
as seen by SA β-gal (14,319 ± 6,005%) and H3K9me3 (9,683 ± 3,683%)
staining, Eµ-myc Suv39h1−/− lymphomas are lacking positive cells when
stained for both markers (0,809 ± 0,12% for SA-β-gal and 2,023 ± 1,409%
for H3K9me3 marker; P <0,0001 for both stainings).
Another potential senescence maker commonly used is HP1γ. HP1 pro-
teins are components of heterochromatinization machinery, they are recruited
upon Suv39h1 tri-methylation of lysine 9 residue on the histone H3, and dock
to tri-methylated lysine 9 residue on histone H3, spreading higher order chro-
matin (Figure 3.17).
Immunofluoresecent staining of HP1γ showed that HP1γ positive cells re-
capitulate the distribution of SA β-galactosidase staining as well as H3K9me3
positivity (Eµ-myc 14,172 ± 4,998%; Eµ-myc Suv39h1−/− 3,118 ± 1,286%;
P=0,004). Although HP1 proteins are abundantly present in cells, they
can most likely be visualized only when in clusters, as seen in figure 3.17,
which occurs when they accumulate through binding to tri-methylated lisine
9 residue.
These experiments demonstrate that Suv39h1 resides in a signaling path-
way activated during Myc lymphomagenesis in order to prevent malignant
transformation by mediating senescence.
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Figure 3.15: Suv39h1 deficient lymphomas show defects in senescence ma-
chinery. Freshly explanted lymphoma cells were subjcted to the flow cytomet-
ric analysis. TOP: Side scatter/ forward scatter distribution was analysed
on flow cytometer, and revealed a sub-population of larger and granule rich
cells only in Eµ-myc (n=5) lymphomas, depicted in green and marked with
an arrow. This sub-population was absent in Eµ-myc Suv39h1−/− (n=4)
lymphomas, as marked with an arrow. BOTTOM: Two-color flow cytometry
of lymphoma cells for the cell cycle marker (Ki67) and senescence marker
(H3K9me3). Cells located in the dark green circle are considered to belong
to the senescent population [As negative controls for the Ki67 staining 20 Gy
γ-irradiated NIH 3T3 cells were used].
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Figure 3.16: Suv39h1 deficient lymphomas are lacking senescent phenotype.
TOP: Senescence associatedβ-galactosidase (SAβ-gal) in situ. Sections of
cryopreserved lymph nodes were stained for the endogenous SA β-gal activity
in situ. Eµ-myc control lymphomas (n=24) were compared to Suv39h1−/−
lymphomas (n=11). Inlay represents an immunofluorescent staining for the
H3K9me3 marker in situ (tested on sections from formalin fixed, paraffin
embeded tissues) [as a negative control for the SA β-gal staining Eµ-myc
p53−/− lymph nodes (n=3) were used]. BOTTOM: Western blot analysis
of histone H3 lysine 9 tri-methylation (H3K9me3) status with respective
tubulin as a loading control in Eµ-myc (n=4) and Eµ-myc, Suv39h1−/− (n=4)
lymphomas.
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Figure 3.17: Suv39h1 deficient lymphomas are lacking in heterochromatin
bound HP1γ positive areas. Sections from the formalin fixed and parafin-
embeded lymph nodes were stained for the HP1γ marker in situ. Control
lymphomas (n=3), were compared to Suv39h1 −/− lymphomas (n=3).
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To investigate the possibility of senescence in lymphoma cells negative
for Ki67 marker in situ, double staining approach was used to stain for the
proliferation marker BrdU and senescence marker SA β-galactosidase in situ.
Those two markers are expected to be mutually exclusive, since BrdU will
not incorporate in arrested cells and SA β-galactosidase was reported to be
active only in senescent cells.
Here we show that the lower proliferation rates, or lower numbers of cells
stained positive for the cell cycle marker observed in Eµ-myc lymphomas
(62,867 ± 3,927% versus 82,100 ± 3,816% observed in Eµ-myc Suv39h1−/−
lymphomas; P=0,0037) are a consequence of cells’ ability to enter oncogene
induced senescence, as shown by the SA β-galactosidase positive staining,
present only in control lymphomas ((Figure 3.18, done in collaboration with
C. Loddenkemper et al).
BrdU [brown]
SA-β gal [blue]
Eµ-myc                                                   Eµ-myc
Suv39h1+/+                                             Suv39h1-/-
Figure 3.18: Suv39h1 proficient lymphomas lose their cells from the prolifer-
ation to senescence. Sections of cryopreserved of Eµ-myc (n=4) and Eµ-myc
Suv39h1−/− (n=4) lymph nodes were stained for the endogenous SAβ-gal ac-
tivity (visualized as blue cells) and subsequently for the BrdU incorporation
(visualized as brown cells; done in collaboration with C. Lodenkemper et al)
in situ.
Results obtained in this experiment reveal that the overall lower number
of cells in cycle observed in Suv39h1 proficient lymphomas could be due to
their loss into senescence.
Concluding from these results: senescence is a ”failsafe program” preclud-
ing a fraction of cells in the Myc-driven lymphoma from contribution to the
further tumor expansion.
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Impact of loss of genes implicated in failsafe pathways on senes-
cence machinery
There are several genes known to be involved in the cellular failsafe pathways.
Here was tested the impact of loss in 4 genes involved in the maintenance
of intact failsafe pathways on senescence in vivo. For that purpose B-cell
lymphomas arising in different genetic background: Eµ-myc p16INK4a−/−
(n=2); Eµ-myc p53 deficient (LOH) (n=3) ; Eµ-myc p19Arf−/− (n=4); Eµ-
myc ATM−/− (n=3); and in addition Eµ- myc p16/p19INK4aArf+/− (n=2)
were tested [for tumor latencies please see appendices section A.1.1; cryopre-
served lymph nodes from Eµ-myc ATM−/− animals were a gift from Dr. M.
Reimann; cryopreserved lymph nodes from Eµ-myc p16/p19INK4aArf−/− ani-
mals were gift from Mrs. B. Teichman]. Significantly lower SA β-galactosida-
se positivity was found in Eµ-myc p53 null (1,95 ± 1,245%; P=0,0107); Eµ-
myc p19Arf−/− (2,32± 1,325%; P=0,0008) and Eµ-myc p16/p19INK4aArf−/−-
(0,71 ± 0,7%; P < 0.0001) when compared to Eµ-myc lymphomas. Eµ-
myc ATM−/− (8,807 ± 7,465%; P=0,1726) showed not significantly reduced
SA β-galactosidase levels when compared to Eµ-myc lymphomas, while Eµ-
myc p16INK4a−/− lymphomas have comparable levels of SA β-galactosidase
(13,970 ± 4,483%; P=0,9631) with the Eµ-myc lymphomas (Figure 3.19).
As indicated in here defects in the p16INK4a locus do not disrupt Myc-
induced senescence, while defects in p19Arf , as well as the loss of the entire
INK4a/Arf locus has a severe impact on the Myc-induced senescence. p53
deficient lymphomas also show strong impairment of the oncogene-induced
senescence, which is in accordance with p53s central role in senescence.
Lastly, ATM deficient lymphomas show reduced levels of Myc-induced senes-
cence, however there is no complete cessation of senescence in this genotpe.
Conclusion from this experiment is that the p53-p19Arf is pathway essential
for triggering Myc-induced senescence. p16INK4a seems fully dispensible for
senescence induction in a Myc-overexpression setting, while ATM might con-
tribute to the extent of senescence induction. This finding lead to further
testing of a specific pathway disruptions in Suv39h1 deficient lymphomas.
Senescence machinery at molecular level
Previous experiments pointed out that Suv39h1 is a mediator of Myc-induced
senescence, as well as it was shown that p53 gene and a INK4aArf locus gene
product p19Arf are crucial for the induction of Myc-mediated senescence.
p19Arf is activated in response to oncogenic Myc, and it transfers Myc sig-
naling to p53, therefore when there is loss of p53 there will be an accumulation
of p19Arf .
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Figure 3.19: Senescence in vivo is fully blocked with p53 and INK4aArf ge-
ne disruption. TOP: Sections from cryopreserved lymph nodes were stained
for the endogenous SA β-gal activity in situ. Following lymphoma geno-
types were compared: Eµ-myc p16−/− (n=2), Eµ-myc p53−/−(n=3), Eµ-myc
Arf−/− (n=4); Eµ-myc ATM−/− (n=3), Eµ-myc p16/p19Ink4aArf+/−(n=2).
BOTTOM: histogram quantification of the staining SA β-gal activity in situ
staining.
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Data from previous research reveal that Suv39h1 deficient lymphomas
select against p19Arf expression. Secondly, it was also reported that p16INK4a
gene is an important factor in Ras-induced senescence[BLL+05], arguing that
the senescence signal is Ras-model is mediated via p16INK4a - pRb axis.
Therefore, in order to test if p16INK4a - pRb axis are mediating Myc-induced
senescence endogenous expression of p16INK4a, as well as pRb was tested. In
addition we tested for expression levels of 2 cyclin dependent kinase inhibitors
p21Cip and p27Kip which are known as mediators between p53 and p16INK4a
signaling pathways.
Whole cell protein lysates were isolated from freshly explanted lymph
nodes of both genotypes and analysed on Western blot (Figure 3.20).
Sign of an intact senescence machinery is present only in Suv39h1 profici-
ent lymphomas, as seen by presence of hypophosphorylated form of pRb only
in case if Suv39h1 is intact. Accumulation of CDK4/6 inhibitor p16INK4a
is already reported for Suv39h1 deficient T-cell lymphomas, and could be
explained by the inability of p16INK4a to transfer signals further downstream
when Suv39h1 is absent. Therefore, this setting will lead to an accumulation
of p16INK4a.
Myc-induced senescence as a feature of pre-neoplastic lymphomas
Presence of the oncogene-induced senescence features in Suv39h1 proficient
manifest lymphomas did not reveal the impact of this mechanism on the
kinetics of the lymphoma development. In order to investigate status of Myc-
induced senescence in a setting with no outer sign of the disease splenic B-cells
of pre-manifest (30 days old) Eµ-myc and Eµ-myc, Suv39h1−/− animals were
used. Additionally non transgenic Suv39h1 proficient and deficient B-cells
were used for the same analysis.
B-cells were subjected to SA β-galactosidase and H3K9me3 stainings.
As shown in figure 3.16, only pre-manifest Eµ-myc B-cells were displaying
senescent characteristics (SA β-gal: 21,850 ± 11,33%; H3K9me3: 13,483
± 5,469%), while senescent marks were absent in the pre-manifest Eµ-myc
Suv39h1−/− B-cells (SA β-gal: 0,637 ± 0,44; H3K9me3: 1,68 ± 1,358%)
(P=0,0139 and P=0,0051 respectively). When the non-transgenic genotypes,
both wild type B-cells did not display positive senscent staining (SA β-
gal: 1,875 ± 0,516%; H3K9me3: 1,018 ± 0,186), as well as Suv39h1−/−
B-cells (SA β-gal: 0,31 ± 0,611%; H3K9me3: 0,57 ± 0,221%; P=0,0322;
Figure 3.21).
Results obtained in this experiment indicate that loss of proliferating
cells by into senescence is a continuous process, starting as early as the pre-
manifest tumor stage, and is induced by the activated oncogene Myc and
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Figure 3.20: Western blot analysis of lymphoma cells isolated from lymph
nodes of animals with intact and disrupted Suv39h1 revealed that a fraction
of pRb is present in its hypophosphorylated form indicating cell cycle arrest
only in Suv39h1 proficient lymphomas. Suv39h1 −/− lymphomas are displa-
ying higher levels of p16INK4a when compared to the control lymphomas.
TOP: pRb and p16INK4a status with respective tubulin as a loading control
[please note that only in Suv39h1 proficient lymphoma pRb is detectable in
hypophosphorylated state, which is characteristic for G1 arrest]. BOTTOM:
p21Cip and p27Kip status with respective tubulin as a loading control in Eµ-
myc (n=4) and Eµ-myc, Suv39h1−/− (n=4) [please note that p21Cip and
p27Kip expression levels do not differ significantly between the 2 genotypes].
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Figure 3.21: Senescence is induced by Myc-overexpression and is occuring as
early as in the pre-manifest lymphoma cells. Splenic B-cell cytospins were
prepared from wild-type (n=3), Suv39h1−/− (n=3), Eµ-myc (n=3) and Eµ-
myc Suv39h1−/− (n=3) 30-day old mice and stained for the endogenous SA
β-gal activity and H3K9me3/DAPI [DAPI is used to visualise cells for the
subsequent quantification, visualized in blue].
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dependent on the presence of intact Suv39h1.
This finding could explain that the lower Ki67 values observed in Suv39h1
proficient setting are the consequence of continuous Myc-induced senescence.
As reported previously, immune cells are recruited to the site of senescent
cells and clear them from the tissue [XZM+07], therefore finding described
in this thesis together with this previous report is exposing Myc-induced
senescence as a dynamic process, where exists a constant balance between
losing cells into senescence and their elimination from the tissue by the cells
of the immune system.
Contribution of bystander cells to the Myc-induced senescence
In order to corroborate previous finding indicating that the ability to undergo
senescence is a property of cells with overexpressed Myc, and to further in-
vestigate whether Eµ-myc driven B-cells and not bystander cells co-existing
in the lymphoma tissue have the ability to undergo senescence, oncogene
induced senescence was tested for the bystander cells. In order to test senes-
cence induction in bystander cells a series of transplantation experiments
in which Suv39h1 deficient lymphomas would develop in a non-transgenic
Suv39h1 proficient background, as well as Suv39h1 proficient lymphomas
would develop in Suv39h1 deficient background were conducted.
Fetal liver cells (FLC) from either Eµ-myc; Eµ-myc, Suv39h1+/− or Eµ-
myc, Suv39h1 −/− mice were used in order not to use already developed
lymphomas with all of the accompanying genetic alterations. These fetal
liver cells were transplanted in either wild-type ( for Eµ-myc, Suv39h1+/−
and Eµ-myc, Suv39h1−/−) or Suv39h1−/− (for Eµ-myc) sublethaly irradi-
ated recipients (4 Gy of γ irradiation, single dose). Mice were monitored
for the time to tumor onset and post mortem lymph nodes were extracted,
cryopreserved and stained for the senescence marker SA β-gal (Figure 3.22).
Tumor bystander cells are not undergoing senescence, as shown in fig-
ure 3.22, but from the data it could not be concluded if they might have a
function in senescence induction.
3.1.4 DNA damage analysis in Myc lymphomas
Recent publications have shown that DNA damage might act as one of
the mediators of senescent response. In order to test for the contribution
of DNA damage response (DDR) to the mediation of senescence in Myc-
lymphoma setting, activation of p53, as a main mediator of the DDR was
tested. In order for DDR machinery to properly function p53 has to be ac-
tivated by checkpoint kinases (ATM/ATR) phosphorylation on the residue
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Figure 3.22: Myc-induced senescence is not present in tumor bystander cells.
LEFT: Experimental setup. Non transgenic mice were transplanted with
fetal liver cells isolated from Eµ-myc; Eµ-myc, Suv39h1+/− and Eµ-myc,
Suv39h1−/− fetuses. Transplanted mice were montored for the time to lym-
phoma onset latencies post fetal liver cell transplantation (as defined by
Kaplan-Meier estimator) for Eµ-myc (n=9, black line); Eµ-myc, Suv39h1+/−
(n=3, blue line); Eµ-myc, Suv39h1−/− (n=3, red line) lymphomas. RIGHT:
Sections of cryopreserved lymph nodes were stained for the endogenous SA
β-gal activity in situ. Control lymphomas transplanted into the Suv39h1 de-
ficient background (n=9) were compared to Suv39h1 −/− lymphomas trans-
planted into the wild-type background (n=3).
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18(p53S18P). Therefore p53 activation in both Suv39h1 proficient and defi-
cient genotypes was tested by Western blot analysis for the presence and the
extent of p53S18P (Figure 3.23).
p53 S18
Tubulin
Eµ-myc                                                   Eµ-myc
Suv39h1+/+                                             Suv39h1-/-
Figure 3.23: Myc-induced DNA damage signaling is intact in Suv39h1 defi-
cient lymphomas. Western blot analysis of lymphoma cells extracted from
lymph nodes of animals with intact and disrupted Suv39h1. p53S18P status
with respective tubulin as a loading control in Eµ-myc (n=4) and Eµ-myc,
Suv39h1−/− (n=4) lymphomas.
Figure 3.23 shows that Myc-induced p53 activation upon stress condi-
tions is not dependent on Suv39h1 status indicating intactness of the DDR
machinery.
Myc-evoked oxidative stress and DNA damage response (DDR)
machinery
Oxidative stress is one of the mediators of senescence. To investigate the
impact of oxidative stress on senescence induction, Eµ-myc mice were con-
tinuously exposed to N-Acetylcysteine (NAC; reactive oxygen species scav-
enger; applied as 0.5% w/v solution in drinking water) starting at birth. It
was reported that N-acetylcysteine prevents DNA damage induced by Myc
in vitro [VWK+02].
No difference in tumor latencies between NAC treated and untreated
group of Eµ-myc mice was detected in this experiment. However, when ass-
esed for the senescence marker SA β-gal it was shown that NAC treated mice
show a reduction in Myc-induced senescence (SAβ-gal: Eµ-myc + NAC=
7,787 ± 4,908%; Eµ-myc= 16,608 ± 9,065%; P= 0,1005). The reduction in
reactive oxygen species (ROS) was confirmed by the 2’7’- dichlorofluorescein
(DCF) reaction. DCF is commonly used to detect generation of reactive
oxygen intermediates. DCF values were measured quantitatively by flow cy-
tometry (Eµ-myc + NAC= 4,061 ± 1,146%; Eµ-myc= 11,498 ± 2,081; P=
0,0474), and shown as an immunofluorescent staining (Figure 3.24).
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Figure 3.24: Eµ-myc mice with impaired DNA damage response machin-
ery develop tumors with indistinguishable latencies from control mice, and
display reduced Myc-induced senescence. TOP Left: Kaplan-Meier ”Time-
to-tumor onset” latencies of Eµ-myc+NAC (n=4; purple line) and Eµ-myc
(n=93; black line). Right: SAβ-gal staining revealed that N-acetylcysteine
(NAC) treated mice develop lymphomas with decreased levels of senescence.
BOTTOM Left: 2’7’- dichlorofluorescein (DCF) visualisation of the presence
of reactive oxygen species (ROS). Right: Reduction in ROS has an impact
on proliferation, apoptosis[RLR+07], and as reported in this work also on
senescence.
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It was previously reported that NAC treated Eµ-myc lymphomas have
decreased levels of both proliferation and apoptotic capacity [RLR+07], which
could explain no impact on tumor development latencies observed here.
Secondly, as seen here reactive oxygen species (ROS) scavanger NAC
was successful in reducing Myc-induced senescence, arguing for an impact of
ROS-DDR on senescence mediation.
Remaining question from this approach is: if there would be no reduction
in proliferation and apoptosis in the similar approach to the one described
above, would an impact of senescence block on tumor latencies in vivo be
detectable?
Disruption of DNA damage checkpoints in Myc-lymphomas
Additional analysis on the DNA damage-mediated senescence was done by
caffeine administration to Eµ-myc mice starting from birth (0.4mg/ml in
drinking water supply). Caffeine is compound that cancels ATM/ATR-
controlled DNA double strand break checkpoint [DMFC+06], therefore blunt-
ing the DDR.
Caffeine administration significantly decreased tumor latencies in Eµ-myc
mice undergoing daily caffeine exposure (n=15). Eµ-myc mice developed
tumors with the median time of 53 days, significantly earlier than in the
non-caffeine treated group (P=0,0003) (Figure 3.25 upper left panel) [see the
appendices section A.1.2 for the Kaplan-Meier ”Time-to-tumor-onset” plot
of wild-type and Eµ-myc caffeine treated mice]. Lymphomas from caffeine
treated mice showed reduced staining for SA-β-galactosidase activity (n=8;
6,372 ± 2,29%; P=0,0002).
Caffeine treated lymphomas also displayed lower frequency of apoptotic
cells by TUNEL staining in situ (n= 7; 7,44 ± 3,11%) when compared to
the untreated controls (n=3; 17,43 ± 2,89%; P=0,0015; Figure 3.25).
These results suggest that the DNA damage response (DDR) pathway
is playing a role in the mediation of oncogene-induced senescence in Eµ-
myc mouse lymphoma model. As shown in the experiment with the caffeine
treatment, apoptosis is also important downstream component of the DDR
machinery. Implication of both apoptosis and senescence in the DDR in this
experiment made it impossible to interpret if the disruption in the senescent
machinery could be responsible for the decrease in tumor latencies as ob-
served in figure 3.25. Also, by reducing DNA damage via caffeine treatment
senescent response was not entirely ablated, suggesting a possibility of an
additional mechanism mediating senescent response. This mechanism could
collaborate with the DDR signals in mediation of senescence.
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Figure 3.25: Caffeine induced shortening of tumor latencies in Eµ-myc mice.
Lymphomas arise as a consequence of impairment in apoptotic and senescent
machinery. LEFT: Kaplan-Meier ”Time-to-tumor-onset” latencies of Eµ-myc
mice with constant water supply of caffeine (n=15, red line) compared to
Eµ-myc mice without caffeine (n=15, black line). RIGHT: Lymph nodes
from Eµ-myc (n=3) and caffeine treated Eµ-myc mice (n=7) were tested for
senescence marker (SA β-gal) and apoptosis marker (TUNEL).
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3.1.5 Triggers of Myc-induced senescence
Following observations that DDR is one of the mediators of Myc-induced
senescence and that there might be another mediator needed in order to
execute senescence. Observing sporadic pattern of senescence positivity in
control lymphoma cells posible influence of the tumor architecture and envi-
ronment was considered as one of triggers of senescence.
Microenvironment as a trigger of Myc-induced senescence
Influence of the tumor microenvironment on senescence induction was tested.
Vascularization of tumor contributes to its better growth, but is also keeping
cells more oxygenated, sensitizing them to ROS induced DDR, which can
potentially lead to induction of senescence. To test for the possible influence
of the vascularization, therefore tumor oxygenation, on senescence induction,
lymph nodes of Eµ-myc mice were tested for CD31 (blood vessel marker, done
in collaboration with C. Lodenkemper et al) and SA β-gal in situ. In order to
analyze obtained data each photomicrograph was divided in 64 equall fields
and checked for the relative co-localization of vascularization (CD31) and
senescence (SA β-gal) markers (Figure 3.26).
These results demonstrate more frequent occurence of senescence in areas
close to the blood vessels [CD31+ SA β-gal+ = 77,0 ± 11,0%; CD31- SA
β-gal+ = 35,0 ± 17,5%; P=0,0006]. Areas close to blood vessels are better
oxygenated areas, results shown in here reveal co-localization of vasculature
and senescent cells, which could indicate that the reactive oxygen species
(ROS) are playing an important role in Myc-induced senescence. This result
indicated that the tumor microenvironment architecture could be used as a
prognostic indicator of tumor progression.
In addition when compared blood vessel density in both Eµ-myc and Eµ-
myc, Suv39h1−/− lymph node sections, it shows indistinguishable pattern of
vessel distribution in both of the genotypes tested. In this experiment a grid
composed of 25 fields per photomicrograph was used in order to distinguish
between positive and negative CD31 areas [Eµ-myc= 48,10 ±11,1%; Eµ-myc,
Suv39h1−/− = 58,20 ±11,0%; P=0,1153] (Figure 3.27).
In conclusion, significantly more senescent cells was found co-localizing
with tumor vasculature. Therefore showing that the better oxygenated tumor
areas with are more prone of entering Myc-induced senescence.
Secondly, defects in Suv39h1 do not influence distribution or the extent
of tumor vascularization, as Suv39h1 deficient lymphomas have a similar
vascularization pattern, exposing them to the same level of oxygen and sub-
sequently to the same level of ROS as Suv39h1 proficient lymphomas.
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Eµ-myc Suv39h1+/+
Figure 3.26: More frequent occurence of senescence is detected in areas with
well developed vasculature. LEFT: Each photomicrograph is divided by grid
into 64 fields (depicted in orange, app.100x 100 µm).To each field could be
assigned (based on minimally one positive event in the given field): 1. Neg-
ative for SA β-gal;negative for CD31; 2. Negative for SA β-gal, positive for
CD31 (purple); 3. Positive for SA β-gal (blue), negative for CD31; 4. Pos-
itive for SA β-gal and CD31. Positive SA β-gal areas were quantified and
compared with respect of CD31 positivity in Eµ-myc lymphomas. Represen-
tative photomicrograph of SA β-gal/ CD31 staining (done in collaboration
with C. Loddenkemper et al). RIGHT: Histogram of quantification obtained
from the approach described on the upper left part of the figure.
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Figure 3.27: Extent of CD31 positive cells is equall in both Suv39h1 profi-
cient and deficient lymphomas. LEFT: Each photomicrograph is divided by
grid into 25 fields (depicted in orange; 175x 175 µm). To each field could be
assigned (based on minimally one positive event in the given field) 1. Pos-
itive for CD31 (purple); 2. Negative for CD31. Positive CD31 areas were
quantified and compared with respect to genotypes. Representative photomi-
crograph of CD31 staining (done in collaboration with C. Loddenkemper et
al). RIGHT: Histogram of quantification obtained from the approach de-
scribed on the left.
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Genetic signature of Myc-induced senescence
In order to investigate deregulation in other genes affected by Suv39h1 loss in
Myc-driven lymphomagenesis RNA isolated from primary Suv39h1 proficient
and deficient lymphomas (n=3 for each group) was subjected to the genome-
wide transcriptional profiling (cDNA synthesis, labeling, hybridization and
statistical analysis was performed by B. Samans et al).
The transcript with the strongest differential regulation (beside Suv39h1
transcript which was 14.4 fold downregulated in the Suv39h1 deficient lym-
phomas) was βIGH3 (Tgfbi or TGFβ-inducible) gene. This gene was previ-
ously linked to senescence [DCFR02], and in this experiment it showed a 3.9
fold higher upregulation in Suv39h1 deficient lymphomas compared to the
control lymphomas.
Further, following genome-wide transcriptional analysis deregulation in
βIGH3 transcript levels was validated on a larger number of samples by a
semi quantitative RT-PCR approach (cycle 28 is depicted in Figure 3.28).
Thus, finding of a new gene potentially involved in the Myc-induced senes-
cence is reported in here. Although previously reported Tgfbi upregulated
expression as a response to retinoid-induced growth arrest[DCFR02], here is
observe upregulation of the same gene in lymphoma setting unable to pro-
duce senescent phenotype. This firstly conflicting findings might work in the
same direction, as Suv39h1 defects in processing signals from the senescence-
related genes positioned upstream in the cascade might be the reason for the
accumulation of βIGH3.
Validation of candidate genes involved in senescence
The semi-quantitative RT-PCR analysis were directed towards validating
genome-wide expression analysis results revealing deregulated gene expres-
sion caused primarily by loss of Suv39h1. Additional primary lymphoma
samples were used to validate expression of several transcripts found dif-
ferentially regulated in previous experiment. These genes were of partic-
ular interest since they were involved in transcription initiation, DNA re-
pair, hystone acetylation and insulin signaling among other functions. They
included: Taf4B [TAF4b RNA polymerase II, TATA box binding protein
(TBP)-associated factor], Mei1 [Meiosis defective 1], Myst 4 [Myst histone
acetyltransferase monocytic leukemia 4], Ryk [Receptor tyrosine kinase], Lsp1
[Lymphocyte specific protein] and Cul 2 [Ubiquitin protein ligase binding]
(semi-quantitative RT-PCR results can be found in the appendices secti-
on A.1.3).
Further work described in this thesis did not focus on elucidating the role
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Eµ-myc                                   Eµ-myc
Suv39h1+/+                             Suv39h1-/-
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TBP
Figure 3.28: Transcript with the highest deregulation in RNA-expression
analysis assay is the βIGH3 (TGFβ-inducible) gene. Left: Histogram
graph representing results of the gene expression array analysis for TGFβ-
inducible gene (3 samples of each genotype were analysed). Right: Vali-
dation of gene expression array analysis results for TGFβ-induced (Tgfbi)
transcript on freshly isolated lymphoma cells from Eµ-myc (n=5) and Eµ-
myc, Suv39h1−/− (n=5) animals, TBP was used as a loading control in a
semi-quantitative RT-PCR approach (shown here is PCR-cycle 28).
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of previously mentioned genes in senescence-induction. Focus of the research
remained on βIGH3 gene and its deregulation. The upstream regulator of
βIGH3 gene is TGFβ, therefore the difference observed in the expression of
βIGH3 gene might reflect a deregulation in TGFβ signaling.
In order to test this hypothesis semi-quanititative RT-PCR analysis of all
three isoforms of TGFβ (TGFβ-1, -2 and -3) was performed. Transcriptional
levels of TGFβ-1 were increased in Suv39h1 deficient lymphomas, which was
in accordance to the TGFβ function as an upstream trigger of βIGH3 (PCR
cycle 33 is depicted in figure 3.29). Levels of TGFβ-2 and TGFβ-3 however
remain unchanged in both genotypes [RT-PCRs for TGFβ-2 and TGFβ-3
can be found in the appendices section A.1.3].
TGFβ-1
TGFβ-
inducible
TBP
TGFβ-1
Eµ-myc                                   Eµ-myc
Suv39h1+/+                             Suv39h1-/-
Figure 3.29: TGFβ-1 is an upstream regulator of βIGH3, and shows de-
regulation in expression depending on Suv39h1 status. LEFT: TGFβ is an
upstream regulator of βIGH3, therefore the difference in the expression levels
of βIGH3 could reflect differences in levels of TGFβ. RIGHT: TGFβ-1 levels
tested by semi-quantitative RT-PCR analysis. TGFβ-1 transcript levels were
tested on freshly isolated lymphoma cells from Eµ-myc (n=5) and Eµ-myc
Suv39h1−/− (n=5) animals, TBP was used as a loading control.
114
As seen here, TGFβ-1 is upregulated upon loss of Suv39h1 in Myc-driven
lymphomas. Role of TGFβ-1 in tumorigenesis was already reported, and it
is complex and often varies depending on the tissue and progression-stage
of a certain tumor. Moreover TGFβ-1 mRNA levels might not be the most
accurate assessment of the TGFβ-1 levels, therefore protein expression profile
of TGFβ-1 was tested in Eµ-myc and Eµ-myc, Suv39h1−/− lymphomas by
Western blot analysis. Isolated proteins from the freshly explanted lymph
nodes (n=4 for each genotype) were tested, and additionally homogenates of
lymph node tissue were tested in ELISA assay for levels of active TGFβ-1
(Figure 3.30).
Eµ-myc                                   Eµ-myc
Suv39h1+/+                             Suv39h1-/-
Tubulin
TGFβ-1
TGFβ-1 levels in tissue [ELISA]
Figure 3.30: Suv39h1 deficient lymphomas display higher expression levels of
TGFβ-1 protein. TOP: TGFβ-1 Western blot analysis of Suv39h1 proficient
and deficient lymphomas (n=4 for each genotype), tubulin was used as a
loading control. BOTTOM: TGFβ-1 levels in the lymph node tissue were
tested in commercialy available ELISA assay (n=4 for each genotype).
These findings implicate a possible role of TGFβ-1 as a mediator of Myc-
induced senescence. The cellular source of TGFβ-1 in lymph nodes is not
known, and it is possible that instead or in addition of lymphoma cells, tumor
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bystander cells are secreting TGFβ.
In order to unveil cellular source of TGFβ freshly explanted lymphoma
cells were propagated in vitro, and after 10 days in culture transcript levels
of TGFβ-1 were assessed. Analysis revealed that levels of TGFβ remain
higher in Suv39h1 deficient lymphoma cells (Figure 3.31)[see the appendices
A.1.3 for the comparison between B-cells of non-transgene origin with the
lymphomas, and for the p15INK4b protein expression levels].
Eµ-myc                                   Eµ-myc
Suv39h1+/+                             Suv39h1-/-
Eµ-myc            Eµ-myc
Suv39h1+/+     Suv39h1-/-
Figure 3.31: Differences in levels of TGFβ-1 expression remain unchanged af-
ter in vitro culture propagation. LEFT: Eµ-myc (n=5) and Eµ-myc Suv39h1
(n=5) cells were cultured for 10 days and subsequently tested for TGFβ-1
and TGFβ-induced transcript levels, TBP was used as a loading control.
RIGHT: Eµ-myc (n=5) and Eµ-myc Suv39h1 (n=5) cells were cultured for
10 days and subsequently cell supernatant was tested for levels of excreted
TGFβ-1 by commercially available ELISA assay.
These results suggest that one of the sources of TGFβ-1 in the cell culture
are lymphoma cells themselves, however as lymphoma cells are cultured on
a layer of feeder cells it can’t be excluded that this cells have contributed to
the TGFβ secretion profile.
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3.1.6 TGFβ-1 gene and its role in senescence
In order to directly analyze potential role for TGFβ-1 in senescence induc-
tion in vitro Suv39h1 proficient and deficient lymphomas were exposed to the
different concentrations of TGFβ-1 (0,10, 100, 1000 pM). This exposure pro-
voked cell death in both control and the Suv39h1 deficient lymphomas in a
time and dose dependent manner. In order to prevent cell death by TGFβ-1
apoptotic blocker bcl2 was stably retroviraly introduced into the lymphoma
cells, and afterwards lymphomas were subjected to a treatment with different
concentrations of TGFβ-1. In the absence of apoptosis it was shown that
external admission of TGFβ-1 decreases the proliferative capacity of the con-
trol lymphomas. With the highest doses of TGFβ-1 administered in control
lymphomas, a complete cessation of proliferation occured, with cells display-
ing strong senescent features, while Suv39h1 deficient lymphomas remain
virtually unaffected (Figure 3.32).
TGFβ-1 induced proliferation block in vitro in control lymphomas was
accompanied by a strong (dose dependent) senescent phenotype, while senes-
cent cells were virtually undetectable in Suv39h1 deficient setting. Results
presented here indicate that TGFβ-1 is able to induce senescent phenotype in
control lymphomas (SA β-gal= 31,11 ± 14,75%; H3K9me3= 36,17 ± 8,95%)
but not in the Suv39h1−/− lymphomas (SA β-gal= 0,12± 0,78%; H3K9me3=
1,5 ± 0,66%; P < 0,005), arguing it might be the additional mechanism in
Myc’s induction of senescent response. This finding suggested that TGFβ-1
might have a role in in vivo Myc-driven lymphomagenesis.
TGFβ-1 role in senescence induction in vitro was tested on two addi-
tional genotypes: Eµ-myc p53−/− and Eµ-myc p19Arf−/− (all of those were
protected from apoptosis by stable transduction with bcl2 (bcl2 transduction
was done in collaboration with Dr. S. Lee; Figure 3.33).
As seen Eµ-myc, p19Arf−/− and Eµ-myc, p53 −/− lymphomas remain
resistant to different doses of TGFβ-1, arguing for the essential role of both
p19Arf and p53 signaling in maintaining cytokine-mediated senescence.
In addition, it was also shown that TGFβ-1 administration preserves
inducibility of previously mentioned target Tgfbi [RT-PCR analysis can be
found in the appendices section A.1.3].
Further, to unveil the acute TGFβ-1 response in lymphomas Suv39h1
proficient and deficient cells were exposed for 24 hours to 100 pM of TGFβ-1,
and subjected to the genome-wide expression array analysis (cDNA synthesis,
labeling, hybridization and statistical analysis was performed by B. Samans
et al) [see the appendices section A.1.3 for validation of the results obtained
in the second set of micro-arrays].
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Figure 3.32: TGFβ-1 induces senescence like growth arrest in a dose depen-
dent manner only in Suv39h1 proficient lymphomas. TOP: Relative viability
of Eµ-myc (n=4) and Eµ-myc, Suv39h1−/− (n=4) cells exposed to different
concentrations of TGFβ-1: 0 pM (black line); 10 pM (red line); 100 pM
(green line) and 1000pM (blue line) for 5 days. BOTTOM: Relative growth
curves and staining on cytospins of TGFβ-1untreated and 100pM treated
cells. Cells were prepared at day 5 post treatment and senescent pheno-
type was tested in Eµ-myc (n=4) and Eµ-myc, Suv39h1−/− (n=4) cells by
SA β-gal and H3K9me3 staining (DAPI[blue] is used for total cell number
visualisation in H3K9me3[red] staining).
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Figure 3.33: TGFβ-1 fails to induce senescence like growth arrest in lym-
phomas challenged in the p53-p19Arf signalling. Relative viability and rela-
tive growth curves of Eµ-myc, p19Arf−/− (n=3) and Eµ-myc, p53−/− (n=3)
cells exposed to different concentrations of TGFβ-1 0 pM (black line); 10 pM
(red line); 100 pM (green line) and 1000pM (blue line) for 5 days.
119
Influence of acute Myc and TGFβ-1 induction on senescence exe-
cution
In order to test the senescence induction by acute Myc overexpression, mouse
embryonic fibroblasts (MEF) were used as experimental platform. Mouse
embryonic fibroblasts both proficient and deficient for Suv39h1 were gener-
ated (for more details please refer to the method section), and by means of
the stable retroviral transduction a 4-hydroxy-tamoxifen (4-OHT)-inducible
Myc protein, fused to a modified estrogen receptor component (Myc-ER) was
introduced [Western blots of induced Myc can be found in the appendices
section A.1.4]. Shown here are cells treated with 100pM of TGFβ-1 with or
without Myc activation, cells were tested for senescent markers 5 days post
treatment by SA β- gal,H3K9me3 and by protein blot for pRb and p15INK4b
(which is a direct target of TGFβ-1, Figure 3.34).
Myc TGFβ-1 Suv39h1+/+ Suv39h1-/-
- -
- +
+ +
Suv39h1+/+ Suv39h1-/-
Myc
TGFβ-1
p15
pRb
Figure 3.34: Mouse embrionic fibroblasts irrespective of Suv39h1status dis-
play senescent phenotype. TOP: Cells from wild-type and Suv39h1−/− back-
ground were prepared 5 days post treatment and stained for SA β-gal activity.
BOTTOM: Cells from wild-type and Suv39h1−/− background were prepared
at day 5 post treatment and analysed for pRb and p15INK4b by Western blot.
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In here is shown that activation of Myc by 4-OH-tamoxifen induces senes-
cent phenotype in Suv39h1 proficient MEFs upon exposure to TGFβ-1 as
well as in Suv39h1−/− MEFs, as seen by SA β-gal and H3K9me3 staining.
MEFs are cellular system in which senescence could be induced even without
the presence of functional Suv39h1, as administration of 100 pM TGFβ-1 is
able to induce senescence irrespective of the Myc status even in the Suv39h1
deficient MEFs.
This result would argue that Suv39h1 is functioning in a cell/tissue spe-
cific manner, and that there are possibly additional histone-methyl trans-
ferases (HMTases) able to induce senescent-like arrest, compensating for the
Suv39h1 loss. Therefore this system was omitted from further studies pre-
sented here.
TGFβ-1 in vivo contributes to Myc-induced senescence
The impact of TGFβ-1 signaling on the Myc-driven lymphoma development
was tested in vivo. For this purpose Eµ-myc mice were exposed daily from
the three weeks of age to the drug lisinopril (60 mg/L in the drinking water
supply; lisinopril is the angiotensin converting enzyme inhibitor, used primar-
ily to treat hypertension, and was also shown to inhibit TGFβ-1 production
[SMN+02]). Mice were monitored for tumor latencies by palpation of periph-
eral lymph nodes. When animals were at the terminal stage of illness lymph
nodes were explanted and subjected to the further analysis (Figure 3.35).
Lisinopril treated mice developed tumors with a median latency of 103
days (compared to the untreated controls P=0,2830; Figure 3.35). When
tested for the senescence marker SA β-gal, as well as for the apoptotic marker
(TUNEL) lisinopril treated lymphomas have shown reduction in senescence
(4.0± 1.3%), whereas apoptosis seemed to be unchanged.
To summarize, although treatment with lisinopril did not significantly
change time to tumor onset, lymphomas explanted from animals treated with
lisinopril showed reduced senescence, without altering the ability of cells to
execute spontaneous apoptosis.
TGFβ-1 status in lymphomas with impaired DNA damage response
machinery
TGFβ-1 blocker lisinopril decreased intensity of Myc-induced senescence.
However, senescence was still detectable, therefore levels of TGFβ-1 protein
in animals with and without lisinopril treatment were tested in order to re-
veal level of the TGFβ-1 reduction. Further, as observed similar senescent
reduction phenotype in DDR compromised lymphomas, and previous publi-
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Eµ-myc
Eµ-myc+
Lisinopril
SA-β-gal TUNEL
Figure 3.35: Lisinopril treatment reduces senescence, not apoptosis. TOP:
Kaplan-Meier ”Time-to-tumor-onset” latencies for Eµ-myc+lisinopril (n=7,
blue line) and Eµ-myc (n=93, black line). BOTTOM: Top. Sections of
cryopreserved lymph nodes from lisinopril treated mice (n=7) were stained
for SA β-gal activity. Bottom: Sections of paraffin embedded, formalin fixed
lymph nodes from lisinopril treated mice (n=7) were stained for TUNEL
activity.
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cations have linked TGFβ-1 to induction of ROS, and potential induction of
senescence, DDR compromised lymphomas were tested on TGFβ-1 levels as
well. Eµ-myc (n=2), as well as Eµ-myc treated with N-Acetylcysteine (n=2),
Eµ-myc treated with caffeine (n=2) and Eµ-myc treated with lisinopril (n=2)
were tested for the TGFβ-1 expression levels (Figure 3.36).
TGFβ-1
Tubulin
untreated N-Acetyl cysteine Caffeine Lisinopril
Figure 3.36: TGFβ-1 expression is reduced upon lisinopril treatment and in-
tact under the treatment with agents compromising DDR. Lymph nodes from
Eµ-myc mice (n=2) without any additional treatment, Eµ-myc mice treated
with N-acetylcysteine (n=2), Eµ-myc mice treated with caffeine (n=2) and
Eµ-myc mice treated with lisinopril (n=2) were tested by Westen blot for
the TGFβ-1 expression levels. Tubulin was used as a loading control.
As seen here TGFβ-1 levels are not affected by compromised DDR re-
sponse, arguing that TGFβ-1 mediation could be positioned upstream of the
DDR (and for that reason more thorough research on possible DDR malfunc-
tions in lisinopril treated lymphomas would be advisable). However intact
spontaneous apoptosis rates in lymph nodes of lisinopril treated mice argue
against that. Another possibility is that TGFβ-1 resides in the parallel path-
way (for that reason mice treated with both lisinopril as the TGFβ-1 blocker
and caffeine or NAC as the DDR blocker should be monitored for the tumor
latencies and tested for the complete cessation of senescent phenotype).
Lymphoma microenvironment in vitro alters TGFβ-1 expression
patterns
As observed earlier in the subsection addressing the tumor microenvironment
and senescence, all of the control lymphomas appeared to have multi-focal
distribution of senescent cells. Therefore, it was possible that local differences
in growth factors as well as oxygen supply might be responsible for the non-
homogenous pattern of the senescence positive cells.
To test the possible influence of oxygen tension on the induction of senes-
cence, lymphoma cells were exposed in vitro to two different oxygen growth
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conditions (21% and 1% of the oxygen, referred as hyperoxia/ normoxia and
hypoxia respectively). Please note that 21% of oxygen exceeds levels nor-
mally found in tissue, since normal levels of oxygen are approximately 3%,
and could reach 1% in not well oxygenated areas of tumor. After 5 days
in culture lymphoma cells were tested for TGFβ-1 levels on ELISA assay,
and after 10 days in culture RT-PCR analysis was performed and TGFβ-1
transcript was detected in order to see eventual changes caused by hypo- or
hyper-oxic conditions (Figure 3.37).
21% O2 1% O2
TGFβ expression analysis
21% 1% 21% 1%
Eµ-myc 
Suv39h1+/+
Eµ-myc 
Suv39h1-/-
TGFβ-1
TBP
TGFβ-1 levels in cultured cells
(relative values)
Eµ-myc 
Suv39h1+/+
Eµ-myc 
Suv39h1-/-
21% O2 1% O2
Eµ-myc 
Suv39h1+/+
Eµ-myc 
Suv39h1-/-
1.0
1.5
0.5
Figure 3.37: TGFβ-1 expression levels change dependent on oxygen con-
ditions in both Suv39h1 proficient and deficient cells. LEFT:Experimental
setup: Suv39h1 proficient and deficient lymphoma cells were cultured in 2
different oxygen conditions (21% and 1%). After 10 days in culture RNA
was isolated from cells, and tested for TGFβ-1 transcript levels. TOP: Eµ-
myc (n=3) and Eµ-myc, Suv39h1 (n=3), TBP was used as a loading control.
RIGHT: Eµ-myc (n=3) and Eµ-myc Suv39h1 (n=3) cells were cultured for
5 days days in different oxygen conditions (21% and 1%), and subsequently
cell supernatant was tested for levels of excreted TGFβ-1 by commercialy
available ELISA assay.
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ELISA analysis of lymphoma supernatant revealed higher levels of TGFβ-
1 in Suv39h1 deficient cells than in control lymphoma cells. Further, it is
shown that TGFβ-1 secretion in both groups (although more pronounced in
the control group) is enhanced by higher oxygen levels in vitro, arguing that
vasculature of tumor could contribute to the TGFβ-1 secretion, as well as to
senescence induction.
Concluding, in vitro hyperoxic growth conditions can cause an accumu-
lation of TGFβ-1.
3.2 Tumor treatment
One of the main questions concerning tumor treatment is: if cells undergo-
ing treatment have intact machinery that will enable them to execute failsafe
programs in a response to conventional chemotherapy. When overexpressed
Myc is known to induce a primary apoptotic response, as opposed to Ras/Raf
signaling inducing a primarily senescent response [SLM+97]. Previously it
was also shown that when treated with anticancer DNA damaging drugs,
Myc-driven lymphomas (protected from apoptosis) are able to undergo drug-
induced senescence[SWBR+00]. The contribution of senescence to the tumor
therapy in a setting where only senescence is specifically genetically termi-
nated was tested.
3.2.1 Suv39h1 deficient lymphoma cells and treatment
induced failsafe pathways
Drug-induced apoptosis
Lymphoma cells from different genetic background were tested in their ability
to execute drug-induced apoptosis in a response to different concentrations
of a DNA-damaging agent [topoisomerase II inhibitor] Adriamycin (ADR)
during the course of 24 hours. Viability of cells was assesed by trypan blue
dye exclusion. Since ADR is known to induce p53 dependant cell death
p53 deficient lymphoma cells were used as a negative control in this setting.
Additionally, cells undergone treatment were tested in dual AnnexinV/ Pro-
pidium iodide [PI] flow cytometric staining for the determination of apoptotic
stage. Annexin V/PI staining is commonly used for distinguishing early to
late apoptotic events. PI is the most commonly used dye for DNA content
analysis, and also to asses integrity of the plasma membrane, which becomes
disrupted in late stages of apoptotic cell death. AnnexinV is detecting reloca-
tion of membrane phosphatidylserine (PS) from intra to extracellular surface,
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which is an early apoptotic event (Figure 3.38).
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Figure 3.38: Suv39h1 deficient lymphomas are able to undergo drug pro-
voked apoptosis. LEFT. Top: Short term cytotoxicity assay (24 hour ex-
posure to different concentrations of Adriamycin) was assesed in Eµ-myc
(black; n=19); Eµ-myc, Suv 39h1 −/− (red; n=12); Eµ-myc, p53 −/− (blue;
n=3) (concentrations of Adriamycin were: 0.5µg/µl, 0.1µg/µl, 0.05µg/µl,
0.01µg/µl, 0.005µg/µl). 24 hours post Adriamycin exposure viability was as-
sesed by trypan-blue count. Bottom: Scheme of Annexin V/PI staining: cells
can score as intact viable cells (AnnV-/PI-), early apoptostic (AnnV+/PI-)
or late apoptotic (AnnV+/PI+). RIGHT: AnnexinV/PI staining of ADR
treated lymphoma cells.
As shown in here both Eµ-myc and Eµ-myc, Suv39h1−/− lymphomas
retain the ability to execute drug induced apoptosis, leading to further test-
ing on status of Suv39h1 deficient lymphomas in execution of drug-induced
senescence.
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Drug induced senescence
After observing defects in Myc-induced senescence that Suv39h1 deficient
lymphomas are displaying, possibility of Suv39h1 deficient lymphomas dis-
playing similar block of drug-induced senescence in a treatment model was
examined. Since there was still no targeted therapeutic aiming only at the
senescence machinery, and although senescence is induced by conventional
chemotherapy, it is often masked with gross acute apoptotic response, apop-
tosis was exogenously blocked by stable retroviral transduction with bcl2.
First, apoptotic blocker bcl2 was stably retrovirally introduced into all of
the lymphomas tested in vitro, then lymphomas were treated with 0.05 µg/ µl
ADR, and 7 days post treatment cell cytospin preparations were stained for
the senescent marker SA β-gal activity. While Suv39h1 proficient lymphomas
displayed their ability to enter senescence upon ADR treatment, Suv39h1
deficient, as well as p53 deficient lymphomas displayed their inability to
execute drug-induced senescence (Figure 3.39).
Results shown in here demonstrate inability of Suv39h1 deficient lym-
phomas to execute senescent arrest in a response to drug therapy. This
finding can have important implications in tumor therapy model, which was
subsequently tested.
3.2.2 Tumor therapy in vivo
In accordance to the observation from section 3.2.1 (i.e. that only control
lymphomas retain their ability to enter senescence upon ADR treatment),
further analysis was conducted on the impact of Suv39h1 loss on the treat-
ment sensitivity in vivo. The disease was recapitulated by transplantation
of Suv39h1 proficient and deficient primary lymphomas. 2-3 million of lym-
phoma cells in 300 µl saline solution suspension was injected into the tail vein
of the recipient wild-type mice. Each lymphoma was transplanted into two
wild-type syngenic 6-8 weeks old mice, and all of the transplanted lymphomas
formed tumors within the range of 20-30 days.
Post transplantation mice were monitored by palpating peripheral lymph
nodes every three days, and when lymph nodes were graded as palpable in
two consecutive times a single dose (300mg/ kg of body weight) of Cyclophos-
phamide (CTX) was administered to the mice. Mice were further monitored
for the long term treatment outcome. All of the studied lymphomas initially
responded to the CTX tretament by regression of tthe palpable lymph nodes,
which occured 3-6 days post treatment (Figure 3.40).
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Figure 3.39: Suv39h1 deficient lymphomas fail to senesce upon therapy
in vitro. Low passage lymphoma cells were retrovirally transduced with
a MSCV-bcl2-puro construct, selected with antibiotic for positive clones,
and then treated with 0.05µg/µl of Adriamycin for 7 days. Post treat-
ment cell cytospin preparations were stained for the senescence marker SA
β-gal in Eµ- myc/bcl2 (n=8), in Eµ-myc,Suv39h1−/−/bcl2 (n=6) and in Eµ-
myc,p53−/−/bcl2 (n=3).
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Figure 3.40: Experimental outline for the treatment study. Wild-type
mice were transplanted with lymphomas extracted from Eµ-myc, Eµ-myc,
Suv39h1+/− and Eµ-myc, Suv39h1−/− mice. Each lymphoma was trans-
planted into 2 recipient mice. Post transplantation mice were monitored
for the onset of the disease by palpation of peripheral lymph nodes. Dis-
ease arised in mice 20-30 days post transplantation. At the point of disease
occurrence mice were treated with a single dose of Cyclophosphamide and
monitored for the time to death or the tumor regression (which occured
within 6 days). After mice were graded as tumor free they were monitored
for the relapse times for the further 100 days. If mouse at day 100 did not
have any visible tumor burden and was not suffering from the severe weight
loss it scored as ”achieved-long-lasting-remission”.
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Impaired long term-treatment outcome in Suv39h1−/− lymphomas
After the initial response to the therapy mice were monitored for the 100 days
to investigate long-term responses to the therapy. While cohort of control
mice achieved long lasting remission in 60% of the cases (15/25), Suv39h1 de-
ficient cohort succumbed to the disease in 80% of the observed cases (13/15)
[for the Suv39h1+/− transplantation data, as well as for the bcl2-lymphoma
data please check appendices section A.2.1 and A.2.1](Figure 3.41).
Time-to-relapse
Time-to-death
Figure 3.41: Suv39h1−/− lymphomas have inferior long term treatment out-
come. TOP: Eµ-myc mice (black line; n=25) and Eµ-myc, Suv39h1−/− mice
(red line; n= 15) were monitored for the ”Time-to-relapse” latencies (as de-
fined by Kaplan-Meier estimator) post Cyclophosphamide (CTX) treatment.
RIGHT: Eµ-myc mice (black line; n=25) and Eµ-myc, Suv39h1−/− mice (red
line; n= 15) were monitored for the ”Time-to-death” latencies (as defined by
Kaplan-Meier estimator) post Cyclophosphamide (CTX) treatment.
Results shown here indicate that animals bearing Suv39h1 deficient lym-
phomas had faster relapse time as well as reduced overall survival when
compared to Eµ-myc mice, indicating that loss of Suv39h1 impairs beneficial
long-time response to the therapy.
130
Correlation between treatment outcome and senescent features of
primary lymphomas
As seen previously significant impact of defects in senescent machinery reflect
on the long term treatment response. Observing differences in the extent of
senescence that each of lymphoma displays, as well as noticing differences in
the treatment response of Eµ-myc lymphoma group, a correlation between
the two by testing for the extent of senescence (assesed by SA β-gal staining)
and comparing it to the long term treatment outcome was attempted to
establish here (Figure 3.42) [for the apoptosis data please check appendices
A.2.1].
Figure 3.42: Correlation between extent of senescence and response to tre-
atment could potentially be a good prognostic marker. Plot is showing cor-
relation between senescence positivity and the treatment outcome. Group
marked as a good prognosis one achieved long term treatment outcome and
was highly positive for senescence marker.
Here is observed a moderate dependency between the treatment outcome
and the initial senescence positivity of the lymph node. However the associ-
ation was not tested for the statistic significance, since many of lymphomas
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achieved long term treatment outcome, but failed to score high for senescence
marker. Therefore SA β-gal should be used together with other senescence
markers to further explore this connection.
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Chapter 4
Discussion
4.1 Aim and scope of the thesis
The aim of the work presented in this thesis was to investigate the role of
Suv39h1 histone methyltransferase in Myc-driven lymphomagenesis in vivo,
and subsequently to test Suv39h1 contribution to the long term therapy
outcome. It was shown in the past decades that most cancers arise as a con-
sequence of insufficient function of cellular failsafe programs. Only recently
has research focused on epigenetic alterations as triggers of cancer[FT04].
Epigenetic contribution to the development of cancer is becoming appar-
ent in cases of hypermethylation of promoter regions found in many of the
genes in the mammalian genome. These changes are associated with the
inappropriate transcriptional silencing of genes and are found as often as
disruptions in tumor suppressor genes, they are therefore part of most of
the human tumors[JB02]. The epigenetic contribution is further shown by
linking changes in post translational histone modifications and development
of malignant disease, as is the case presented in this thesis. Lastly, described
here is finding of an additional failsafe mechanism mediator, TGFβ, oppos-
ing hyperproliferation triggered by Myc-induced signaling and forcing cells
to undergo premature proliferative arrest, senescence. Cytokine signaling
is a novel concept in the oncogene-induced senescence, and its involvement
in senescence induction provides insight into the complexity of senescence
regulation.
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4.2 Tumor development
4.2.1 Loss of histone methyltransferase Suv39h1 accel-
erates Myc-driven lymphomagenesis
The Eµ-myc transgenic mouse model is a well established and valuable sys-
tem to investigate impact of disruptions in apoptotic machinery on B-cell
lymphoma development and treatment outcome. Accordingly to previoous
reports, as shown in the figure 3.6 all of the mice tested succumbed to B-
cell lymphomas. Further, results presented in figure 3.6 of the thesis clearly
show that disruption in Suv39h1 gene causes shortened tumor latencies in
Eµ-myc. This finding is in accordance to the previous report by Braig et
al that Suv39h1 histone methyltransferase is a gene with an important role
in the execution of the oncogene-induced senescence in Ras-driven tumor
setting[BLL+05]. In this model Suv39h1 was identified as a downstream
mediator of senescence. Senescence was firstly introduced as an oncogene
induced failsafe program in a Ras-overexpressing system[SLM+97], and in
the same system it was identified that the Rb-mediated heterochromatin
formation is the mechanism leading to transcriptional silencing (senesce-
nce)[NNH+03].
However, for oncogenic Myc apoptosis was the first, and until recently the
only known failsafe mechanism to prevent uncontrolled proliferation of cells.
Therefore results obtained in figure 3.6 reflect critical finding of the work
presented in the thesis, that intact Suv39h1 is a prerequisite for longer tumor
latencies of Eµ-myc driven lymphomas. Although lymphomas do develop in
a setting where Suv39h1 is intact, it became clear that their latencies were
about 50 % longer. This finding revealed presence of senescence as a failsafe
mechanism in Myc-induced lymphomas. Senescence in this model can be
exploited to be investigated as a prognostic indicator as well as to be a basis
for a design of a new treatment modalities aiming at the aggressively growing
lymphomas.
One of the previous reports revealed that block in the B-cell maturation
causes more aggressive phenotype in lymphomas[EWR+99], which could po-
tentially be one of the Suv39h1 mechanism of action. However histology ob-
servations in figures 3.2 and 3.3 , as well as results obtained by phenotyping
for the B-cell lineage commitment and differentiation in figure 3.4 revealed
indistinguishable characteristics in lymphomas arising in both Suv39h1 pro-
ficient and deficient animals.
Additional observation in figure 3.6 revealed that the tumor latencies
are virtually overlapping for Suv39h1−/− and Suv39h1+/− lymphoma bear-
ing animals. Further examined in figure 3.7 lymphomas arising in Suv39h1
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heterozygous background were shown to develop in the cellular environ-
ment where the remaining functional Suv39h1 allele is inactivated, which
occurs via the random X-chromosome inactivation, therefore making tumors
in Suv39h1+/− mice nullyzygous. Process of X-chromosome inactivation,
which is normally occurring in female mice should be random, and the cells
from the animal, including the B-cells should be in about 50% of the cases
Suv39h1 proficient. In the case of Suv39h1 loss tumor cells have an advantage
growing in a genetic setting lacking Suv39h1 expression, which is seen by the
drastically shortened tumor latencies. This finding, supported by the same
pattern of Suv39h1 loss contributing to the shorter survival latencies in the
Eµ-N-Ras model[BLL+05] is confirming tumor-suppressive role of Suv39h1
in Myc-lymphoma model.
Concluding from the first part of research presented here intact Suv39h1
gene is important in Myc-driven lymphomagenesis, since disruption in it will
lead to significantly faster, however not more aggressive formation of B-cell
lymphomas.
4.2.2 Eµ-myc lymphomas enter senescence
Here, for the first time alteration in tumor latencies of lymphomas developing
in a Eµ-myc mouse model was linked to the defect in the epigenetic modifi-
cations machinery, in particular to the action of Suv39h1 gene. Suv39h1 is a
histone methyltransferase, tri-methylating lysine 9 residue on the histone H3
(H3K9me3), and by this methylation it creates docking site for the HP1 pro-
teins, in particular HP1γ, initiating heterochromatin formation. H3K9me3
mark is found to co-localize with senescence associated heterochromatic foci
(SAHF) present in senescent cells. Since Suv39h1 is an Rb bound protein,
and SAHF are Rb-mediated as well as they map to E2f responsive promoters
of the S-phase genes[NNH+03] it was predicted that Suv39h1 is silencing E2f
responsive genes. By this silencing Suv39h1 is repressing proliferation, and
leading to the cell cycle arrest.
Eµ-myc lymphomas with intact Suv39h1 gene displayed less cells in cycle
on account of constant loss of cells into Myc-induced senescence. Lymphoma
cells undergone myc-induced senescence displayed all the main characteris-
tic of senescent cells: enlarged size and granularity, tri-methylated mark on
histone H3 lysine 9 residue, SA β-gal positivity, as well as accumulation of
the HP1γ marks. However, due to technical reasons SAHF are not visible
in murine cells, therefore it was not possible to overlay H3K9me3 mark or
of HP1γ mark with the DAPI-visualised SAHF regions. Despite this tech-
nical difficulties with SAHF visualization, both H3K9me3 and HP1γ marks
present usually only in senescent cells were visible only in Suv39h1 proficient
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lymphoma cells.
Protein analyses of the Suv39h1 proficient and deficient lymphomas re-
vealed intact senescence machinery only in control lymphomas, as shown
by the fraction of hypophosphorylated Rb, as well as by the presence of
H3K9me3. This result confirmed that Eµ-myc lymphoma cells are able to
enter oncogene-induced senescence program, as observed by histone modi-
fications indicative of chromatin state changes these cells exhibit. Further,
Rb signaling is shown to be indispensible for the downstream silencing, as it
exists in its ”active”/ hypophosphorylated form only when intact Suv39h1 is
present.
Senescence was primarily identified as a Ras-inducible program, however
since this finding there were reports that senescence can be activated via p53
modulation of failsafe machinery pathways. This finding initiated testing on
other genetic components of the p53 pathway and their ability to convey
signals needed for the senescence induction. Myc-induced senescence was
tested on several genes known to be involved in senescence and apoptosis.
Results revealed that in the Myc setting p16INK4a is completely dispensable
for the senescence induction, as sporadic pattern of senescent cells seems
to be unchanged, indirectly confirming previous findings by Krimpenfort et
al [KQM+01] showing no significant impact of p16INK4a loss on the tumor
latencies. However, sporadic senescence pattern was not detectable when
genes residing in Arf/p53 pathway were absent, pointing to a crucial role of
p53 gene in Myc-induced senescence. Interestingly deletion in ATM, a major
DNA damage response mediator did not fully impair senescence induction,
directly leading to the idea of a novel mechanism to partially mediate Myc-
induced senescence.
Until recently there was a debate whether senescent cells are ”end-of-the-
tumorigenesis” byproduct, hence being present/accumulated only in the end
stage of the tumor, as it was not shown how are senescent cells cleared out
of the tissue. Recent finding of Xue et al show that tumor cells entering
senescence will be removed from the tumor tissue by the immune system.
This finding together with our results showing that Myc-induced senescence
is a critical tumor suppressive mechanism present as early as in the pre-
manifest stage of lymphoma supported the idea of a constant loss/constant
production, hence active dynamics of tumor senescent cells[XZM+07].
Taken together, this part of the research has unveiled Myc-induced senes-
cence as an Arf-p53-Suv39h1 dependent program, and unveiled partial depen-
dency upon DNA damage response machinery, as seen by the partial senes-
cence inhibition upon ATM deficiency. Further, oncogene-induced senescence
is a dynamic process, starting as early as at the pre-manifest stage of tumor
development.
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4.2.3 p53 loss in Eµ-myc lymphomas is sufficient to
protect from additional Suv39h1 loss
Lymphoma cells with Myc overexpression often exhibit disruptions in apo-
ptotic machinery, caused by loss of tumor suppressor p53 leading to the
significantly shortened tumor latencies, displaying more aggressive pheno-
type[EWR+99]. p53 collaboration with Myc inEµ-myc p53+/- mouse model
is well documented through the loss of the additional p53 allele (loss of
heterozygosity-LOH)[LHCA86]. Possibility of Suv39h1 defect collaborating
with p53 defects were tested in the work presented here. If such a collabora-
tion in the loss of the 2 genes would exist, it would impact tumor latencies in
Eµ-myc mice. Results presented in figure 3.12 reveal that tumor latencies are
not shortened in Eµ-myc mice with the disruption of p53 and Suv39h1 when
compared to the Eµ-myc mice with an intact p53, but disrupted Suv39h1.
Further, when lymphomas obtained from the diverse Suv39h1/p53 deficient
settings were tested for the intactness of the wild-type p53 allele as well as
for the presence of Suv39h1 transcript it was revealed that in the setting with
disrupted p53 lymphomas will develop in both Suv39h1 proficient and defi-
cient cells in Eµ-myc, Suv39h1+/− mice. This finding revealed p53 loss as a
primary genetic event in Myc-driven lymphomagenesis, which is in line with
the current knowledge of p53 being central mediator of both apoptosis and
senescence. In this setting losing Suv39h1 expression is becoming redundant,
since p53 is co-controlling Myc-induced senescence, and the defects in p53
will therefore be enough to disable both apoptotic and senescent machinery.
This finding is in line with findings of Xue et al that p53 activation leads
to senescence[XZM+07]. Also, it is shown that p53 action can opt for ei-
ther apoptosis or senescence; probably much of the decision depends on the
tumor cell type. Further, p53 activation in Eµ-myc model is dependent on
p19Arf [SMdS+99], finding not observed in many human tumors. Another dif-
ference of the mouse system used here is the extraordinary telomere length,
which disrupts one of the pathways leading to p53 activation. If p53 path-
way is intact is irrespective of Suv39h1 status,however in the case of pre
targeted disruptions in both p53 and Suv39h1, p53 will be the first gene to
be functionally inactivated, as it mediates both apoptosis and senescence.
4.2.4 Can loss of Suv39h1 be compensated for?
As seen in the Eµ-myc lymphoma mouse model, Suv39h1 is necessary for the
mediation of oncogene-induced senescence. However, results obtained using
another system: mouse embryo fibroblast (MEF) unveils the possibility of the
cell-type specific function of Suv39h1, or a possible compensation by the other
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histone methyltransferases, as it was possible to induce senescent-like arrest
irrespective of Suv39h1 status. Results obtained in this part of the thesis
could question cell-type specific functions of Suv39h1, and could indicate
necessity for search of an additional (compensatory) mechanism existing in
the mouse embryo fibroblast system.
4.2.5 DDR machinery impacts Myc-induced senesce-
nce
DNA damage response (DDR) emerged as an early barrier to the further
development of tumor. Outcome of DDR induced signaling can be mapped
to apoptosis and senescence, and activated Myc is able to produce DNA
damage in vivo [VWK+02], directly questioning if a Myc-activation could
lead to senescence via DNA damage response(DDR). In vivo experiments
alleviating DDR by either scavenging reactive oxygen species (ROS, by N-A-
cetylcysteine) or inhibiting kinase (ATM/ATR)-governed DNA double strand
break (DSB) checkpoint (by caffeine) revealed reduction, but not the com-
plete absence of sporadic senescence in Eµ-myc lymphomas. Reduction in
the senescent phenotype was accompanied either by reduction in apoptosis
(as observed in the caffeine treatment approach, in line with its function in
degradation of p53 and its nuclear export) or by alterations in apoptosis and
proliferation (as described by Reimann et al in N- Acetylcysteine approach).
Although ablation of senescence in vivo by the improperly functioning DDR
machinery as a contributing factor to the shortened tumor latencies would be
a quite elegant finding, deregulated apoptotic and proliferation machinery in
our system prevented resolving the full contribution of DDR to senescence in
vivo in this model. Persistent Myc-induced DDR is shown to be the upstream
mediator of senescence. However, by data shown here it became apparent
that DDR is not the only regulator of senescence, as cells are showing reduced
sporadic senescence in cases when DDR machinery is blocked.
4.2.6 Cytokine signaling impacts Myc-induced senes-
cence
The gene expression analysis screen was set to identify genes that are dereg-
ulated due to the Suv39h1 loss in Myc-lymphomagenesis. TGFβ- induced
(Tgfbi or βIGH3) gene was one with the strongest deregulation between
Suv39h1 proficient and deficient genotypes. βIGH3 gene was reported to
be upregulated upon treatment with differentiation- inducing agents that
provoke cellular senescence[DCFR02]. Recent findings show that βIGH3
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can also promote metastasis in a colon cancer model[MRR+08]. In Myc-
lymphomagenesis model the βIGH3 gene product could be a senescence medi-
ator, acting upstream of Suv39h1. Alternatively, βIGH3 deregulation found
as a consequence of Suv39h1 deregulation could serve as an indicator of an-
other mechanism, namely of TGFβ. The identification of TGFβ, a known
upstream regulator of βIGH3, as a cytokine displaying higher expression
levels when Suv39h1 is ablated, unveiled cytokine-mediated senescence as a
component of Myc-induced senescence. Research conducted in this thesis
did not reveal the stage in tumor development when TGFβ starts mediating
senescence, therefore it is possible that the DNA damage response machin-
ery could serve as a primary mechanism of senescence mediation[VWK+02],
later accompanied by TGFβ.
TGFβ is a potent cytokine, with a very complex function, being inducer
of the arrest in the late G1 phase of the cell cycle by inhibition of CDKs which
phosphorylate pRb and other components [LDL+90],[KOP+93], or a driving
force in the tissue growth and morphogenesis in embryo[HMF+87]. TGFβ
upregulates p15INK4b and induces cell cycle arrest by directly inhibiting
CDK4/6 and by indirectly inactivating cyclin E/ CDK2 via the displacement
and shuttling of p27Kip from CDK4/6 to cyclin E/CDK2[KOP+93]. Find-
ings of this thesis did not shown that there is a difference in the expression
of p15INK4b depending on the Suv39h1 status. However, there was found an
increased expression of p16INK4a, proposing an alternative TGFβ-mediated
signaling cascade in Eµ-myc induced senescence. Elevated p16INK4a levels
in the context of elevated cyclin E levels would also suggest for the impair-
ment in p27Kip function, however p27Kip was tested and its function seems
to be intact, arguing again for the alternative mechanism connecting TGFβ
signaling to p16INK4a. Further experiments have to be conducted in order
to verify this hypothesis. As previously shown, much of TGFβ functions
are time and cellular context dependent. As reported in the breast cancer
model TGFβ acts at an early stage as a tumor suppressor, changing it’s func-
tion at more advanced stages of cancerogenesis, where cancer cells are able
to bypass primary TGFβ tumor suppressive functions and use it for their
own advantage[AFG99],[Gol99]. This could be the case in already end-stage
lymphomas of Eµ-myc mice and could explain that p15INK4b is not anymore
necessary for the arrest state. If TGFβ can signal through p16INK4a it would
still be mediating senescence in a late-stage tumorigenesis.
Experiments conducted here showed if apoptosis is blocked, Suv39h1 pro-
ficient cells will arrest in senescence-like mode, while Suv39h1 deficient cells,
as well as p19Arf and p53 deficient cells will continue their growth. This
experiment established TGFβ’s potential in inducing senescence arrest in
vitro. After cell culture propagation differences in levels of TGFβ expression
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remained unchanged in lymphoma cells, indicating that they may be the
source of TGFβ.
One of the possible modes of TGFβ production regulated is by the differ-
ent oxygen conditions cell is exposed to in vitro. This finding was supported
by the in vivo finding of more senescent cells being detected in the proximity
of the blood vessels. Although only correlative, these two findings point out
that TGFβ could be more concentrated around the well oxygenated areas in
tumor. Here should be taken in consideration the fact that HIF-1α , present
in the hypoxic areas will be inducing angiogenesis[Sem00], which makes it
hard to claim that these areas are all equally well oxygenated. Therefore fur-
ther set of experiments with substances like pimonidazole (”hypoxia marker”)
tracking oxygenation in vivo[BRD02] should be used to test the correlation
of oxygen levels in the areas with high senescence positivity. Also, impact
of the TGFβ signaling on DNA damage response (DDR) and possible co-
localization with reactive oxygen species (ROS) should be investigated, as
ROS are also found to be more abundantly present in well oxygenated areas.
In vivo treatment with a potential TGFβ-1 blocker revealed reduction in
senescent phenotype in Eµ-myc lymphomas, although there was no signifi-
cant shift in the tumor latencies found. Protein expression levels of TGFβ-1
were tested and it was established that there is only partial reduction as a
response to this treatment, which might be the reason of not observing more
solid differences in tumor latencies.
Myc-induced, cytokine mediated senescence is a novel concept providing
more insight into the at least dual regulation of senescence (cytokine and
DNA damage response mediated).
4.3 Tumor treatment
Tumor model used in this thesis is a Burkitt’s like B-cell lymphoma. Burkitt’s
lymphoma is a childhood tumor, characterized by reciprocal translocations
between the cMyc gene on chromosome 8 and one of the immunoglobulin
(Ig) loci on chromosome 2, 14 and 22[Kle89]. The hallmark of Burkitt’s lym-
phomas is constitutively activated cMyc gene driving tumor growth[HA00].
Further, mutations of p53 were found in more than 30% of Burkitt’s lym-
phomas, additionally p16INK4a is silenced via hypermethylation[GBG+91],-
[KOM+98]. Tumors developing in Eµ-myc mice also carry mutations in
p53 (30%) and INK4a/Arf deletions (20%) [EWR+99]. Lymphomas lack-
ing INK4aArf locus displayed the same characteristics as p53 mutated lym-
phomas, their latencies were shortened on account of aberrant apoptosis-
[SMdS+99].
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When aggressively growing Myc lymphomas received standard treatment
with cyclophosphamide they entered longer remission periods, and many of
them even achieved long lasting remissions, when compared to mice bear-
ing lymphomas with disrupted p53, in a setting with and without external
apoptotic block[SL02]. Data presented by Schmitt et al had shown that
Myc-lymphomas can utilize prognostically valuable program of drug induced
senescence only when p53 remains intact. Results in this thesis show that lack
of the functional Suv39h1 leads to significantly inferior treatment responses
in vivo. Although Suv39h1 deficient lymphomas are able to execute drug
induced apoptosis they fail to execute drug induced senescence in vitro and
in vivo. Their inability to execute senescence in vivo leads animals bearing
Suv39h1 deficient lymphomas to relapse shortly after remission is achieved.
Their initial response revealed their capability to execute drug induced apop-
tosis in vivo, and their shortened relapse latencies revealed dysfunction in
another mechanism that seems to be intact in the Suv39h1 proficient lym-
phomas, later revealed by the experiment with an apoptosis blocker to be the
senescence. However, due to the low number of animals tested in the experi-
ment with the apoptosis block, it would be reasonable to increase the number
of animals for reaching the statistical significance. Additionally it was ob-
served that the difference in the extent of the sporadic senescence varies
even within the group of Suv39h1 proficient mice, this could be the factor
influencing final outcome to the therapy. When extensively tested a weak
correlation between senescent phenotype and a relapse latencies occurred.
However it should be mentioned that only one of the available markers for
senescence was used, and that by broadening the panel of markers for senes-
cence in the future one could possibly make a better estimation then the one
observed here. Concluding from the treatment data: senescence disruption
by Suv39h1 impairment leads to the significantly shorter relapse times in
Eµ-myc mice, resulting in the inferior treatment outcome.
4.4 Future prospects
Myc was identified more than 2 decades ago as the oncogene which is de-
regulated by Ig translocations in B-cells [DFMG+83], and it was used in
mouse models of cancer to mimic Burkitt like B-cell lymphomas found in
humans[VH06]. Recently models of sporadic Myc oncogene activation emer-
ged[CRS+08], which recapitulate disease onset in humans more accurately,
and would be a valid model to use in the future research. In this thesis efforts
have been made to discover an additional factor triggering oncogene-induced
senescence. Recent reports have pointed out that the cytokine signaling
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plays a central role in both apoptosis and senescence[KMV+08],[AOB+08],-
[WSZ+08]. Here is proposed cytokine TGFβ mediation of the senescence
induction. Further research on this topic would require series of data re-
vealing the role, mechanism and the regulation of the production of TGFβ
in the induction of senescence in lymphoma model. Also, now it is known-
[KMV+08],[AOB+08],[WSZ+08] that there are other cytokines eliciting the
same senescent response as TGFβ-1 does in Myc-driven lymphomagenesis as
tested here. Therefore additional cytokine profiling would reveal if TGFβ is
the only deregulated cytokine in this model, or if there are other cytokines
contributing to the senescence phenotype observed in the current research.
One of the approaches to further specifically dissect TGFβ impact could be
treatment of mice at a risk of developing Myc-driven lymphomas with one
of the reported TGFβ inhibitors[INC+02],[DBMLR04],[YDT+02]. Also, it
would be necessary to expand testing to the pre-manifest stage of the lym-
phoma development, as TGFβ is reported to have mostly dual action in the
tumor development, changing from anti- to pro- tumor survival, therefore
comparing pre-manifest stage with a manifest stage of a tumor could provide
some clues on how does TGFβ function in this model.
One of the key findings of this thesis was that Myc overexpression is in-
ducing senescence in vivo, however induction of senescence in Myc driven
lymphomas in vitro could not be shown. One of the reasons might be the
”cell culture shock”, since culture conditions differ greatly from the in vivo
conditions in which these lymphomas are formed and grown. So far there
was only one report of Myc-induced senescence in in vitro setting, for human
diploid fibroblasts cell model[DRJ+03]. Although this finding indicates that
there is such in vitro senescence induction, there are no other reports con-
firming this findings in other cell models. Another conflicting finding, by Wu
et al [WvRY+07] shows that upon inactivation of Myc in tumors senescence
is triggered, this work was dealing with a ”oncogene-inactivation-induced-
senescence” (OIIS) model, in which upon Myc-inactivation in a different
model there is onset of senescence. However, senescence occurred shortly
after Myc-inactivation and was present during a period of few days and then
was again undetectable, which would indicate that there might be a residual
activity of Myc-overexpression induced machinery able to induce senescence.
This work was done in another model, and possible differences arising as a
consequence of a work in the different cell context should not be excluded.
Although until recently only apoptosis is found to be triggered by Myc’s
overexpression[LHCA86], senescence became interesting mechanism in a con-
text of Myc action. Presence of Myc induced senescence was shown to exist as
early as in the pre-manifest stage [BHK+05], and as shown here is contribut-
ing to the anti-proliferative failsafe machinery with the same percentage of
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arrested cells as does apoptosis.
Here is shown that the oncogene-induced senescence is dependent on in-
tact Suv39h1 in a Myc-driven lymphoma model, starting to functioning as
early as the pre-manifest tumor stages. Also, lymphomas developed in Eµ-
myc animals lacking p19Arf or p53 are not displaying any sporadic senescence,
which is in line with their tumor development kinetics. This finding under-
lines necessity of p19Arf -p53 signaling cascade for proper functioning of both
failsafe pathways. It would be interesting to further study if these lymphomas
are missing H3K9me3 mark in its entirety. It would also be important to
find if the cells of pre-manifest lymphomas of p19Arf or p53 deficient animals
could induce senescence despite non functional p19Arf -p53 cascade, revealing
if there might be another mechanism governing Myc-induced senescence in a
stage where tumor is not fully developed.
This another mechanism mediating senescence could be TGFβ related. It
is known that TGFβ is able to block endogenous Myc[AM95], however when
Myc is under the Eµ promoter TGFβ will not be able to block it, as shown
by equal expression levels of Myc protein in both Suv39h1 proficient and
deficient lymphomas. Also, It is important to note that TGFβ action on the
plethora of the genes deregulated in Myc-driven lymphoma model was not
investigated, which would be an interesting set of experiments for the future
researcher on this topic. Role of TGFβ in the DNA damage response (DDR)
machinery is not fully investigated. Some reports shown that TGFβ silences
BRCA1 dependent DDR via SMAD3[DKL+05], this provided an insight into
DDR regulatory role of TGFβ. This finding has not yet been addressed in
a lymphoma mouse model. Compromised DDR machinery (using caffeine
or N-Acetylcysteine[NAC] treatment in vivo) partially impairs senescent re-
sponse, however not in its entirety. Attempts to block TGFβ signaling in vivo
by using drug lisinopril (angiotensin converting enzyme inhibitor[SMN+02])
elicited similar senescence phenotype as treatment with NAC or caffeine aim-
ing to compromise DDR machinery. Reduction in sporadic senescence with-
out significant difference in the tumor onset latencies was observed, which
might be due to only about 50 % reduction in TGFβ protein levels. Answer
if TGFβ and DDR signaling reside in the same pathway or are 2 independent
pathways mediating senescence in Myc-induced lymphomagenesis could be
provided by combination of treatments that are blocking both TGFβ and
DDR action. This experiment could prove to be hard to conduct as all of
the so-far tested compounds also invoke other cellular effects.
It was reported by Knies-Bamforth et al [KBFP+04] that widespread
Myc expression can induce angiogenesis in hypoxic areas of tumor. The
work in this thesis suggests oxygen tension has an impact on the induc-
tion of senescence, as seen by co-localization of staining for the blood ves-
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sel marker (CD31) with the senescence marker (SA β-gal). In some views
hypoxia might be the trigger of senescence[MK06], which is challenged by
finding that hyperoxic environment contributes to the increase of reactive
oxygen species (ROS), directly triggering the DNA damage, and leading to
senescence[ZLSP05]. It was shown by the work from Evan group that inter-
leukin1γ is mediating Myc-dependent angiogenic switch in pancreatic cancer
cells[SSR+06]. It was shown that hypoxic stress induces G9a methyltrans-
ferase activity, leading to the increased global H3K9me2 patterns[CYD+06],
and it would interesting to test impact of hypoxic stress on Suv39h1 activity.
It would be interesting to obtain data in the respect to connection of TGFβ
and reactive oxygen species (ROS), oxygen tension in lymphomas in vivo,
since in vitro experiments so far were conducted in highly non-physiological
conditions. One of the key experiments in respect to TGFβ’s role in Myc-
driven lymphomagenesis would be in vivo, crossing between Eµ-myc and
TGFβ knockout animals, unfortunately this is not achievable since TGFβ
knockout mice succumb to a wasting syndrome accompanied by a multifo-
cal, mixed inflammatory cell response and tissue necrosis (leading to organ
failure) about 20 days after birth[SOK+92]. Conditional knockout of TGFβ-
RI could prove to be equally good model for investigating a role of TGFβ in
Myc-driven lymphomagenesis[HBK+07]. In this model TGFβ might exert its
action on cyclin E, as observed in slight deregulation of cyclin E regulation
between Suv39h1 proficient and deficient groups. Discrepancy observed in
the p27Kip expression levels in respect to the cyclin E expression levels could
also be due to the more direct action of TGFβ on cyclin E[KOP+93]. How-
ever, if and why TGFβ has more pronounced impact on Suv39h1 proficient
lymphoma molecular machinery should be investigated in the full detail. In
the recent view of the cytokine mediated (or enhanced) senescence one could
argue that a senescent cell would be able to change proliferation status of its
neighboring cells, in this respect full cytokine profile of tumor cells should be
investigated.
One of the recent, and very important points of clearance of senescent cells
in the tumor system has been shown for the the liver tumor. In this system
senescent cells are cleared from the tissue by the immune system[XZM+07],
this finding showed that senescence has properties of a dynamic process (as
apoptosis). This finding should be tested in lymphoma environment, to con-
firm if the same clearance by immunological system applies. The question
of actual dynamics of clearance of senescent cells as opposed to dynamics
of cytokine signaling and impact on the possible arrest could be tested in
future.
The second part of the work is focused on the therapy induced senescence
as a beneficial program that might enhance better outcome to the tumor ther-
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apy. Eµ-myc, Suv39h1 model presented in this thesis is one of the first genetic
models in vivo dealing with the question of contribution of senescence to the
treatment outcome. However, as Suv39h1 function seem not to be impaired
in human lymphoma patients it is important to investigate function of other
histone methyltransferases (HMTase). Indeed, there are HMTases (like Riz1)
found to be mutated in human cancers, mechanistically fitting the epigenetic
involvement in the senescence model theory. In the past years an exploding
new field of research appeared which is directed towards histone demethy-
lases. Currently there are two models present describing possible mecha-
nisms that cell employs in order to continuously counteract H3K9 HMTase
activities, acting both in eu-chromatin and hetero-chromatin. One of these
models states that mutations in lysine demethylase will cause a disruption
in the heterochromatin status. It has been shown that lysine demethylase
hLSD1[SLM+04] is capable of demethylating H3K9[MWY+05], following by
demonstration of LSD1’s H3K9 demethylase activity in vivo [LZV+07]. Of
a particular interest in a context of Suv39h1 would be a specific histone
K3 (trimethylated lysine) demethylase JMJD2a and JMJD2b (Jumonji do-
main containing 2a and 2b), since they would be able to counteract actions
of Suv39h1 on the histone H3 lysine residues. Recent characterization of a
broad spectrum of cancers revealed presence of the chromatin changes in the
tumor suppressor or proto-oncogenes, and in turn their deregulated transcrip-
tion will enhance cancer progression[Est07]. Future biochemical experiments
(immunohistochemistry for a diverse range of histone methylases or histone
demethylases) on human lymphoma samples might teach us more about in-
volvement of other HMTases or equally important histone demethylases in
these processes, and might help to design better strategies for the cancer
treatment.
In summary,
The origin of cancer is shaped by the alterations in oncogenes and/or tumor
suppressor genes, which can be accomplished amongst other by modifica-
tions in the ”histone code”. This shows complexity of the tumor formation,
since main mutation leading to tumorigenesis is often accompanied by addi-
tional changes, each of them giving specific selective advantage to the tumor
cell. Fate of the tumor cell is dependent on the mutations it accumulated
throughout time. Research described in this thesis takes advantage of several
features of the tumor suppressor Suv39h1:
1. Suv39h1 loss collaborates efficiently with the Myc overexpression dur-
ing lymphomagenesis, as shown by the observation that tumors arise in
Suv39h1 deficient mice with significantly shorter tumor latencies.
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2. Suv39h1 loss elegantly ablates oncogene-induced senescence providing
a straightforward model to test impact of drug induced senescence on the
long term therapy.
This study underscores the requirement for the active Suv39h1 in senes-
cence pathway when Myc is overexpressed, directly showing that this process
is governed by epigenetic alterations. By further analysis it is revealed that
senescence in Myc-induced lymphomagenesis requires the cytokine TGFβ
signaling pathway as well as the DNA damage pathway.
Concluding, as observed in the treatment studies with the genetic ablation
of senescence in vivo, this is a potent mechanism of tumor treatment, equally
important as apoptosis, and one that can be exploited in the further clinical
studies.
Appendix A
Appendices
A.1 Tumor development
A.1.1 Defects of failsafe machinery in Suv39h1 defi-
cient lymphomas
Impact of loss of genes implicated in failsafe pathways on senes-
cence machinery
Eµ-myc mice were crossed to either p19Arf+/− or p16INK4a+/− mice and
monitored for tumor latencies by palpation of peripheral lymph nodes every
three days. Latencies were plotted as a Kaplan-Meier ”Time-to-tumor onset”
plot (Figure 58). All of the animals succumbed to B-cell lymphoma; with
the time to tumor onset in Eµ-myc, p19Arf−/− (n=6) being 56 days and
in Eµ-myc, p19Arf+/− (n=4) being 30 days. Eµ-myc, p16INK4a−/− mice
(n=2) succumbed to the lymphoma at median age of 147 days, and Eµ-myc,
p16INK4a+/− (n=15) at the median age of 170 days (Figure A.1).
A.1.2 DNA damage analyses in Myc lymphomas
Disruption of DDR checkpoints in Myc-induced lymphomas
Caffeine was administered via the water supply to Eµ-myc and the wild-type
mice starting from their birth (0.4 mg/ ml). Caffeine administration signif-
icantly decreased tumor latencies in the Eµ-myc mice, but did not interfere
with the life expectancy of the wild-type mice (n= 3, Figure A.2).
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Figure A.1: Defects in p19Arf , but not in p16INK4a accelerate Myc-lym-
phomagenesis. LEFT: Kaplan-Meier ”Time-to-tumor-onset” latencies plot:
Eµ-myc, p19Arf−/− (6; magenta line); Eµ-myc, p19Arf+/−(n=4; gray li-
ne). RIGHT: Kaplan-Meier ”Time-to-tumor-onset” latencies plot: Eµ-myc,
p16INK4a−/− (n=2; green line); Eµ-myc, p16INK4a+/−(n=15; pink line) were
compared to Eµ-myc (n=93; black line).
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Figure A.2: Kaplan-Meier ”Time-to-tumor-onset” latencies in Eµ-myc mice
treated with caffeine (n=15, red line) compared to the wild-type mice (n=3,
blue line) treated with caffeine.
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A.1.3 Triggers of Myc-induced senescence
Validation of candidate genes involved in senescence
Semi-quantitative RT-PCR analyses were directed towards validating pre-
viously found deregulated gene expression caused by loss of Suv39h1. In
addition to the lymphomas used for the gene-expression analysis more pri-
mary lymphoma samples were analyzed for: Taf4B [TAF4b RNA polymerase
II, TATA box binding protein (TBP)-associated factor], Mei1 [Meiosis defec-
tive 1], Myst 4 [Myst histone acetyltransferase (monocytic leukemia) 4], Ryk
[Receptor tyrosine kinase], Lsp1 [Lymphocyte specific protein 1] and Cul 2
[Cullin 2, Ubiquitin protein ligase binding]. Lymphomas were tested before
and after propagation in vitro, in order to establish source of gene expression
(by propagation in vitro lymphoma cells outgrow bystander cells, figure A.3).
Levels of TGF β-2 and TGF β-3 transcripts are not differing between the
genotypes (Figure A.4).
TGF β-1 gene and its role in senescence
In order to unveil accute response to TGF β-1 signaling in lymphomas
Suv39h1 proficient and deficient cells were exposed for 24 hours to 100 pM of
TGF β-1 and subjected to the genome-wide expression analysis. Genes found
to be differentially expressed were validated by semi-quantitative RT-PCR
analysis (Figure A.7).
TGF β-1 induced βIGH3 was also shown (Figure A.8).
A.1.4 Influence of acute Myc and TGFβ-1 induction
on senescence execution
In mouse embryo fibroblasts (MEF) with different Suv39h1 status inducible
Myc-protein was introduced by means of the stable retroviral transduction
[4-hydroxy-tamoxifen (4-OHT)-inducible Myc protein fused to a modified
estrogen receptor component (Myc-ER)]. MEFs were tested by Western blot
analysis for the Myc-levels post stable transduction (Figure A.9).
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Figure A.3: Validation of microarray results, differentialy regulated genes
were tested by RT-PCR analysis. Additional genes were tested on RT-PCR
level for the expression of the following genes: Cul2, Lsp 1, Myst4, Ryk,
Taf4b and Mei, on freshly isolated lymphoma cells from Eµ-myc (n=3) and
Eµ-myc Suv39h1−/− (n=3) (marked as non cultured lymphomas, N) as well
as 10 days cultured lymphoma samples (marked as C). TBP was used as a
loading control.
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Figure A.4: TGF β-2 and and -3 transcripts remain unchanged in lympho-
mas with different Suv39h1 status. Expression of the TGFβ-2 and -3 genes
was tested by semi-quantitative RT-PCR on freshly isolated lymphoma cells
from Eµ-myc (n=3) and Eµ-myc Suv39h1−/− (n=3) (marked as non cultured
lymphomas, N) as well as 10 days cultured lymphoma samples (marked as
C). TBP was used as a loading control.
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Figure A.5: TGFβ-1 is the upstream regulator of TGFβ-induced (βIGH3),
and shows deregulation in expression depending on Suv39h1 status. TGFβ-1
levels were tested by semi-quantitative RT-PCR. TGFβ-1 transcript levels
were tested on freshly isolated lymphoma cells from Eµ-myc (n=5) and Eµ-
myc Suv39h1−/− (n=5) animals, B-cells from the wild-type animals (n=3)
and Suv39h1-/- animals (n=2). TBP was used as a loading control.
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Figure A.6: p15INK4b protein levels do not differ between Suv39h1 proficient
and deficient lymphomas. p15INK4b levels were tested by Western blot on
freshly isolated lymphoma cells from Eµmyc (n=4) and Eµ-myc Suv39h1−/−
(n=4) animals. Tubulin was used as a loading control.
A.2 Tumor treatment
A.2.1 Tumor therapy in vivo
Impaired long term-treatment outcome in Suv39h1+/− lymphomas
The disease was recapitulated by transplantation of Suv39h1 proficient and
deficient primary lymphomas. 2-3 million of lymphoma cells in 300 µl saline
solution suspension was injected into the tail vein of the recipient wild-type
mice. Each lymphoma was transplanted into two wild-type 6-8 weeks old
mice, and all of the transplanted lymphomas formed tumors within the range
of 20-30 days.
Post transplantation mice were monitored by palpating peripheral lymph
nodes every three days, and when lymph nodes were graded as palpable in
two consecutive times, a single dose (300mg/kg of body weight) of cyclophos-
phamide (CTX) was administered to the mice. Mice were further monitored
for the long term treatment outcome. All of the studied lymphomas initially
responded to the CTX tretament by regression of the palpable lymph nodes,
which occured three to six days post treatment.
Two Kaplan-Meier plots show ”Time-to-death” latencies and ”Time-to-
tumor-onset” latencies in Eµ-myc, Suv39h1+/− mice (Figure A.10).
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Figure A.7: Semi-quantitative RT-PCR validation of genes found differen-
tially expressed in the second genome-wide expression analysis. Differential
expression of genes in the response to TGF β-1 signaling (upon treatment
with 100pM of TGFβ-1) was found in TGFβ-1 treated (100pM) lymphoma
cells from Eµ-myc (n=7) when compared to Eµ-myc Suv39h1−/− (n=7) an-
imals.
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Figure A.8: βIGH3 levels are regulated by TGF β-1. Exogenous addition of
TGFβ-1 to lymphoma cells of both Suv39h1 proficient (n=3) and deficient
(n=3) background revealed induction of βIGH3 expression in both genotypes.
TBP was used as a loading control.
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Figure A.9: Analysis of stable transduction by protein expression levels.
Expression of Myc was checked in wild-type and Suv39h1 deficient mouse
embrionyc fibroblasts (MEFs) post stable retroviral transduction of Myc-ER
construct, Eµ-myc (n=2) lymphomas were used as positive controls. Tubulin
was used as a loading control.
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Figure A.10: Animals bearing Suv39h1+/− lymphomas have inferior long
term treatment outcome when compared to animals bearing lymphomas
with intact Suv39h1. LEFT: Eµ-myc, Suv39h1+/− mice (yellow line; n=
8) were monitored for the ”Time-to-relapse” latencies after Cyclophospha-
mide (CTX) treatment. RIGHT: Eµmyc, Suv39h1+/− mice (yellow line; n=
8) were monitored for the ”Time-to-death” latencies post Cyclophosphamide
(CTX) treatment.
Impaired long term-treatment outcome in bcl2 protected Suv39h1-
/- lymphomas
In the same experimental design as for the primary lymphomas of both geno-
types, additionally transplanted lymphomas were stably transduced with the
apoptotic blocker bcl2. In this experimental setting senescence was tested
as the only intact mechanism upon the therapy. In this experiment each
lymphoma was transplanted into the 3 wild-type 6-8 weeks old mice, upon
lymphoma formation mice were treated with the single dose of Cyclophos-
phamide (CTX) and monitored for the 100 days to investigate the long-term
response to the therapy (Figure A.11).
Correlation between treatment outcome and induction of sponta-
neous apoptosis in primary lymphomas
Defects in apoptotic machinery have a tremendous impact on the long term
treatment outcome. Therefore to exclude the possibility of apoptotic defects
in the original lymphoma pool used for the transplantation studies impact-
ing treatment outcome, both Suv39h1 proficient and deficient lymphomas
were tested by TUNEL staining for Myc-induced apoptosis. It was shown
that all of the tested lymphomas retained the ability to execute spontaneous
apoptosis. However, this result could not be compared to the correlation
of senescence and the long-term treatment outcome since paraffin embedded
sections were not done for each of lymphoma samples (Figure A.12).
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Figure A.11: Drug induced senescence is contributing to the long term treat-
ment outcome when apoptosis is blocked. Eµ-myc/bcl2 (black line, n=11)
and Eµ-myc, Suv39h1−/−/bcl2 mice (red line; n= 7) were monitored for the
”Time-to-death” latencies upon Cyclophosphamide (CTX) treatment.
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Figure A.12: Correlation between the extent of apoptosis (TUNEL) and the
response to the long-term treatment outcome in Suv39h1 proficient mice.
160
Abbreviations
Abbreviations Erklärung
ADR Adriamycin
ARF Alternative reading frame
Bcl2 B-cell lymphoma 2
βIGH3 TGFβ-inducible gene
BrdU 5-bromo-2’-deoxyuridine
CDK Cyclin-dependent kinase
CTX Cyclophosphamide
DNA Desoxyribonucleic acid
DDR DNA damage response
Eµ immunoglobulin heavy chain (IgH) enhancer
FITC Fluoresceinisothiocyanat
H3K9 Lysine 9 residue on histone H3
H3K9me3 Tri-methylated lysine 9 residue on histone H3
H3S10P Phosphorylated serine 10 residue on histone H3
HMT Histone-methyltransferase
HP1 Heterochromatin protein 1
INK4 Inhibitor of CDK4
mRNA Messenger ribonucleic acid
MSCV Murine stem cell virus
NAC N-Acetylcytsteine
NOC Nocodazole
p53 Tumor protein 53
PI Propidium iodide
Rb Retinoblastoma protein
ROS Reactive oxygen species
RNA Ribonucleic acid
SA β-gal Senescence-associated β-galactosidase
Su(var)3-9 Suppressor of variegation 3-9
TGFβ Transforming growth factorβ
TUNEL Terminal deoxynucleotidyl transferase dUTP
nick end labelling
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